6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2014

Commission File No. 00-30082

MERUS LABS INTERNATIONAL INC.
(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151
Toronto, ON M5K 1H1
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [   ]

SUBMITTED HEREWITH

Exhibits
99.1	Credit Agreement dated September 5, 2014
99.2	News Release dated September 8, 2014
99.3	Material Change Report dated September 8, 2014
99.4	Asset Purchase Agreement dated September 8, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 19, 2014

MERUS LABS INTERNATIONAL INC.

“Andrew Patient”

Andrew Patient

Chief Financial Officer

EX-99.1

MERUS LABS INTERNATIONAL INC.

as Borrower

- and -

BANK OF MONTREAL

CIT FINANCIAL LTD.

EXPORT DEVELOPMENT CANADA and

LAURENTIAN BANK OF CANADA

as Lenders

- and -

BANK OF MONTREAL and CIT GROUP SECURITIES (CANADA) INC.

as Co-Lead Arrangers

- and -

BANK OF MONTREAL,

as Administrative Agent

CREDIT AGREEMENT

September 5, 2014

TABLE OF CONTENTS

		Page
ARTICLE I - INTERPRETATION
1.01	Definitions	1
1.02	Accounting Principles	21
1.03	Currency References	22
1.04	Extended Meanings	22
1.05	Luxembourg Terms	22
1.06	Exhibits and Schedules	23
Article II - FACILITY 1
2.01	Establishment of Facility 1	24
2.02	Purpose	24
2.03	Non-Revolving Nature	24
2.04	Repayment	24
2.05	Availment Options	25
2.06	Interest and Fees	26
2.07	Voluntary Repayments	26
ARTICLE III - HEDGE TRANSACTIONS
3.01	Hedge Transactions	28
ARTICLE IV - BANKERS’ ACCEPTANCES, BA EQUIVALENT LOANS AND LIBOR LOANS
4.01	Commitment to Purchase Bankers' Acceptances and BA Equivalent Notes	29
4.02	Special Provisions Regarding Bankers' Acceptances	29
4.03	Special Provisions regarding BA Equivalent Notes	31
4.04	Special Provisions Regarding LIBOR Loans	32
4.05	No Repayment of Certain Availment Options	33
ARTICLE V - GENERAL CONDITIONS
5.01	Matters relating to Interest	34
5.02	Notice Periods	34
5.03	Minimum Amounts, Multiples and Procedures re Draws, Conversions and Repayments	35
5.04	Place of Repayments	36
5.05	Evidence of Obligations (Noteless Advances)	37
5.06	Determination of Equivalent Amounts	37
5.07	Illegality	37
5.08	Anti-Money Laundering	37
5.09	Terrorist Lists	38

- ii -

	ARTICLE VI - REPRESENTATIONS AND WARRANTIES
6.01	Representations and Warranties	39
6.02	Survival of Representations and Warranties	45
	Article VII - COVENANTS
7.01	Positive Covenants	46
7.02	Negative Covenants	48
7.03	Financial Covenants	51
7.04	Reporting Requirements	52
7.05	Sintrom Marketing Authorizations	53
	Article VIII - SECURITY
8.01	Security to be Provided by the Companies	54
8.02	Security to be Provided by Others	55
8.03	General Provisions re Security; Registration	55
8.04	Opinions re Security	56
8.05	After-Acquired Property, Further Assurances	56
8.06	Security for Hedge Transactions	56
8.07	Luxembourg Guarantee Limitation	56
8.08	Insurance by Agent	57
8.09	Insurance Proceeds	58
8.10	Successors and Assigns	58
	ARTICLE IX - CONDITIONS PRECEDENT
9.01	Conditions Precedent to First Advance	59
	ARTICLE X - DEFAULT AND REMEDIES
10.01	Events of Default	62
10.02	Acceleration, etc.	63
10.03	Acceleration of Certain Contingent Obligations	64
10.04	Combining Accounts, Set-Off	64
10.05	Appropriation of Monies	65
10.06	No Further Advances	65
10.07	Judgment Currency	65
10.08	Remedies Cumulative	65
10.09	Performance of Covenants by Agent	66
	ARTICLE XI - THE AGENT AND THE LENDERS
11.01	Decision-Making	67
11.02	Security	68
11.03	Application of Proceeds of Realization	68

- iii -

11.04	Payments by Agent	69
11.05	Protection of Agent	70
11.06	Duties of Agent	71
11.07	Lenders' Obligations Several; No Partnership	72
11.08	Sharing of Information	72
11.09	Acknowledgement by Borrower	72
11.10	Amendments to Article XI	72
11.11	Deliveries, etc	73
11.12	Agency Fees	73
11.13	Assignment Fee	73
11.14	Non-Funding Lender	73
	ARTICLE XII - CBA MODEL PROVISIONS
12.01	CBA Model Provisions Incorporated by Reference	75
12.02	Inconsistencies with CBA Model Provisions	76
	Article XIII - GENERAL
13.01	Waiver	77
13.02	Expenses of Agent and Lenders	77
13.03	Debit Authorization	77
13.04	General Indemnity	77
13.05	Environmental Indemnity	78
13.06	Survival of Certain Obligations despite Termination of Agreement	78
13.07	Interest on Unpaid Costs and Expenses	79
13.08	Notice	79
13.09	Severability	80
13.10	Further Assurances	80
13.11	Time of the Essence	80
13.12	Promotion and Marketing	80
13.13	Public Filing of Agreement	80
13.14	Entire Agreement; Waivers and Amendments to be in Writing	81
13.15	Inconsistencies with Security	81
13.16	Governing Law	81
13.17	Execution by Fax and Counterparts	81
13.18	Binding Effect	81

- iv -

Exhibits
"A"	-	Lenders and Lenders' Commitments
"B"	-	Draw Request
"C"	-	Rollover Notice
"D"	-	Conversion Notice
"E"	-	Repayment Notice
"F"	-	Compliance Certificate
"G"	-	Form of BA Equivalent Note
"H"	-	CBA Model Provisions
Schedules
6.01(b)	-	Corporate Information
6.01(h)	-	Material Permits
6.01(i)	-	Specific Permitted Liens
6.01(j)	-	Owned Properties
6.01(k)	-	Leased Properties
6.01(l)	-	Intellectual Property
6.01(m)	-	Insurance Policies
6.01(n)	-	Material Agreements
6.01(o)	-	Labour Agreements
6.01(p)	-	Environmental Matters
6.01(q)	-	Litigation
6.01(r)	-	Pension Plans

Execution Copy

CREDIT AGREEMENT

This Agreement dated September 5, 2014 is made among:

MERUS LABS INTERNATIONAL INC.

as Borrower

- and -

BANK OF MONTREAL

CIT FINANCIAL LTD.

EXPORT DEVELOPMENT CANADA and

LAURENTIAN BANK OF CANADA

as Lenders

- and -

BANK OF MONTREAL and CIT GROUP SECURITIES (CANADA) INC.

as Co-Lead Arrangers

- and -

BANK OF MONTREAL,

as Administrative Agent

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each party, the parties agree as follows:

ARTICLE I - INTERPRETATION

1.01 Definitions

In this Agreement, the words and phrases set out in the CBA Model Provisions (as hereinafter defined) shall have the respective meanings set forth therein (subject to section 12.01 hereof). In addition, the following words and phrases shall have the respective meanings set forth below:

"Acceleration Date" means the earliest to occur of: (i) the occurrence of an Insolvency Event; (ii) the date on which the Borrower fails to repay all or any portion of the Obligations pursuant to an Acceleration Notice issued by the Agent.

- 2 -

"Acceleration Notice" is defined in section 10.02.

"Advance" means an extension of credit by one or more of the Lenders to the Borrower pursuant to this Agreement, including for greater certainty an extension of credit in the form of a Loan, a Bankers' Acceptance or a BA Equivalent Loan.

"Affiliate" is defined in the CBA Model Provisions.

"Agent" means BMO in its capacity as the administrative agent hereunder, and its successors in such capacity.

"Agreement" means this credit agreement (including the exhibits and schedules) as it may be amended, supplemented, replaced or restated from time to time.

"AML Legislation" means the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), the United Nations Act (Canada), Special Economic Measures Act (Canada), Export and Import Permits Act (Canada), Freezing Assets of Foreign Corrupt Officials Act (Canada), Criminal Code (Canada), Anti-Terrorism Act (Canada) and all other applicable anti-money laundering, anti-terrorist financing, government sanction and "know your client" laws, whether within Canada or elsewhere, including any guidelines or orders thereunder.

"Annual Business Plan" is defined in paragraph 7.04(c) .

"Applicable Law" is defined in the CBA Model Provisions.

"Applicable Margin" means, in respect of each Availment Option in the following table, the percentage set out opposite such Availment Option:

Availment Option	Applicable Margin
Prime Rate Loans	3.00%
Base Rate Loans	3.00%
LIBOR Loans	4.50%
Bankers’ Acceptances	4.50%
BA Equivalent Notes	4.50%

"Associate" has the meaning ascribed thereto in the Business Corporations Act (British Columbia).

"Availment Option" means a method of borrowing which is available to the Borrower as provided herein.

"BA Equivalent Loan" means an Advance in Canadian Dollars made by a Non-BA Lender to the Borrower in respect of which the Borrower has issued a BA Equivalent Note.

- 3 -

"BA Equivalent Note" means a promissory note payable by the Borrower to a Non-BA Lender in the form of Exhibit "G" attached hereto.

"BA Lender" means a Lender identified in Exhibit "A" attached hereto as a Lender which will accept Bankers' Acceptances hereunder.

"Bankers' Acceptance" means a bill of exchange or a blank non-interest bearing depository bill as defined in the Depository Bills and Notes Act (Canada) drawn by the Borrower and accepted by a BA Lender in respect of which the Borrower becomes obligated to pay the face amount thereof to the holder (which may be a third party or such BA Lender) upon maturity.

"Base Rate" means the greater of the following: (i) the rate of interest announced from time to time by BMO as its reference rate then in effect for determining rates of interest on U.S. Dollar loans to its customers in Canada and designated as its U.S. base rate; and (ii) the Federal Funds Rate plus one-half percent (0.5%) per annum.

"Base Rate Loan" means an Advance made by a Lender to the Borrower in Canada by way of a direct loan in U.S. Dollars, in respect of which interest is determined by reference to the Base Rate.

"BIA" means the Bankruptcy and Insolvency Act (Canada).

"BMO" means Bank of Montreal and its successors and permitted assigns.

"Borrower" means Merus Labs International Inc., a corporation subsisting under the laws of the Province of British Columbia, and its successors and permitted assigns.

"Business Day" means any day on which the Agent is open for over-the-counter business in both Toronto, Ontario and Montreal, Quebec (and for greater certainty, excluding Saturday, Sunday and any other day that is a statutory holiday in either Toronto, Ontario or Montreal, Quebec); provided further that (i) with respect to Base Rate Loans, "Business Day" shall also exclude any day that the Agent is not open for over-the-counter business in New York, New York, and (ii) with respect to LIBOR Loans, "Business Day" shall also exclude any day on which the Agent is not open for over-the-counter business in New York, New York and any day on which dealings in U.S. Dollar deposits are not conducted by and between banks in the London interbank Eurodollar market.

"Canadian Dollars" or "CDN$" means the lawful money of Canada.

"Capital Expenditures" means expenditures made directly or indirectly which are considered to be in respect of the acquisition or leasing of capital assets in accordance with GAAP, including the acquisition or improvement of Land, plant, machinery or equipment, whether fixed or removable.

"Capital Lease" means any lease of assets which in accordance with GAAP is required to be capitalized on the balance sheet of the lessee.

- 4 -

"Cash Taxes" in respect of any fiscal period means amounts actually paid by the Companies in such fiscal period in respect of income and capital Taxes (whether relating to such fiscal period or any other fiscal period).

"CBA Model Provisions" means the model credit agreement provisions attached hereto as Exhibit "H", which have been revised under the direction of the Canadian Bankers' Association Secondary Loan Market Specialist Group from provisions prepared by The Loan Syndications and Trading Association, Inc.

"CDOR Rate" means on any day the annual rate of interest which is the rate determined as being the arithmetic average of the quotations of all institutions listed in respect of the rate for Canadian Dollar denominated bankers’ acceptances for the relevant period displayed and identified as such on the “Reuters Screen CDOR Page” (as defined in the International Swap Dealer Association, Inc. definitions, as modified and amended from time to time) as of 10:00 a.m. Toronto, Ontario local time on such day and, if such day is not a Business Day, then on the immediately preceding Business Day (as adjusted by the Agent after 10:00 a.m. Toronto, Ontario local time to reflect any error in a posted rate of interest or in the posted average annual rate of interest with notice of such adjustment in reasonable detail evidencing the basis for such determination being concurrently provided to the Borrower); provided that if such rates are not available on the Reuters Screen CDOR Page on any particular day, then the CDOR Rate on that day shall be the average of the rates applicable to Canadian Dollar bankers’ acceptances for the relevant period quoted for customers in Canada by the Agent as of 10:00 a.m. Toronto, Ontario local time on such day; or if such day is not a Business Day, then on the immediately preceding Business Day.

“Closing Date” means the date confirmed in writing by the Agent as the date on which the conditions precedent listed in section 9.01 herein have been satisfied and the Borrower is thereby entitled to receive the first Advance hereunder.

"Collateral" means all property, assets and undertaking of the Credit Parties encumbered by the Security, together with all proceeds of the foregoing.

"Commitment" means, in respect of any Lender, such Lender's commitment to make Advances to the Borrower under Facility 1.

"Companies" means the Borrower and all of its Subsidiaries from time to time; and "Company" means any of them as the context requires.

"Compliance Certificate" means a certificate delivered by the Borrower to the Agent in the form of Exhibit "F".

"Control" is defined in the CBA Model Provisions.

"Conversion" means the substitution of one Availment Option for another, and does not constitute a fresh or new Advance.

"Conversion Notice" means a notice substantially in the form of Exhibit "D" given by the Borrower to the Agent for the purposes of requesting a Conversion.

- 5 -

“Copyrights” means all rights, title and interests (and all related IP Ancillary Rights) arising under any requirement of law in copyrights and all mask work, database and design rights, whether or not registered or published, all registrations and recordations thereof and all applications in connection therewith.

"Credit Parties" means, collectively, the Borrower and the Material Subsidiaries.

"Currency Hedge Transactions" means Hedge Transactions entered into for the purpose of hedging currency risk, including currency exchange agreements and foreign exchange forward contracts.

"Default" is defined in the CBA Model Provisions (and for greater certainty includes an Event of Default).

“Defined Benefit Pension Plan” means any Pension Plan which contains a “defined benefit provision” as defined in subsection 147.1(1) of the Income Tax Act (Canada).

"Distribution" means any amount paid to or on behalf of the directors, officers or the shareholders of any Company or to any Related Person thereto, by way of salary, bonus, commission, management fees, directors' fees, dividends, redemption of shares or otherwise, and whether payments are made to such Persons in their capacity as shareholders, directors, officers, employees or creditors of any Company or otherwise, or any other direct or indirect payment in respect of earnings or capital of any Company; provided however that the following shall not be considered Distributions: salaries, bonuses, fees, commissions and other amounts related to employment paid by a Company from time to time to its directors, officers and employees in the ordinary course of business at reasonable levels and payments for any reason by a Company to its shareholder provided that such shareholder is a Secured Company.

"Draw Request" means a notice in the form of Exhibit "B" given by the Borrower to the Agent for the purpose of requesting an Advance.

"EBITDA" means, in respect of any fiscal period, the consolidated net income of the Companies in such fiscal period determined in accordance with GAAP (but excluding extraordinary gains and non-cash gains (such as unrealized foreign exchange gains)), plus the following amounts (to the extent such amounts were deducted in determining such consolidated net income, and without duplication): (i) Interest expense, (ii) income taxes, (iii) depreciation and amortization, (iv) non-cash losses (such as unrealized foreign exchange losses), (v) expenses related to or arising in connection with the establishment of Facility 1, provided that the aggregate amount of such expenses added back in all fiscal periods shall not exceed Two Million Dollars ($2,000,000); (vi) non-cash share-based compensation, (vii) extraordinary, unusual and non-recurring non-cash expenses; and (viii) extraordinary, unusual and non-recurring cash expenses approved in writing by the Required Lenders in their discretion.

"Equivalent Amount" means, in relation to an amount in one currency, the amount in another currency that could be purchased by the amount in the first currency, determined by reference to the applicable Exchange Rate at the time of such determination.

"Event of Default" is defined in section 10.01.

- 6 -

"Excess Cash Flow" in respect of any fiscal period means EBITDA in such fiscal period, less the following amounts (without duplication):

• income (and also in the case of any Luxembourg Guarantor, capital) Taxes paid or payable in respect of such fiscal period;

• Capital Expenditures paid during such fiscal period to the extent incurred in compliance with paragraph 7.02(g) (but excluding any portion thereof financed by Permitted Funded Debt);

• Interest paid or payable during such fiscal period in respect of Permitted Funded Debt;

• to the extent approved by the Lenders in their discretion, amounts paid or payable in respect of the termination or unwinding of Hedging Transactions (but for greater certainty, no amount shall be deducted in respect of Hedging Transactions which remain outstanding);

• transaction costs related to the Sintrom Purchase Transaction, provided that the aggregate amount of such transaction costs deducted in determining Excess Cash Flow in all fiscal periods shall not exceed Three Million Dollars ($3,000,000);

• scheduled principal payments paid during such fiscal period in respect of the Outstanding Advances under Facility 1 and other Permitted Funded Debt; and

• voluntary Repayments made in respect of the Outstanding Advances under Facility 1 in such fiscal period.

"Exchange Rate" means, on the date of determination of any amount of Canadian Dollars to be converted into another currency pursuant to this Agreement for any reason, or vice-versa, the spot rate of exchange for converting Canadian Dollars into such other currency or vice-versa, as the case may be, established by the Bank of Canada at approximately noon (Toronto time) on the date of such determination (or such other date as may be specified herein).

"Excluded Subsidiaries" means the Subsidiaries of the Borrower listed in Schedule 7.01(b) attached hereto under the heading "Excluded Subsidiaries", and any other any Subsidiaries of the Borrower so designated in writing by the Required Lenders in their discretion from time to time.

"Facility 1" is defined in section 2.01.

"Facility 1 Maximum Amount" means Eighty Million Dollars ($80,000,000).

"Federal Funds Rate" means, for any day, the weighted average (rounded upwards, if necessary, to the next 1/100 of one percent) of the per annum interest rates on overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers as published in respect of such day on the next succeeding Business Day by the Federal Reserve Bank of New York or, if such rate is not so published for any day that is a Business Day, the average (rounded upwards, if necessary, to the next 1/100 of one percent) of the quotations for such day for such transactions received by the Agent from three federal funds brokers of recognized standing selected by it.

- 7 -

"First-Ranking Security Interest" in respect of any Collateral means a Lien in such Collateral which is registered as required under this Agreement to record and perfect the charges contained therein and which ranks in priority to all other Liens in such Collateral, except for any Permitted Liens which may have priority in accordance with Applicable Law.

"Fiscal Quarter" means a fiscal quarter of the Borrower, ending on the last day of December, March, June or September in each year.

"Fiscal Year" means a fiscal year of the Borrower, ending on the last day of September in each year.

"Fixed Charge Coverage Ratio" means, in respect of any Fiscal Quarter, the ratio of: (i) EBITDA in the fiscal period comprised of such Fiscal Quarter and the immediately preceding three Fiscal Quarters, less Capital Expenditures paid by the Borrower on a consolidated basis during such fiscal period to the extent not financed by Permitted Funded Debt, less Cash Taxes paid by the Companies during such fiscal period, less the aggregate amount of Distributions paid in cash in such fiscal period; to (ii) Funded Debt Service in respect of such fiscal period.

"Funded Debt" in respect of any Person means obligations of such Person which are considered to constitute debt in accordance with GAAP, including indebtedness for borrowed money (in the case of the Borrower, specifically including the Outstanding Advances), Subordinated Debt, obligations secured by Purchase-Money Security Interests, obligations under Capital Leases, capitalized interest, Hedging Obligations which are due and payable, and the redemption price of any securities issued by such Person having attributes substantially similar to debt (such as securities which are redeemable at the option of the holder); but excluding the following: accounts payable, payroll accruals, accruals in respect of normal business expenses, future income Taxes (both current and long-term) and Hedging Obligations which are not due and payable. For greater certainty and notwithstanding the forgoing, the Series A Preferred Shares of the Borrower shall not constitute Funded Debt.

"Funded Debt Service" means, in respect of any fiscal period, without duplication: (i) the aggregate amount of Interest paid or payable in respect of the Funded Debt of the Borrower on a consolidated basis in respect of such fiscal period (but for greater certainty, excluding any Interest which is capitalized and not paid or payable during such fiscal period); plus (ii) the aggregate amount of scheduled principal payments and scheduled Capital Lease payments paid or payable in respect of the Funded Debt of the Borrower on a consolidated basis in respect of such fiscal period (except the portion of any final payment due in respect of such Funded Debt which constitutes a "balloon payment" and any amount paid in connection with the exercise of an option to purchase equipment under a Capital Lease).

"GAAP" means generally accepted accounting principles in Canada as in effect from time to time as set forth in the opinions and pronouncements of the relevant Canadian public and private accounting boards and institutes which are applicable to the relevant Person and the circumstances as of the date of determination, consistently applied including, without limitation, International Financial Reporting Standards adopted by the Accounting Standards Board of the Canadian Institute of Chartered Accountants (which have been adopted by the Borrower).

- 8 -

"Governmental Authority" is defined in the CBA Model Provisions.

"Guarantee" means any agreement by which any Person assumes, guarantees, endorses, contingently agrees to purchase or provide funds for the payment of, or otherwise becomes liable upon, the obligation of any other Person, or agrees to maintain the net worth or working capital or other financial condition of any other Person or otherwise assures any creditor of such Person against loss, and shall include any contingent liability under any letter of credit or similar document or instrument.

"Hazardous Materials" means any contaminant, pollutant, waste or substance that is likely to cause immediately or at some future time harm or degradation to the surrounding environment or risk to human health; and without restricting the generality of the foregoing, including any pollutant, contaminant, waste, hazardous waste or dangerous goods that is regulated by any Requirements of Environmental Law or that is designated, classified, listed or defined as hazardous, toxic, radioactive or dangerous or as a contaminant, pollutant or waste by any Requirements of Environmental Law.

"Hedge Transaction" means a Hedging Transaction entered into between the Borrower and a Lender in compliance with section 3.01 of this Agreement.

"Hedging Obligations" means all obligations of the Borrower to the Lenders pursuant to or arising in connection with all Hedge Transactions made between the Borrower and any Lenders.

"Hedging Transactions" means (a) any and all interest rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any international foreign exchange master agreement, or any other master agreement, including any such obligations or liabilities under any such master agreement and its related schedules, in each case for the purpose of hedging exposure to interest or exchange rates, or loan, credit exchange, security or currency valuations.

"Indemnitees" means the Lenders, the Agent and their respective successors and permitted assignees, any agent of any of them (specifically including a receiver or receiver-manager) and the respective officers, directors and employees of the foregoing.

"Insolvency Event" means, in respect of any Person, the occurrence of any one or more of the following events:

- 9 -

• such Person ceases to carry on its business; or commits an act of bankruptcy or becomes insolvent (as such terms are used in the BIA); or makes an assignment for the benefit of creditors, files a petition in bankruptcy, makes a proposal or commences a proceeding under Insolvency Legislation; or petitions or applies to any tribunal for, or consents to, the appointment of any receiver, trustee or similar liquidator in respect of all or a substantial part of its property; or admits the material allegations of a petition or application filed with respect to it in any proceeding commenced in respect of it under Insolvency Legislation; or takes any corporate action for the purpose of effecting any of the foregoing; or

• any proceeding or filing is commenced against such Person seeking to have an order for relief entered against it as debtor or to adjudicate it a bankrupt or insolvent, or seeking liquidation, winding-up, reorganization, arrangement, adjustment or composition of it or its debts under any Insolvency Legislation, or seeking appointment of a receiver, trustee, custodian or other similar official for it or any of its property or assets; unless (i) such Person is diligently defending such proceeding in good faith and on reasonable grounds as determined by the Required Lenders and (ii) such proceeding does not in the reasonable opinion of the Required Lenders materially adversely affect the ability of such Person to carry on its business and to perform and satisfy all of its obligations.

"Insolvency Legislation" means legislation in any applicable jurisdiction relating to reorganization, arrangement, compromise or re-adjustment of debt, dissolution or winding-up, or any similar legislation, and specifically includes for greater certainty the BIA, the Companies' Creditors Arrangement Act (Canada), and the Winding-Up and Restructuring Act (Canada).

“Intellectual Property” means all rights, title and interests in intellectual property and all IP Ancillary Rights relating thereto, including all Copyrights, Patents, Trademarks, Internet Domain Names, Trade Secrets, industrial designs, integrated circuit topographies, plant breeders’ rights and rights under IP Licenses.

"Interest" means interest on loans, stamping fees in respect of bankers' acceptances, the difference between the proceeds received by the issuers of bankers' acceptances and the amounts payable upon the maturity thereof, issuance fees in respect of letters of credit, and any other charges or fees in connection with the extension of credit which are determined by reference to the amount of credit extended, plus standby fees in respect of the unutilized portion of any credit facility; but for greater certainty "Interest" shall not include agency fees, arrangement fees, structuring fees, fees relating to the granting of consents, waivers, amendments, extensions or restructurings, the reimbursement of costs and expenses, and any similar amounts which may be charged from time to time in connection with the establishment, administration or enforcement of Facility 1.

"Interest Rate Hedge Transactions" means Hedge Transactions entered into for the purpose of hedging interest rate risk, including interest rate exchange agreements (commonly known as "interest rate swaps") and forward rate agreements; and for greater certainty, including interest rate exchange agreements in U.S. Dollars (commonly known as "cross-currency swaps").

"Interim Financial Statements" in respect of any Fiscal Quarter means the unaudited financial statements of the Borrower on a consolidated basis in respect of such Fiscal Quarter (and also on a year-to-date basis in respect of such Fiscal Quarter and all previous Fiscal Quarters in the same Fiscal Year).

- 10 -

“Internet Domain Names” means all right, title and interest (and all related IP Ancillary Rights) in internet domain names.

"Investment" means any of the following by a Company: (i) an investment made or held, directly or indirectly, in another Person (for greater certainty, whether such investment was made in such other Person or was acquired from a third party); (ii) the acquisition or holding of common or preferred shares, debt obligations, partnership interests and interests in joint ventures; (iii) the acquisition of all or substantially all of the assets used in connection with a business; and (iv) the acquisition of Intellectual Property rights (including the IP Ancillary Rights) in respect of any drug product; but excluding the following:

• loans or advances made to employees or officers of any Company in the ordinary course of business in connection with their employment, provided that the amounts thereof are commercially reasonable;

• transactions between or among any two or more Secured Companies;

• transactions with Related Persons that are not Companies in the ordinary course of business and on commercially reasonable terms;

• extensions of credit to customers on normal trade terms in respect of the sale of inventory in the ordinary course of business; and

• any transaction which constitutes a “Capital Expenditure” as defined herein.

“IP Ancillary Rights” means, with respect to an item of Intellectual Property all foreign counterparts to, and all divisionals, reversions, continuations, continuations-in-part, reissues, reexaminations, renewals and extensions of, such Intellectual Property and all income, royalties, proceeds and liabilities at any time due or payable or asserted under or with respect to any of the foregoing or otherwise with respect to such Intellectual Property, including all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution, violation or other impairment thereof, and, includes in each case, all rights to obtain any other IP Ancillary Right.

“IP License” means all contractual obligations (and all related IP Ancillary Rights), whether written or oral, granting any right, title and interest in any Intellectual Property.

“Key Products” means, collectively, (i) all Intellectual Property rights (including IP Ancillary Rights) in Canada and certain European countries in respect of the drug product known as “Enablex” (and marketed in Europe under the name “Emselex”), which said rights are owned by Merus Luxco or Merus Netherlands; and (ii) all Intellectual Property rights (including IP Ancillary Rights) in respect of the drug product known as Vancomycin, which rights are owned by the Borrower (but for greater certainty it is acknowledged that all patents in respect of Vancomycin have expired); and (iii) all Intellectual Property rights (including IP Ancillary Rights) in respect of Sintrom, which rights are owned by the Borrower (but for greater certainty it is acknowledged that all patents in respect of Sintrom have expired).

- 11 -

"Land" means real property (including a leasehold interest in land) and all buildings, improvements, fixtures and plant situated thereon.

"Landlord Agreement" means an agreement in form and substance satisfactory to the Agent given by the landlord of a Leased Property in favour of the Agent, which shall include the following provisions: such landlord consents to the granting of a security interest in the lease by the Credit Party which is a tenant thereunder in favour of the Agent, agrees to give written notice to the Agent in respect of and a reasonable opportunity to cure any default before terminating the lease, and agrees to waive (or subordinate and defer the enforcement of) its rights and remedies and any security it may hold in respect of any assets owned by such Credit Party located on such Leased Property or affixed to such Leased Property which the tenant is entitled to remove under Applicable Law or pursuant to the terms of the lease.

"Laws" means all statutes, codes, ordinances, decrees, rules, regulations, municipal by-laws, judicial or arbitral or administrative or ministerial or departmental or regulatory judgments, orders, decisions, rulings or awards, or any provisions of such laws, including general principles of common and civil law and equity or policies or guidelines, to the extent such policies or guidelines have the force of law, binding on the Person referred to in the context in which such word is used; and "Law" means any of the foregoing.

"Leased Properties" means all Land leased by the Companies as tenants from time to time, specifically including as at the date of this Agreement the Land described in Schedule 7.01(k) attached hereto.

"Leases" means the leases pertaining to the Leased Properties.

"Lender-Related Distress Event" means, with respect to any Lender or any Person that directly or indirectly Controls such Lender (such Lender and each such Person being individually referred to in this definition as a "distressed person"), (i) the commencement of a voluntary or involuntary proceeding with respect to such distressed person under any Insolvency Legislation, (ii) the appointment of a custodian, conservator, receiver or similar official in respect of such distressed person or any substantial part of its assets, (iii) a forced liquidation, merger, sale or other change of Control of such distressed person supported in whole or in part by guarantees or other support (including, without limitation, the nationalization or assumption of ownership or operating control of such distressed person by any Governmental Authority), or (iv) such distressed person makes a general assignment for the benefit of its creditors or is otherwise adjudicated as, or determined by any Governmental Authority having regulatory authority over such distressed person or its assets to be, insolvent, bankrupt, or deficient in meeting any capital adequacy or liquidity standard of any such Governmental Authority.

"Lenders" means the lenders identified in Exhibit "A" attached hereto and any other Persons which may from time to time become lenders pursuant to this Agreement; and their respective successors and permitted assigns.

"LIBO Rate" or "LIBOR" means, with respect to any LIBOR Period for any LIBOR Loan, the rate listed on the page of the Reuters Libor01 screen (or any successor thereto as may be selected by the Agent), applicable to the relevant LIBOR Period, at which deposits in U.S. Dollars are offered to financial institutions in the London interbank market at 11:00 a.m. (London local time) on the date two (2) Business Days in advance of the commencement of the applicable LIBOR Period. If the Reuters Libor01 screen, including any successor or similar service is not available, “LIBO Rate” or “LIBOR” shall mean the rate at which the Agent, in accordance with its normal practice, has offered on such date (or if no such offer has been made on such date, would be prepared to offer) to leading banks in the London interbank market for delivery by the Agent on the first day of the applicable LIBOR Period for a period equal to the number of days in such LIBOR Period, deposits in U.S. Dollars of amounts comparable to the principal amount of such LIBOR Loan to be outstanding during such LIBOR Period.

- 12 -

"LIBOR Loan" means a Loan that bears interest at a rate determined with reference to LIBOR.

"LIBOR Period" means, with respect to any LIBOR Loan, the period commencing on the date on which such LIBOR Loan is advanced or continued or another Loan is converted into such LIBOR Loan, as applicable, and ending on the date that is one, two or three months thereafter (subject to availability), as selected by the Borrower in its Draw Request; provided that:

(a)	any LIBOR Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless such Business Day falls in another month, in which case such LIBOR Period shall end on the immediately preceding Business Day;
(b)	any LIBOR Period that begins on the last Business Day of a month (or on a day for which there is no numerically corresponding day in the month at the end of such LIBOR Period) shall end on the last Business Day of the month at the end of such LIBOR Period; and
(c)	no LIBOR Period shall extend beyond the Maturity Date.

"Lien" means: (i) a lien, charge, mortgage, hypothec, pledge, security interest or conditional sale agreement; (ii) an assignment, lease, consignment, trust or deemed trust that secures payment or performance of an obligation; (iii) a garnishment; (iv) any other encumbrance of any kind; and (v) any commitment or agreement to enter into or grant any of the foregoing.

"Loan" means a Prime Rate Loan, a Base Rate Loan or a LIBOR Loan.

"Loan Documents" collectively, this Agreement, the Security, any promissory notes issued by the Borrower to the Agent or the Lenders hereunder, all agreements made between the Borrower and the Lenders with respect to Hedge Transactions, any certificate completed and executed by a Credit Party and all other certificates, instruments, agreements and other documents (including without limitation any agreements pertaining to Hedge Transactions and Service Agreements) delivered, or to be delivered, to the Agent or the Lenders or any of them, as applicable, under or in connection with this Agreement or Facility 1 and any fee letters entered into between the Borrower and the Agent in respect of fees payable to the Agent or the Lenders.

"Luxembourg" means the Grand Duchy of Luxembourg.

"Luxembourg Companies Register" means the Luxembourg Register of Commerce and Companies.

- 13 -

"Luxembourg Guarantor" means Merus Luxco and any other Person providing a Guarantee and whose registered office/place of central administration is in Luxembourg.

"Luxembourg Insolvency Event" means, in relation to any Luxembourg Guarantor or any of its assets, any corporate action, legal proceedings or other procedure or step in relation to bankruptcy (faillite), insolvency, judicial or voluntary liquidation (liquidation judiciaire ou volontaire), composition with creditors (concordat préventif de faillite), moratorium or reprieve from payment (sursis de paiement), controlled management (gestion contrôle),fraudulent conveyance (action paulienne), general settlement with creditors, reorganization or similar laws affecting the rights of creditors generally.

“Marketing Authorization” means, with respect to any drug product, the authorizations, consents and approvals granted by Governmental Authorities permitting the distribution and sale of such drug product in the relevant countries.

"Material Adverse Change" means any change or event which: (i) could reasonably be expected to constitute a material adverse change in the business, operations, condition (financial or otherwise) or properties of any Credit Party; (ii) could reasonably be expected to materially impair the ability of any Credit Party to timely and fully perform its obligations under any Loan Document to which it is a party, or (iii) could reasonably be expected to materially impair the ability of the Agent and the Lenders to enforce their rights and remedies under this Agreement or the Security.

"Material Agreement" means, in respect of any Company, an agreement made between such Company and another Person which if terminated would result, or would have a reasonable likelihood of resulting, in a Default or a Material Adverse Change, specifically including each agreement listed in Schedule 7.01(n) .

"Material Permit" means, in respect of any Company, a licence, permit, approval, registration or qualification granted to or held by such Company which if terminated would result, or would have a reasonable likelihood of resulting, in a Default or a Material Adverse Changes, specifically including all Marketing Authorizations issued by Governmental Authorities permitting the distribution and sale of the Key Products, and each other permit and licence listed in Schedule 7.01(h) .

"Material Subsidiaries" means all Subsidiaries of the Borrower other than the Excluded Subsidiaries.

"Maturity Date" means September 5, 2019.

"Merus Luxco" means Merus Labs Luxco S. r.l., a wholly-owned Subsidiary of the Borrower in the form of a private limited liability company (socit responsabilit limite) organized and established under the laws of Luxembourg, having its registered office at 26-28, rue Edward Steichen L-2540 Luxembourg, with a share capital of EUR 367,137 and registered with the Luxembourg Companies Register under number B170.130.

"Merus Netherlands" means Merus Labs Netherlands B.V., a wholly-owned Subsidiary of the Borrower organized and established under the laws of the Netherlands.

- 14 -

"Non-BA Lender" means a Lender identified in Exhibit "A" attached hereto as a Lender which will make BA Equivalent Loans instead of accepting Bankers' Acceptances hereunder.

"Non-Funding Lender" means any Lender (i) that has failed to fund any payment or Advance required to be made by it hereunder or to purchase all participations required to be purchased by it hereunder and under the Loan Documents, or (ii) that has given verbal or written notice to the Borrower, the Agent or any other Lender, or has otherwise publicly announced, that it believes that it may be unable to fund advances under one or more credit agreements to which it is a party, or (iii) with respect to which one or more Lender-Related Distress Events has occurred, or (iv) with respect to which the Agent believes, acting reasonably, that such Lender has defaulted or may default in fulfilling its obligations (whether as an agent, lender or letter of credit issuer) under one or more other credit agreements to which it is a party, or (v) with respect to which the Agent believes, acting reasonably, that there is a reasonable chance that such Lender will fail to fund any payment or Advance required to be made hereunder.

"Novartis" means, collectively, Novartis AG and Novartis Pharma AG, each being a company organized under the laws of Switzerland, and their respective successors and assigns.

"Novartis Agreements" means, collectively, the Novartis Enablex Agreements and the Novartis Sintrom Agreements.

"Novartis Enablex Agreements" means, collectively, the asset purchase agreement between Novartis Pharma AG and Merus Luxco dated as of July 11, 2012 under which Merus Luxco acquired all Intellectual Property rights in Canada and certain European countries in respect of the drug product marketed in Canada under the name “Enablex” and marketed in Europe under the name “Emselex”, and all agreements ancillary thereto including the License Agreement and the Supply Agreement (each as defined therein).

"Novartis Sintrom Agreements" means, collectively, the Sintrom Purchase Agreement, the Sintrom License Agreement and the Sintrom Supply Agreement.

"Obligations" means, at any time and without duplication: (i) all direct and indirect, contingent and absolute indebtedness, obligations and liabilities of the Companies to the Agent and the Lenders (or if the context requires, to any Lender) under or in connection with this Agreement and the Loan Documents (specifically including for greater certainty all Guarantees provided hereunder) at such time, specifically including the Outstanding Advances, all accrued and unpaid Interest thereon, and all fees, expenses and other amounts payable pursuant to this Agreement and the Loan Documents; plus (ii) the Hedging Obligations (if any) at such time; plus (iii) any obligations under Service Agreements at such time; provided that if otherwise specified or required by the context, "Obligations" shall mean any portion of the foregoing.

"Outstanding Advances" means, at any time, the aggregate of the Borrower's obligations to any Lender in respect of all Advances made under Facility 1 which have not been repaid or satisfied at such time, determined as follows: (i) in the case of Prime Rate Loans, the principal amount thereof; (ii) in the case of Bankers’ Acceptances and BA Equivalent Notes, the face amount thereof; and (iii) in the case of Base Rate Loans and LIBOR Loans, the Equivalent Amount thereof expressed in Canadian Dollars.

- 15 -

"Owned Properties" means all Land owned by the Companies from time to time, specifically including as at the date of this Agreement the Land described in Schedule 7.01(j) attached hereto.

“Patents” means all rights, title and interests (and all related IP Ancillary Rights) arising under any requirement of law in or relating to letters patent and applications therefor.

"Pension Plan" means (i) a "pension plan" or "plan" which is subject to the funding requirements of applicable pension benefits legislation in any jurisdiction, or (ii) any pension benefit plan or similar arrangement applicable to employees of any Company.

"Permitted Funded Debt" means, without duplication: (i) the Outstanding Advances; (ii) indebtedness of the Borrower to each holder of a Bankers' Acceptance (and for greater certainty, the Borrower's contingent obligation to each Lender which has accepted a Bankers' Acceptance comprises part of the Outstanding Advances); (iii) indebtedness of any Company to any Secured Company; (iv) Subordinated Debt; (v) indebtedness of the Companies secured by Permitted Purchase-Money Security Interests; and (vi) unsecured indebtedness which is convertible into common shares of the Borrower at the option of the Borrower, provided that the Borrower is in compliance with the financial covenants in Section 7.03 both immediately before and immediately after the incurrence of such convertible indebtedness.

"Permitted Liens" means:

(a)	Statutory Liens in respect of any amount which is not at the time overdue;
(b)	Statutory Liens in respect of any amount which may be overdue but the validity of which is being contested in good faith and in respect of which reserves have been established in accordance with GAAP;
(c)	Liens or rights of distress reserved in or exercisable under any lease for rent not at the time overdue or for compliance with the terms of such lease not at the time in default; and security deposits given under leases not in excess of six (6) months' rent;
(d)	any obligations or duties affecting any Land due to any public utility or to any municipality or government, or to any statutory or public authority, with respect to any franchise, grant, licence or permit in good standing and any defects in title to structures or other facilities arising solely from the fact that such structures or facilities are constructed or installed on Land under government permits, leases or other grants in good standing; which obligations, duties and defects in the aggregate do not materially impair the use of such property, structures or facilities for the purpose for which they are held;
(e)	Liens incurred or deposits of cash made or pledged to secure obligations under workers' compensation legislation or similar legislation, or in connection with contracts, bids, tenders or expropriation proceedings, surety or appeal bonds, costs of litigation when required by law, public and statutory obligations, and warehousemen's, storers', repairers', carriers' and other similar Liens and deposits;

- 16 -

(f)	security given to a public utility or any municipality or government or to any statutory or public authority to secure obligations incurred to such utility, municipality, government or other authority in the ordinary course of business and not at the time overdue;
(g)	Liens and privileges arising out of a judgment or an award (not otherwise constituting an Event of Default) in respect of which an appeal or proceeding for review has been commenced and a stay of execution pending such appeal or proceedings for review has been obtained, and in respect of which reserves have been established in accordance with GAAP;
(h)	any Lien affecting any Land arising in connection with the construction or improvement of such Land or arising out of the furnishing of materials or supplies therefor, provided that such Lien secures moneys not at the time overdue (or if overdue, the validity of which is being contested in good faith and in respect of which reserves have been established as reasonably required by the Required Lenders), notice of such Lien has not been given to the Agent or any Lender and such Lien has not been registered against title to such Land;
(i)	Liens affecting any Land arising in connection with registered restrictions, covenants, land use contracts, building schemes, declarations of covenants, conditions and restrictions, servicing agreements in favour of any Governmental Authority, easements, rights-of-way, servitudes or other similar rights in or with respect to such Land (including open space and conservation easements, restrictions or similar agreements and rights of way and servitudes for railways, water, sewer, drainage, gas and oil pipelines, electricity, light, power, telephone, telegraph, internet or cable television services and utilities) granted to or reserved by other Persons or properties, which, in the aggregate, do not materially impair the use of such Land for its intended purposes or the operation of the business thereon, and provided that same have been complied with;
(j)	Liens affecting any Land arising in connection with site plan agreements, subdivision agreements, development agreements and similar instruments registered or recorded in the ordinary course of business which do not, in the aggregate, materially impair the use of such Land for its intended purposes or the operation of the business thereon, and provided that same have been complied with;
(k)	Liens affecting any Land arising in connection with any right reserved to or vested in any Governmental Authority, by the terms of any permit, licence, certificate, order, grant, classification (including any zoning Laws and ordinances and similar legal requirements), registration or other consent, approval or authorization acquired by such Person from any Governmental Authority or by any Law, to terminate any such permit, licence, certificate, order, grant, classification, registration or other consent, approval or authorization or to require annual or other payments as a condition to the continuance thereof and which, in the aggregate, do not materially impair the use of such Land for its intended purposes or the operation of the business thereon, and provided that same have been complied with;

- 17 -

(l)	Liens affecting any Land arising in connection with the reservations, limitations, provisos and conditions, if any, expressed in any grants of such Land from any Governmental Authority, which, in the aggregate, do not materially impair the use of such Land for its intended purposes or the operation of the business thereon, and provided that same have been complied with;
(m)	Permitted Purchase-Money Security Interests;
(n)	Liens securing Subordinated Debt;
(o)	Liens securing indebtedness of a Company to a Secured Company;
(p)	the Specific Permitted Liens; and
(q)	the Security;

provided that the use of the term "Permitted Liens" to describe the foregoing Liens shall mean that such Liens are permitted to exist (whether in priority to or subsequent in priority to the Security, as determined by Applicable Law); and for greater certainty such Liens shall not be entitled to priority over the Security by virtue of being described in this Agreement as "Permitted Liens".

"Permitted Purchase-Money Security Interests" means Purchase-Money Security Interests incurred or assumed in connection with the purchase, leasing or acquisition of capital equipment in the ordinary course of business and without resulting in a contravention of any applicable provisions of this Agreement (for greater certainty, specifically including paragraphs 7.02(g) and 7.03(c)); and provided further that the aggregate amount thereof incurred or assumed in each Fiscal Year does not exceed One Hundred Thousand Dollars ($100,000).

"Person" is defined in the CBA Model Provisions.

"Prime Rate" means the greater of the following: (i) the rate of interest announced from time to time by BMO as its reference rate then in effect for determining rates of interest on Canadian dollar loans to its customers in Canada and designated as its prime rate; and (ii) the thirty (30) day CDOR Rate plus one-half percent (0.5%) per annum.

"Prime Rate Loan" means a loan made by a Lender to the Borrower in Canadian Dollars in respect of which interest is determined by reference to the Prime Rate, but excluding Advances in the form of BA Equivalent Loans.

"Proceeds of Realization", in respect of the Security or any portion thereof, means all amounts received by the Agent or any Lender in connection with:

• any realization thereof, whether occurring as a result of enforcement or otherwise;

• any sale, expropriation, loss or damage or other disposition of the Collateral or any portion thereof (other than a disposition of Collateral made pursuant to paragraph 7.02(c)); and

- 18 -

• the dissolution, liquidation, bankruptcy or winding-up of any Company or any other distribution of its assets to creditors;

and all other amounts which are expressly deemed to constitute "Proceeds of Realization" in this Agreement.

"Properties" means the Owned Properties and the Leased Properties.

"Proportionate Share" in respect of any Lender means:

• in the context of such Lender's obligation to make Advances under Facility 1, such Lender's Commitment to make Advances under Facility 1 divided by the aggregate amount of all Lenders' Commitments to make Advances under Facility 1; and

• subject to section 11.03, in the context of each Lender's entitlement to receive payments of principal, interest or fees under Facility 1, the Outstanding Advances due to such Lender under Facility 1 divided by the aggregate amount of the Outstanding Advances due to all Lenders under Facility 1;

"Purchase-Money Security Interest" means (i) a Capital Lease; or (ii) a Lien on any property or asset which is created, issued or assumed to secure the unpaid purchase price thereof, provided that such Lien is restricted to such property or asset (and all additions thereto, replacements and proceeds thereof) and secures an amount not in excess of the purchase price thereof and any interest and fees payable in respect thereof.

"Related Person" in relation to any Person means a Subsidiary, Affiliate, Associate or employee of such Person.

"Repayment" means a repayment by the Borrower on account of the Outstanding Advances.

"Repayment Notice" means a notice delivered by the Borrower to the Agent committing it to make a Repayment, in the form of Exhibit "E".

"Required Lenders" means, (i) at any time prior to the occurrence of an Event of Default which is continuing, any two or more Lenders which have issued Commitments hereunder representing two-thirds (2/3) or more of the aggregate amount of all Lenders' Commitments; and (ii) at any time after the occurrence of an Event of Default which is continuing, any two or more Lenders which have Outstanding Advances representing two-thirds (2/3) or more of the total amount of the Outstanding Advances under Facility 1; provided however that if at any time there are only two (2) Lenders under this Agreement, "Required Lenders" shall mean both such Lenders, and if at any time there is only one (1) Lender under this Agreement, "Required Lenders" shall mean such Lender.

"Requirements of Environmental Law" means: (i) obligations under common law; (ii) requirements imposed by or pursuant to statutes, regulations and by-laws whether presently or hereafter in force; (iii) directives, policies and guidelines issued or relied upon by any Governmental Authority to the extent such directives, policies or guidelines have the force of law; (iv) permits, licenses, certificates and approvals from Governmental Authorities which are required in connection with air emissions, discharges to surface or groundwater, noise emissions, solid or liquid waste disposal, the use, generation, storage, transportation or disposal of Hazardous Materials; and (v) requirements imposed under any clean-up, compliance or other order made pursuant to any of the foregoing, in each and every case relating to environmental, health or safety matters including all such obligations and requirements which relate to (A) solid, gaseous or liquid waste generation, handling, treatment, storage, disposal or transportation of Hazardous Materials and (B) exposure to Hazardous Materials.

- 19 -

"Rollover" means the renewal of an Availment Option upon its maturity in the same form.

"Rollover Notice" means a notice substantially in the form of Exhibit "C" given by the Borrower to the Agent for the purpose of requesting a Rollover.

"Secured Company" means a Company which (i) is not an Excluded Subsidiary; and (ii) has provided in favour of the Agent all Security required to be provided by it hereunder.

"Security" means all Guarantees, security agreements, mortgages, debentures and other documents required to be provided to the Agent or the Lenders pursuant to Article VIII and all other documents and agreements delivered by the Companies and any other Persons to the Agent for the benefit of the Lenders from time to time as security for the payment and performance of the Obligations, and the security interests, assignments and Liens constituted by the foregoing.

"Senior Funded Debt" means the Outstanding Advances and all other Funded Debt of the Companies on a consolidated basis, excluding Subordinated Debt.

“Series A Preferred Shares” means the series A preferred shares issued by the Borrower (which, in accordance with the conditions attached thereto, will not be redeemable at the option of the holder following the completion of the Sintrom Purchase Transaction).

"Service Agreements" means all agreements from time to time made between any Company and BMO or any of its Affiliates in respect of cash management, payroll or other banking services, including agreements relating to any corporate MasterCards issued by BMO to the Companies’ employees from time to time at the request and for the account of the Borrower.

"Sintrom" means the drug product known as Sintrom, which is defined in the Sintrom Purchase Agreement as the “Product”.

"Sintrom License Agreement" means the license agreement among Novartis, the Borrower and Merus Luxco dated as of September 5, 2014 under which Novartis grants in favour of Merus Luxco (i) an exclusive, perpetual, royalty-free, fully paid-up license under the Licensed IP and Trademarks to market, sell, use and commercialize the Product in the Field in the Territory and to manufacture or have manufactured the Product for use in the Field in the Territory; and (ii) a non-exclusive, perpetual, and fully-paid license under the Licensed IP to develop and use New Technical IP, subject to certain exceptions as set out therein (the terms “Licensed IP”, “Trademarks”, “Product”, “Field” and “Territory” having the respective meanings ascribed thereto in the Sintrom Purchase Agreement and the term “New Technical IP” having the meaning ascribed thereto in the Sintrom License Agreement).

- 20 -

"Sintrom Marketing Authorizations" means the Marketing Authorizations in respect of Sintrom for each country in the Territory (as such term is defined in the Sintrom Purchase Agreement), specifically including for greater certainty Spain, Italy, Greece, Bulgaria and Romania.

“Sintrom Purchase Agreement” means the asset purchase agreement between Novartis, the Borrower and Merus Luxco dated as of September 5, 2014.

“Sintrom Purchase Transaction” means the transaction contemplated by the Novartis Sintrom Agreements.

"Sintrom Rights" means, collectively: (i) the “Transferred Assets” as such term is defined in the Sintrom Purchase Agreement; (ii) all rights of the Borrower under the Sintrom License Agreement; and (iii) all rights of the Borrower and Merus Netherlands under the Sintrom Supply Agreement.

“Sintrom Supply Agreement" means the supply agreement between Novartis, the Borrower, Merus Luxco and Merus Netherlands dated as of September 5, 2014.

“Solvent” means, with respect to any Credit Party as of the date of determination, (i) the aggregate property of such Credit Party is sufficient, if disposed of at a fairly conducted sale under legal process, to enable payment of all its obligations, due and accruing due; (ii) such Credit Party is able to meet its obligations as they generally become due; and (iii) such Credit Party has not ceased paying its current obligations in the ordinary course of business as they generally become due; for purposes of this definition, the amount of any contingent obligation at such time shall be computed as the amount that, in light of all of the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability; provided however that with respect to any Credit Party incorporated or organized under the laws of a jurisdiction other than Canada, such Credit Party shall be considered “Solvent” if it satisfies the foregoing requirements and also satisfies all other solvency requirements under Applicable Law in such jurisdiction; and, with respect to a Luxembourg Guarantor, such entity is not unable to pay its debts (in particular, it is not in a state of cessation of payments (cessation de paiements) and has not lost its commercial creditworthiness).

"Specific Permitted Liens" means the Liens described in Schedule 7.01(i), as such Liens may be amended or replaced from time to time on substantially similar terms and conditions provided that the principal amount of the indebtedness secured thereby is not increased.

"Statutory Lien" means a Lien in respect of any property or assets of a Company created by or arising pursuant to any applicable legislation in favour of any Governmental Authority to secure any obligation, including a Lien for the purpose of securing such Company's obligation to deduct and remit employee source deductions and goods and services tax pursuant to the Income Tax Act (Canada), the Excise Tax Act (Canada), the Canada Pension Plan (Canada), the Employment Insurance Act (Canada) and any legislation in any jurisdiction similar to or enacted in replacement of the foregoing from time to time.

"Subordinated Debt" means indebtedness of any Company to any Person in respect of which all of the following requirements are satisfied: (i) the Lenders acting reasonably have provided their written consent thereto, (ii) if incurred after the date hereof, the Borrower was in compliance with the financial covenants in Section 7.03 both immediately before and immediately after the incurrence of such indebtedness, and (iii) the holder thereof has entered into a subordination and postponement agreement in favour of the Agent in form and substance satisfactory to the Agent and registered in all places where necessary or desirable to protect the priority of the Security, which shall provide (among other things) that: (A) the maturity date of such indebtedness is later than the Maturity Date; (B) the holder of such indebtedness may not receive any payments on account of principal or interest thereon (except to the extent, if any, expressly permitted therein); (C) any security held in respect of such indebtedness is subordinated to the Security; (D) the holder of such indebtedness may not take any enforcement action in respect of any such security (except to the extent, if any, otherwise expressly provided therein) without the prior written consent of the Agent; and (E) any enforcement action taken by the holder of such indebtedness will not interfere with the enforcement action (if any) being taken by the Agent in respect of the Security.

- 21 -

"Subsidiary" means a business entity which is Controlled, directly or indirectly, by another business entity (as used herein, "business entity" includes a corporation, company, partnership, limited partnership, trust or joint venture); and for greater certainty includes a Subsidiary of a Subsidiary.

"Taxes" is defined in the CBA Model Provisions.

"Total Funded Debt" means the Outstanding Advances and all other Funded Debt of the Companies on a consolidated basis, for greater certainty specifically including Subordinated Debt.

“Trade Secrets” means all right, title and interest (and all related IP Ancillary Rights) arising under any requirement of law in or relating to trade secrets.

“Trademark” means all rights, title and interests (and all related IP Ancillary Rights) arising under any requirement of law in trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers and, in each case, all goodwill associated therewith, all registrations and recordations thereof and all applications in connection therewith.

"U.S. Dollars" or "U.S.$" means the lawful money of the United States.

"Year-end Financial Statements" means, in respect of any Fiscal Year, the audited financial statements of the Borrower on a consolidated basis in respect of such Fiscal Year, including the notes thereto.

1.02 Accounting Principles

Unless otherwise specifically provided herein, any accounting term used in this Agreement shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP consistently applied. That certain items or computations are explicitly modified by the phrase "in accordance with GAAP" shall in no way be construed to limit the foregoing. If there occurs after the date hereof any change in GAAP from that used in the preparation of the financial statements referred to herein, after the date hereof the Borrower and its Subsidiaries adopt any other accounting principles for use in the preparation of their financial statements (such changes in GAAP and such adoption being referred to herein as "Accounting Changes") that affects in any respect the calculation of any covenants contained in this Agreement (including those in section 7.03), the Lenders and the Borrower shall discuss whether they wish to amend any relevant provisions of this Agreement that relate to the calculation of such covenants with the intent of having their respective positions after such Accounting Changes conform as nearly as possible to their respective positions as of the date of this Agreement. Unless any such amendments have been agreed upon by all parties hereto in writing, compliance with the financial covenants in this Agreement shall be determined as if no such Accounting Change had occurred. In such event, the financial statements required to be provided by the Borrower hereunder shall be prepared in accordance with GAAP in effect on the date of such financial statements (after giving effect to such Accounting Change), and the Borrower shall concurrently deliver to the Agent a reconciliation in form and substance satisfactory to the Lenders showing all adjustments made to financial statements in order to determine compliance with such financial covenants on the basis of GAAP in effect prior to such Accounting Change.

- 22 -

1.03 Currency References

All amounts referred to in this Agreement are in Canadian Dollars unless otherwise noted.

1.04 Extended Meanings

Unless otherwise specified, words importing the singular include the plural and vice versa and words importing gender include all genders. Unless otherwise specified, references in this Agreement to sections, Schedules and Exhibits are to sections of, and schedules and Exhibits to, this Agreement. Unless otherwise specified, each reference to an enactment of legislation is deemed to be a reference to that enactment of legislation, and to the regulations made under that enactment, as amended or re-enacted from time to time. Unless otherwise specified, references to time of day or date mean the local time or date in the City of Toronto, Ontario. "Including" means "including without limitation" and the term "including" shall not be construed to limit any general statement that precedes such term to the specific or similar items or matters immediately following it. Unless expressly qualified by the phrase "acting reasonably" or an equivalent phrase, the phrase "discretion" means "sole discretion" and any action to be taken or decision to be made by the Agent or the Lenders in their discretion shall mean that such discretion is absolute and unfettered.

1.05 Luxembourg Terms

Without prejudice to the generality of any provision of this Agreement, in this Agreement where it relates to a Luxembourg Guarantor, a reference to: (a) a winding-up, administration or dissolution includes, without limitation, bankruptcy (faillite), insolvency, liquidation, composition with creditors (concordat prventif de faillite), moratorium or reprieve from payment (sursis de paiement), controlled management (gestion contrle), fraudulent conveyance (action paulienne), general settlement with creditors, reorganization or similar laws affecting the rights of creditors generally; (b) a receiver, administrative receiver, administrator, trustee, custodian, sequestrator, conservator or similar officer includes, without limitation, a juge dlgu, commissaire, juge-commissaire, mandataire ad hoc, administrateur provisoire, liquidateur or curateur; (c) a lien or security interest includes any hypothèque, nantissement, gage, privilege, sûret relle, droit de rtention, and any type of security in rem (sret relle) or agreement or arrangement having a similar effect and any transfer of title by way of security; (d) a person being unable to pay its debts includes that person being a state of cessation de paiements; (e) creditors process means an executory attachment (saisie excutoire) or conservatory attachment (saisie conservatoire); (f) a guarantee includes any garantie which is independent from the debt to which it relates and excludes any suretyship (cautionnement) within the meaning of Articles 2011 and seq. of the Luxembourg Civil Code; (g) by-laws or constitutional documents includes its up-to-date (restated) articles of association (statuts coordonns) and (h) a director includes a grant or an administrateur.

- 23 -

1.06 Exhibits and Schedules

The following exhibits and schedules are attached to this Agreement and incorporated herein by reference (but with respect to Exhibit H, subject to section 12.01 hereof):

Exhibits
"A"	-	Lenders and Lenders' Commitments
"B"	-	Draw Request
"C"	-	Rollover Notice
"D"	-	Conversion Notice
"E"	-	Repayment Notice
"F"	-	Compliance Certificate
"G"	-	Form of BA Equivalent Note
"H"	-	CBA Model Provisions
Schedules
6.01(b)	-	Corporate Information
6.01(h)	-	Material Permits
6.01(i)	-	Specific Permitted Liens
6.01(j)	-	Owned Properties
6.01(k)	-	Leased Properties
6.01(l)	-	Intellectual Property
6.01(m)	-	Insurance Policies
6.01(n)	-	Material Agreements
6.01(o)	-	Labour Agreements
6.01(p)	-	Environmental Matters
6.01(q)	-	Litigation
6.01(r)	-	Pension Plans

- 24 -

ARTICLEII - FACILITY 1

2.01 Establishment of Facility 1

Subject to the terms and conditions in this Agreement, each Lender hereby establishes a committed, non-revolving credit facility for the Borrower in the maximum principal amount indicated opposite such Lender's name in Exhibit "A" under the heading "Facility 1 Commitments". The said credit facilities are established by the Lenders severally and not jointly, and are hereinafter collectively referred to as "Facility 1". Each Advance by a Lender under Facility 1 shall be made in its Proportionate Share of Facility 1.

2.02 Purpose

The proceeds of the Advance under Facility 1 shall be used by the Borrower for the following purposes: (i) to repay and satisfy in full all indebtedness of the Borrower under its existing credit facilities; and (ii) to assist the Borrower in completing the Sintrom Purchase Transaction in accordance with the terms and conditions of the Novartis Sintrom Agreements.

2.03 Non-Revolving Nature

Facility 1 shall be a non-revolving facility, and any Repayment under Facility 1 may not be reborrowed. A single Advance shall be made under Facility 1 on the Closing Date, and any unadvanced portion of Facility 1 thereafter shall be cancelled.

2.04 Repayment

(a)	The Obligations under Facility 1 shall become due and payable upon the earliest of: (i) the occurrence of an Insolvency Event (for greater certainty, without the necessity of a demand for payment by the Agent); (ii) the Maturity Date (for greater certainty, without the necessity of a demand for payment by the Agent); and (iii) delivery by the Agent to the Borrower of written notice that all Obligations under Facility 1 are immediately due and payable, following the occurrence and during the continuation of an Event of Default other than an Insolvency Event.
(b)	Subject to the Obligations under Facility 1 becoming due and payable in accordance with paragraph (a), the Borrower shall make quarterly Repayments on account of the Outstanding Advances under Facility 1 on the last day of each Fiscal Quarter, the first such Repayment to be made on the last day of the first complete Fiscal Quarter following the Closing Date. The amount of each said quarterly Repayment shall be equal to five percent (5%) of the amount of the Outstanding Advances under Facility 1 immediately following the Advance under Facility 1 on the Closing Date. The remaining balance of the Outstanding Advances under Facility 1 shall be due and payable on the Maturity Date.
(c)	In addition to all other Repayments required under this section 2.04, not later than one hundred twenty (120) days after the end of each Fiscal Year the Borrower shall make a Repayment in an amount equal to fifty percent (50%) of the Excess Cash Flow in such Fiscal Year. For greater certainty, the first such Repayment shall be made in respect of the Fiscal Year ending September 30, 2015.

- 25 -

(d) If any Company receives:

(i)	payments under a policy of insurance, except to the extent that such payments are permitted to be retained or used by such Company as provided in section 8.09; or
(ii)	net proceeds from a transaction involving the sale, leasing or other disposition of any individual asset or group of related assets (other than inventory sold in the ordinary course of business) in one or a series of related transactions, less the portion of such net proceeds (if any) used to purchase replacement capital assets within one hundred eighty (180) days after such disposition;

then the Borrower agrees to make a Repayment under Facility 1 in an amount equal to such payments or net proceeds within five (5) Business Days after such payments or net proceeds are received by such Company in the case of clause (i) above, and within one hundred eighty-five (185) days after such payments or net proceeds are received by such Company in the case of clause (ii) above; provided further that the first One Million Dollars ($1,000,000) of net proceeds received by the Companies pursuant to clause (ii) above and not used to purchase replacement capital assets in each Fiscal Year shall not be required to be paid to the Agent under clause (ii) above. As used herein, "net proceeds" in respect of any such transaction means the gross amount payable to the Company in respect of such transaction less any sales commissions, reasonable costs and expenses of such transaction paid to Persons other than Related Persons, usual and reasonable adjustments in connection with the transaction, Taxes payable in connection with or as a result of the transaction, and any other amount specifically approved by the Agent, acting reasonably, in writing. Each Repayment made pursuant to this paragraph 2.04(d) shall be applied against the Outstanding Advances under Facility 1 on a pari passu basis, or as may be otherwise determined by the Lenders in their discretion.

(e) Each Repayment under each paragraph (c) and (d) in this section 2.04 is in addition to and not in substitution for all other Repayments required under each other paragraph in this section 2.04. All such Repayments shall be applied in reverse chronological order.

2.05 Availment Options

Subject to the restrictions contained in this Agreement (and in particular, sections 5.02 and 5.03), the Borrower may receive Advances under Facility 1 by any one or more of the following Availment Options (or any combination thereof):

(a)	Prime Rate Loans; or
(b)	Bankers' Acceptances from BA Lenders with a maturity between 28 and 182 days (inclusive), subject to availability; or
(c)	BA Equivalent Loans from Non-BA Lenders with a maturity between 28 and 182 days (inclusive), subject to availability; or
(d)	Base Rate Loans; or

- 26 -

(e) LIBOR Loans with a LIBOR Period of one (1), two (2) or three (3) months, subject to availability.

Bankers' Acceptances, BA Equivalent Loans and LIBOR Loans will not be issued with a maturity date later than the Maturity Date. The Borrower may convert all or any portion of the Outstanding Advances under Facility 1 in the form of any above Availment Option into another form of Availment Option, subject to and in accordance with the terms and conditions of this Agreement (but for greater certainty, Bankers' Acceptances, BA Equivalent Loans and LIBOR Loans may not be converted into another Availment Option prior to the maturity thereof).

2.06 Interest and Fees

In respect of Advances under Facility 1, the Borrower agrees to pay the following:

(a)	interest on Prime Rate Loans at the Prime Rate plus the Applicable Margin per annum, payable monthly in arrears on the last day of each and every month;
(b)	interest on Base Rate Loans at the Base Rate plus the Applicable Margin per annum, payable monthly in arrears on the last day of each and every month;
(c)	in respect of each Bankers' Acceptance, a stamping fee equal to the Applicable Margin, multiplied by the face amount of the Bankers' Acceptance with the product thereof further multiplied by the number of days to maturity of the Bankers' Acceptance and divided by 365, payable at the time of acceptance;
(d)	in respect of each BA Equivalent Note, a stamping fee equal to the Applicable Margin multiplied by the face amount of the BA Equivalent Note with the product thereof further multiplied by the number of days to maturity of the BA Equivalent Note and divided by 365, payable at the time of acceptance; and
(e)	interest on LIBOR Loans at the LIBO Rate plus the Applicable Margin per annum calculated on the basis of a year of three hundred and sixty (360) days, payable in the manner set out in paragraph 4.04(b).

Except as otherwise provided in this Agreement, such payments shall be made to the Agent on behalf of the Lenders; and the Agent shall promptly remit to each Lender its Proportionate Share of each such payment.

- 27 -

2.07 Voluntary Repayments

Upon not less than three (3) Business Days' prior written notice to the Agent, the Borrower may make a Repayment on account of Prime Rate Loans outstanding under Facility 1 in a minimum amount and multiple of One Hundred Thousand Dollars ($100,000), or Base Rate Loans outstanding under Facility 1 in a minimum amount and multiple of One Hundred Thousand United States Dollars (U.S.$100,000), without payment of any penalty or fee. Any such voluntary Repayment shall be applied against the Borrower's obligations to make scheduled Repayments under Facility 1 in reverse chronological order; and the Facility 1 Maximum Amount shall be automatically and permanently reduced by any such voluntary Repayment. The Agent shall promptly remit to each Lender its Proportionate Share of any such voluntary Repayment. For greater certainty however, Bankers' Acceptances, BA Equivalent Loans and LIBOR Loans may not be repaid prior to the maturity thereof.

- 28 -

ARTICLE III - HEDGE TRANSACTIONS

3.01 Hedge Transactions

(a)	BMO (for greater certainty, in its capacity as a Lender hereunder and not in its capacity as the Agent) shall act as lead arranger for all Hedge Transactions to be entered into between the Borrower and the Lenders hereunder which are willing to enter into Hedge Transactions. Each Hedge Transaction entered into between the Borrower and a Lender shall be upon such terms as may be offered by such Lender in its discretion, subject to the terms of this Agreement.
(b)	Hedge Transactions may not be entered into for speculative purposes.
(c)	The term of each Currency Hedge Transaction shall expire not later than the earlier of (a) twelve (12) months from the date of such Currency Hedge Transaction, and (b) the Maturity Date.
(d)	The term of each Interest Rate Hedge Transaction shall expire not later than the earlier of (a) five (5) years from the date of such Interest Rate Hedge Transaction, and (b) the Maturity Date.
(e)	In respect of each Hedge Transaction entered into between the Borrower and a Lender, the Borrower agrees to execute and deliver to such Lender all such Loan Documents as it may reasonably require (for greater certainty, specifically including an ISDA master agreement).
(f)	The Security shall secure all obligations owing under or in respect of each Hedge Transaction; and the priority of such obligations shall rank on a pari passu basis with all other Obligations as provided in section 8.01.
(g)	The Borrower will not enter into or be a party to any Hedge Transactions with any Persons other than the Lenders (provided that, for greater certainty, it shall be in the discretion of each Lender to enter into any Hedge Transaction).
(h)	Each Hedge Transaction made with a Lender shall include such Lender's standard early termination events. Without limiting the generality of the foregoing, each Hedge Transaction shall also stipulate that the termination of Facility 1 shall constitute an Early Termination Event (as defined in the applicable ISDA Master Agreement) and the Affected Party (as defined in such ISDA Agreement) shall be the counter-party to the Lender in such contract. The Lender shall have the right to choose the payment measure and the payment method (as such terms are understood in the ISDA Master Agreement) in respect of such Early Termination Event.
(i)	On or before the Maturity Date the Borrower shall (i) unwind all Hedge Transactions (and pay all applicable unwinding costs in respect thereof); or (ii) provide cash collateral in favour of the Agent in respect of all outstanding Hedge Transactions in an amount satisfactory to the applicable Lender. For greater certainty, the Agent shall have no obligation to release all or any portion of the Security unless and until all Hedge Transactions are terminated or such cash collateral is provided in respect thereof.

- 29 -

ARTICLE IV - BANKERS’ ACCEPTANCES, BA EQUIVALENT LOANS AND LIBOR LOANS

4.01 Commitment to Purchase Bankers' Acceptances and BA Equivalent Notes

(a) In connection with the issuance of each Bankers' Acceptance or BA Equivalent Note, the amount payable by the purchaser thereof to the Borrower shall be determined in accordance with the following formula:

             F             
1 + (D x T/365)

where:

F     means the face amount of such Bankers’ Acceptance or BA Equivalent Note,

D     means the discount rate (being the Applicable Margin in respect of the issuance of Bankers’ Acceptances or BA Equivalent Notes), and

T     means the number of days to maturity of such Bankers’ Acceptance or BA Equivalent Note,

with the amount as so calculated being rounded up or down to the fifth decimal place and with 0.000005 being rounded up.

(b)	Each BA Lender which is a bank listed in Schedule I of the Bank Act (Canada) agrees to purchase those Bankers' Acceptances which it has accepted at a discount from the face amount thereof equal to the CDOR Rate for the relevant period in effect on the issuance date thereof; provided however that if BMO is the only BA Lender, the discount rate shall be the applicable discount rate established by BMO on the issuance date thereof.
(c)	Each BA Lender which is a bank listed in Schedule II or Schedule III of the Bank Act (Canada) agrees to purchase those Bankers' Acceptances which it has accepted at a discount from the face amount thereof equal to the CDOR Rate for the relevant period in effect on the issuance date thereof plus a premium determined by such BA Lender not in excess of one-tenth of one percent (0.10%) per annum.
(d)	Each Non-BA Lender agrees to purchase BA Equivalent Notes issued by it hereunder at a discount from the face amount thereof equal to the CDOR Rate for the relevant period in effect on the issuance date thereof.
(e)	The discount applicable to each Bankers' Acceptances and BA Equivalent Note shall be determined on the basis of a year of 365 days.

4.02 Special Provisions Regarding Bankers' Acceptances

The following provisions are applicable to Bankers' Acceptances issued by the Borrower and accepted by any BA Lender hereunder:

- 30 -

Payment of Bankers' Acceptances

(a) The Borrower agrees to provide for each Bankers' Acceptance by payment of the face amount thereof to the Agent on behalf of the BA Lender on the maturity of the Bankers' Acceptance or, prior to such maturity, on the Acceleration Date; and the Agent shall remit the said amount to such BA Lender and such BA Lender shall in turn remit such amount to the holder of the Bankers' Acceptance. If the Borrower fails to provide for the payment of the Bankers' Acceptance accordingly, any amount not so paid shall be immediately payable by the Borrower to the Agent on behalf of the BA Lender together with interest on such amount calculated daily and payable monthly at the rate and in the manner applicable to Prime Rate Loans under Facility 1. The Borrower agrees not to claim any days of grace for the payment at maturity of any Bankers' Acceptance and agrees to indemnify and save harmless the BA Lender in connection with all payments made by the BA Lender (or by the Agent on its behalf) pursuant to Bankers' Acceptances accepted by the BA Lender, together with all reasonable costs and expenses incurred by the BA Lender in this regard. The Borrower hereby waives any defences to payment which might otherwise exist if for any reason a Bankers' Acceptance is held by the BA Lender for its own account at maturity.

Availability of Bankers' Acceptances

(b) If at any time and from time to time the Agent determines, acting reasonably, that there no longer exists a market for Bankers' Acceptances for the term requested by the Borrower, or at all, the Agent shall so advise the Borrower, and in such event the BA Lenders shall not be obliged to accept and the Borrower shall not be entitled to issue Bankers' Acceptances.

Power of Attorney

(c) The Borrower hereby appoints each BA Lender as its true and lawful attorney to complete and issue Bankers' Acceptances on behalf of the Borrower in accordance with written (including facsimile) transmitted instructions provided by the Borrower to the Agent on behalf of such BA Lender, and the Borrower hereby ratifies all that its said attorney may do by virtue thereof except anything done that constitutes negligence or wilful misconduct by the BA Lender. The Borrower agrees to indemnify and hold harmless the Agent and the BA Lenders and their respective directors, officers and employees from and against any charges, complaints, costs, damages, expenses, losses or liabilities of any kind or nature which they may incur, sustain or suffer, arising from or by reason of acting, or failing to act, as the case may be, in reliance upon this power of attorney, except to the extent caused by the negligence or wilful misconduct of the Agent or the BA Lender or their respective directors, officers and employees. The Borrower hereby agrees that each Bankers' Acceptance completed and issued and accepted in accordance with this section by a BA Lender on behalf of the Borrower is a valid, binding and negotiable instrument of the Borrower as drawer and endorser. The Borrower agrees that each BA Lender's accounts and records will constitute prima facie evidence of the execution and delivery by the Borrower of Bankers' Acceptances. This power of attorney shall continue in force until the earlier of (i) delivery of written notice of revocation by the Borrower to the Agent on behalf of the BA Lender at the Agent's address provided in section 13.08, and (ii) the termination of this Agreement.

- 31 -

4.03 Special Provisions regarding BA Equivalent Notes

Each Non-BA Lender will not accept Bankers' Acceptances hereunder, and shall instead from time to time make BA Equivalent Loans to the Borrower. Each BA Equivalent Loan shall be evidenced by a non-interest bearing promissory note payable by the Borrower to the Non-BA Lender substantially in the form of Exhibit "G" attached hereto, which will be purchased by the Non-BA Lender. Each BA Equivalent Note shall be negotiable by the Non-BA Lender without notice to or the consent of the Borrower, and the holder thereof shall be entitled to enforce such BA Equivalent Note against the Borrower free of any equities, defences or rights of set-off that may exist between the Borrower and the Non-BA Lender. In this Agreement, all references to a BA Equivalent Note shall mean the loan evidenced thereby if required by the context; and all references to the "issuance" of a BA Equivalent Note by a Non-BA Lender and similar expressions shall mean the making of a BA Equivalent Loan by the Non-BA Lender which is evidenced by a BA Equivalent Note. The following provisions are applicable to each BA Equivalent Loan made by a Non-BA Lender to the Borrower hereunder:

Payment of BA Equivalent Notes

(a) The Borrower agrees to provide for each BA Equivalent Note by payment of the face amount thereof to the Agent on behalf of the Non-BA Lender on the maturity of the BA Equivalent Note or, prior to such maturity, on the Acceleration Date; and the Agent shall remit the said amount to such Non-BA Lender and such Non-BA Lender shall in turn remit such amount to the holder of the BA Equivalent Note. If the Borrower fails to provide for the payment of the BA Equivalent Note accordingly, any amount not so paid shall be immediately payable by the Borrower to the Agent on behalf of the Non-BA Lender together with interest on such amount calculated daily and payable monthly at the rate and in the manner applicable to Prime Rate Loans under Facility 1. The Borrower agrees not to claim any days of grace for the payment at maturity of any BA Equivalent Note and agrees to indemnify and save harmless the Non-BA Lender in connection with all payments made by the Non-BA Lender (or by the Agent on its behalf) pursuant to BA Equivalent Notes accepted by the Non-BA Lender, together with all reasonable costs and expenses incurred by the Non-BA Lender in this regard. The Borrower hereby waives any defences to payment which might otherwise exist if for any reason a BA Equivalent Note is held by the Non-BA Lender for its own account at maturity.

Availability of BA Equivalent Loans

(b) The Non-BA Lender shall have no obligation to make BA Equivalent Loans during any period in which the BA Lenders' obligation to issue Bankers' Acceptances is suspended pursuant to section 3.5 of the CBA Model Provisions.

Power of Attorney

(c) The Borrower hereby appoints the Non-BA Lender as its true and lawful attorney to complete BA Equivalent Notes on behalf of the Borrower in accordance with written (including facsimile) transmitted instructions delivered by the Borrower to the Agent, and the Borrower hereby ratifies all that its said attorney may do by virtue thereof except anything done that constitutes negligence or wilful misconduct by the Non-BA Lender. The Borrower agrees to indemnify and hold harmless the Agent and the Non-BA Lender and their respective directors, officers and employees from and against any charges, complaints, costs, damages, expenses, losses or liabilities of any kind or nature which they may incur, sustain or suffer, arising from or by reason of acting, or failing to act, as the case may be, in reliance upon this power of attorney except to the extent caused by the negligence or wilful misconduct of the Agent or the Non-BA Lender or their respective directors, officers and employees. The Borrower hereby agrees that each BA Equivalent Note completed by the Non-BA Lender on behalf of the Borrower is a valid, binding and negotiable instrument of the Borrower as drawer and endorser. The Borrower agrees that the Non-BA Lender's accounts and records will constitute prima facie evidence of the execution and delivery by the Borrower of BA Equivalent Notes. This power of attorney shall continue in force until the earlier of (i) delivery of written notice of revocation by the Borrower to the Agent on behalf of the Non-BA Lender at the Agent's address provided in section 13.08, and (ii) the termination of this Agreement.

- 32 -

4.04 Special Provisions Regarding LIBOR Loans

The following provisions are applicable to LIBOR Loans made by any Lender to the Borrower:

Draw Procedures

(a) Upon receipt by the Agent from the Borrower of a Draw Request, Conversion Notice or Rollover Notice in respect of a LIBOR Loan, the Agent will promptly advise the Borrower of the LIBO Rate, such rate to be determined as at approximately 11:00 a.m. London, England time, two (2) LIBOR Business Days before the commencement of the LIBOR Period for such LIBOR Loan.

Interest Payment Dates for LIBOR Loans

(b) Interest in respect of each LIBOR Loan shall be calculated on the basis of a year of three hundred and sixty (360) days. Interest in respect of any LIBOR Loan with a LIBOR Period of between one (1) and three (3) months (inclusive) shall be payable on the last day of each LIBOR Period.

Laws Applicable to LIBOR Loans

(c) The Borrower acknowledges that the ability of the Lenders to maintain or provide any LIBOR Loan and/or to charge interest on any LIBOR Loan at the LIBO Rate is and will be subject to any statute, law, regulation, rule or direction by any Governmental Authority having jurisdiction which may prohibit or restrict or limit such loans and/or such interest. The Borrower agrees that the Lenders shall have the right to comply with any such requirements and, if the Agent determines it to be necessary as a result of such requirement, the Agent may convert any LIBOR Loan to a Base Rate Loan or require immediate repayment of all LIBOR Loans, including accrued interest thereon.

- 33 -

4.05 No Repayment of Certain Availment Options

The Borrower acknowledges that Bankers' Acceptances, BA Equivalent Loans and LIBOR Loans may not be repaid prior to the maturity thereof. If prior to the maturity of such Availment Option the Agent receives any funds from the Borrower or any other Person which are intended to be applied as a Repayment thereof, the Agent may retain such funds without any obligation to invest such funds or pay interest thereon, and shall apply such funds against such Availment Option on the scheduled maturity date thereof.

- 34 -

ARTICLEV - GENERAL CONDITIONS

5.01 Matters relating to Interest

(a)	Unless otherwise indicated, interest on any outstanding principal amount and all other amounts payable hereunder (including unpaid interest) shall be calculated daily and shall be payable monthly in arrears on the last day of each and every month; and if the maturity date of Facility 1 is not the end of a month, all accrued and unpaid interest in respect of Facility 1 shall be paid on such maturity date. If the last day of a month is not a Business Day, the interest payment due on such day shall be made on the next Business Day, and interest shall continue to accrue on the said principal amount and shall also be paid on such next Business Day. Interest shall accrue from and including the day upon which an Advance is made or is deemed to have been made, and ending on but excluding the day on which such Advance is repaid or satisfied. Any change in the Prime Rate shall cause an immediate adjustment of the interest rate applicable to Prime Rate Loans, and any change in the US Base Rate shall cause an immediate adjustment of the interest rate applicable to Base Rate Loans, in each case without the necessity of any notice to the Borrower.
(b)	Unless otherwise stated, in this Agreement if reference is made to a rate of interest, fee or other amount "per annum" or a similar expression is used, such interest, fee or other amount shall be calculated on the basis of a year of three hundred and sixty-five (365) or three hundred and sixty-six (366) days, as the case may be. If the amount of any interest, fee or other amount is determined or expressed on the basis of a period of less than one year of three hundred and sixty-five (365) or three hundred and sixty-six (366) days, as the case may be, the equivalent yearly rate is equal to the rate so determined or expressed, divided by the number of days in the said period, and multiplied by the actual number of days in that calendar year.
(c)	Notwithstanding any other provisions of this Agreement, if the amount of any interest, premium, fees or other monies or any rate of interest stipulated for, taken, reserved or extracted under this Agreement or the Security would otherwise contravene the provisions of section 347 of the Criminal Code (Canada), section 8 of the Interest Act (Canada) or any successor or similar legislation, or would exceed the amounts which any Lender is legally entitled to charge and receive under any law to which such compensation is subject, then such amount or rate of interest shall be reduced to such maximum amount as would not contravene such provision; and to the extent that any excess has been charged or received such Lender shall apply such excess against the Outstanding Advances and refund any further excess amount.

5.02 Notice Periods

(a) The Borrower shall provide written notice to the Agent in respect of Advances, Rollovers, Conversions and Repayments as set out below:

(i) notice is required for each voluntary Repayment in accordance with section 2.07;

- 35 -

(ii)	except as provided in clauses (i) and (ii) above, one (1) Business Day's notice is required before 10:00 a.m. Toronto time in respect of any Advance, Rollover or Conversion if the amount is less than Ten Million Canadian Dollars (CDN$10,000,000);
(iii)	except as provided in clauses (i) and (ii) above, two (2) Business Days' notice is required before 10:00 a.m. Toronto time in respect of any Advance, Rollover or Conversion if the amount is equal to or greater than Ten Million Dollars (CDN$10,000,000) but less than Twenty-Five Million Canadian Dollars (CDN$25,000,000);
(iv)	except as provided in clauses (i) and (ii) above, three (3) Business Days' notice is required before 10:00 a.m. Toronto time in respect of any Advance, Rollover or Conversion if the amount is equal to or greater than Twenty-Five Million Canadian Dollars (CDN$25,000,000);
(v)	notwithstanding the foregoing, if an Advance relates to the issuance of a Bankers' Acceptance or BA Equivalent Loan, two (2) Business Days' notice is required before 10:00 a.m. Toronto time; and
(vi)	notwithstanding the foregoing, if an Advance, Rollover or Conversion relates to a LIBOR Loan, three (3) Business Days' notice is required before 10:00 a.m. Toronto time.

(b)	Notice of any Advance, Rollover or Conversion referred to in paragraph (a) above shall be given in the form of a Draw Request, Rollover Notice or Conversion Notice, as the case may be, attached hereto as Exhibits, and shall be given to the Agent at its address set out in section 13.08.
(c)	If notice is not provided as contemplated herein with respect to the maturity of any LIBOR Loan, Bankers' Acceptance or BA Equivalent Loan, the Agent may in its discretion convert such LIBOR Loan upon its maturity into a Base Rate Loan and may convert such Bankers' Acceptance or BA Equivalent Loan upon its maturity into a Prime Rate Loan.
(d)	Any conversion from one form of Availment Option to another shall be subject to satisfaction of all of terms and conditions applicable to the form of the new Availment Option.

5.03 Minimum Amounts, Multiples and Procedures re Draws, Conversions and Repayments

(a)	Each request by the Borrower for an Advance or Conversion in the form of a Prime Rate Loan shall be in a minimum amount of One Hundred Thousand Dollars ($100,000) and a multiple of One Hundred Thousand Dollars ($100,000).
(b)	Each request by the Borrower for an Advance or Conversion in the form of a Base Rate Loan shall be in a minimum amount of One Hundred Thousand United States Dollars (U.S.$100,000) and a multiple of One Hundred Thousand United States Dollars (U.S.$100,000).

- 36 -

(c)	Each request by the Borrower for an Advance or Conversion in the form of a Bankers' Acceptance or BA Equivalent Loan shall be in a minimum amount of One Million Dollars ($1,000,000) and a multiple of One Hundred Thousand Dollars ($100,000) and in such amount as will result in the face amount of each Bankers' Acceptance or BA Equivalent Note issued by a Lender being in a multiple of One Hundred Thousand Dollars ($100,000).
(d)	Each request by the Borrower for an Advance or Conversion in the form of a LIBOR Loan shall be in a minimum amount of One Million United States Dollars (U.S.$1,000,000) and a multiple of One Hundred Thousand United States Dollars (U.S.$100,000).
(e)	Upon receipt of a Draw Request, the Agent shall promptly notify each Lender of the contents thereof and such Lender's Proportionate Share of the Advance. Such Draw Request shall thereafter be irrevocable.
(f)	Each Advance shall be made by the applicable Lenders to the Agent at its address referred to in section 13.08 or such other address as the Agent may designate by notice in writing to the Lenders from time to time. Each Lender shall make available its Proportionate Share of each said Advance to the Agent. Unless the Agent determines that any condition of the Advance has not been satisfied or waived, the Agent shall make the funds so received from the Lenders available to the Borrower by 2:00 p.m. (Toronto time) on the requested date of the Advance. No Lender shall be responsible for any other Lender's obligation to make available its Proportionate Share of the said Advance.
(g)	The Borrower agrees to deliver in favour of each Lender such other agreements and documentation as such Lender may reasonably require (not inconsistent with this Agreement) in respect of such Lender's requirements for the acceptance of Bankers' Acceptances or the issuance of BA Equivalent Notes.
(h)	All payments of principal, interest and other amounts made by the Borrower to the Agent in respect of the Outstanding Advances shall be paid by the Agent to the respective Lenders in accordance with each Lender's Proportionate Share thereof. For greater certainty, however, stamping fees in respect of Bankers' Acceptances and BA Equivalent Notes shall be received and retained by the respective Lenders which issued or accepted such Bankers' Acceptances and BA Equivalent Notes.

5.04 Place of Repayments

(a)

All payments of principal, interest and other amounts to be made by the Borrower to the Agent pursuant to this Agreement shall be made at its address noted in section 13.08 or to such other address as the Agent may direct in writing from time to time. All such payments received by the Agent on a Business Day before 2:00 p.m. (Toronto time) shall be treated as having been received by the Agent on that day; payments made after such time on a Business Day shall be treated as having been received by the Agent on the next Business Day.

(b)

Whenever any payment shall be due on a day which is not a Business Day, the date for payment thereof shall be extended to the next succeeding Business Day. Interest shall continue to accrue and be payable thereon as provided herein, until the date on which such payment is received by the Agent.

- 37 -

5.05 Evidence of Obligations (Noteless Advances)

The Agent shall open and maintain, in accordance with its usual practice, accounts evidencing the Obligations; and the information entered in such accounts shall constitute prima facie evidence of the Obligations. The Agent may, but shall not be obliged to, request the Borrower to execute and deliver promissory notes from time to time as additional evidence of the Obligations, in form and substance satisfactory to the Agent acting reasonably.

5.06 Determination of Equivalent Amounts

Whenever it is necessary or desirable at any time to determine the Equivalent Amount in Canadian Dollars of an amount expressed in U.S. Dollars, or vice-versa (specifically including for greater certainty the determination of whether the Outstanding Advances under Facility 1 exceed the Facility 1 Maximum Amount), the Equivalent Amount shall be determined by reference to the Exchange Rate on the date of such determination.

5.07 Illegality

The obligation of any Lender to make Advances under Facility 1 shall be suspended if and for so long as it is unlawful or impossible for such Lender to make Advances thereunder as a result of the adoption of any applicable law, rule or regulation, or any change in any applicable law, rule or regulation, or any change in the interpretation or administration thereof by any Governmental Authority, central bank or comparable agency charged with the interpretation or administration thereof, or compliance by such Lender with any request or directive (whether or not having the force of law) of any such Governmental Authority, central bank or comparable agency.

5.08 Anti-Money Laundering

The Borrower acknowledges that pursuant to AML Legislation the Agent and the Lenders may be required to obtain, verify and record information regarding the Companies and their respective directors, authorized signing officers, direct or indirect shareholders, partners or other persons in control of the Companies and the transactions contemplated hereby. The Borrower shall promptly provide all such information, including any supporting documentation and other evidence, as may be requested by the Agent or any Lender, or any prospective assignee or participant of a Lender or the Agent, in order to comply with any applicable AML Legislation, whether now or hereafter in existence. If the Agent has ascertained the identity of any Company, or any authorized signatories of any Company, for the purposes of applicable AML Legislation, then the Agent shall:

(a)	be deemed to have done so as an agent for each Lender, and this Agreement shall constitute a "written agreement" in such regard between each Lender and the Agent within the meaning of applicable AML Legislation; and
(b)	provide each Lender with copies of all information obtained in such regard without any representation or warranty as to its accuracy or completeness.

- 38 -

Notwithstanding the foregoing each Lender acknowledges and agrees that the Agent has no obligation to ascertain the identity of any Company, or any authorized signatories of any Company, on behalf of such Lender or to confirm the completeness or accuracy of any information that the Agent obtains from any Company, or any such authorized signatory, in doing so.

5.09 Terrorist Lists

Each Company is and will remain in compliance in all material respects with all AML Legislation. No Company (i) is a Person designated by the Canadian government on any list set out in the United Nations Al-Qaida and Taliban Regulations, the Regulations Implementing the United Nations Resolutions on the Suppression of Terrorism or the Criminal Code (collectively, the “Terrorist Lists”) with which a Canadian Person cannot deal with or otherwise engage in business transactions, (ii) is a Person who is otherwise the target of Canadian economic sanctions laws or (iii) is controlled by (including without limitation by virtue of such Person being a director or owning voting shares or interests), or acts, directly or indirectly, for or on behalf of, any Person that is the target of Canadian economic sanctions prohibitions such that the entry into, or performance under, this Agreement or any other Loan Document would be prohibited under Canadian law.

- 39 -

ARTICLE VI - REPRESENTATIONS AND WARRANTIES

6.01 Representations and Warranties

Notwithstanding that this Agreement has been executed and delivered by the parties hereto prior to the completion of the Sintrom Purchase Transaction, the representations and warranties set out herein are hereby deemed to have been made as if the Sintrom Purchase Transaction had been completed. The Borrower hereby represents and warrants to the Agent and the Lenders as follows:

(a)	Status - Each Company has been duly incorporated (or amalgamated) and organized and is validly subsisting under the laws of its jurisdiction of incorporation and is up-to-date in respect of all material corporate filings.
(b)	Corporate Information - Schedule 6.01(b) attached hereto contains a list of the Companies (indicating those which are Excluded Subsidiaries) and the following information in respect of each Company: its prior names and predecessor corporations, its governing jurisdiction and all prior governing jurisdictions, its registered office, principal place of business, all locations at which it has places of business or owns assets, the number and classes of its issued and outstanding shares, and (other than the Borrower) a list of its shareholders including the number and class of shares held by each. The office (administration centrale), the place of effective management (sige de direction effective) and the centre of main interests of Merus Luxco is located at the place of its registered office (sige statutaire) in Luxembourg and Merus Luxco has no establishment outside Luxembourg (the terms “centre of main interests” and “establishment” having the meanings ascribed thereto in Council Regulation (EC) no. 1346/2000 of 29 May 2000 on insolvency proceedings). Each Excluded Subsidiary does not carry on business, does not own any assets which are material to the business and operations of the Companies taken as a whole, and owns assets having an aggregate fair market value of less than Ten Thousand Dollars ($10,000).
(c)	Solvency – Each Company is Solvent. Without limiting the generality of the foregoing, each Luxembourg Guarantor, is in compliance with all requirements of the Luxembourg legislation and regulations on the domiciliation of companies, and in particular with the Luxembourg Act dated May 31, 1999 on the domiciliation of companies, as amended from time to time. No Luxembourg Guarantor has filed and, to the best of its knowledge, no Person has filed a request with any competent court seeking that any Luxembourg Guarantor be declared subject to any Luxembourg Insolvency Event (and which include foreign court decision as to faillite, concordat or analogous procedures according to Council Regulation (EC) n°1346/2000 of 29 May 2000 on insolvency proceedings).
(d)	No Pending Changes - No Person has any agreement or option or any right or privilege (whether by law, pre-emptive or contractual) capable of becoming an agreement, including convertible securities, warrants or convertible obligations of any nature, for the purchase of any properties or assets of any Company out of the ordinary course of business or for the purchase, subscription, allotment or issuance of any debt or equity securities of any Company.

- 40 -

(e)	No Conflicting Agreements - Neither the execution and delivery of the Security, nor compliance with the terms, provisions and conditions of this Agreement or the Security will conflict with, result in a breach of, or constitute a default under the charter documents or by-laws of any Company or any agreement or instrument to which it is a party or is otherwise bound, and does not require the consent or approval of any Person, other than those which have been obtained.
(f)	No Conflict with Charter Documents - There are no provisions in the charter documents, by-laws or partnership agreement of any Company or in any unanimous shareholder agreement affecting it which restrict or limit its powers to borrow money, issue debt obligations, guarantee the payment or performance of the obligations of others, or otherwise encumber all or any of its property, now owned or subsequently acquired.
(g)	Loan Documents; Novartis Sintrom Agreements - The Borrower has the corporate capacity, power, legal right and authority to borrow from the Lenders, perform its obligations under this Agreement and provide the Security required to be provided by it hereunder; and each other Company has the corporate capacity, power, legal right and authority to guarantee payment to the Agent and the Lenders of the Borrower's obligations and provide the Security required to be provided by it hereunder. The execution and delivery of the Loan Documents by the Companies and the performance of their respective obligations therein have been duly authorized by all necessary corporate action. This Agreement and the other Loan Documents constitute legal, valid and binding obligations of the Companies, enforceable against them in accordance with the terms and provisions thereof, subject to laws of general application affecting creditors' rights (including Insolvency Legislation) and the discretion of the court in awarding equitable remedies. The Borrower has the capacity, power, legal right and authority to enter into and perform its obligations under the Novartis Sintrom Agreements. The execution and delivery of the Novartis Sintrom Agreements by the Borrower and the performance of its obligations therein have been duly authorized by all necessary action and constitute legal, valid and binding obligations of the Borrower, enforceable against it in accordance with the terms and provisions thereof, subject to laws of general application affecting creditors' rights and the discretion of the court in awarding equitable remedies.
(h)	Conduct of Business; Material Permits - Each of the Companies is in compliance in all material respects with all Applicable Laws of each jurisdiction in which it carries on business and is duly licensed, registered and qualified to do business and is in good standing in each jurisdiction in which the nature of the business conducted by it or the property owned or leased by it make such qualification necessary, except to the extent that the failure to hold any such licences, registrations and permits would not constitute a Material Adverse Change; and all such licences, registrations and qualifications are valid and subsisting and in good standing. Attached hereto as Schedule 6.01(h) is a true and complete list of all Material Permits, and all such Material Permits are valid and subsisting and in good standing in all material respects.
(i)	Ownership of Assets; Specific Permitted Liens - Each Company owns, and possesses its property free and clear of any and all Liens except for Permitted Liens. No Company has any commitment or obligation (contingent or otherwise) to grant any Liens except for Permitted Liens. No event has occurred which constitutes, or which with the giving of notice, lapse of time or both would constitute, a material default under any Lien which has been granted by any of the Companies. Schedule 6.01(i) attached hereto contains a true and complete list of the Specific Permitted Liens.

- 41 -

(j)	Owned Properties - Schedule 6.01(j) attached hereto contains a true and complete list of the Owned Properties.
(k)	Leased Properties - Schedule 6.01(k) attached hereto contains a true and complete list of all Leased Properties including in respect of each Lease the names of the parties, the municipal address and legal description of the Leased Property, the rent payable under the Lease, the term of the Lease and all renewal options, and the existence of any purchase option or right of first refusal in respect of the purchase of the Leased Property.
(l)	Intellectual Property - Each of the Companies possesses or has the right to use all Intellectual Property material to the conduct of its business, each of which is in good standing in all material respects; and has the right to use such Intellectual Property without violation of any material rights of others with respect thereto. Attached hereto as Schedule 6.01(l) is a list of all such material Intellectual Property held by the Companies, including a description of the nature of such rights. To the Borrower’s knowledge, no Person has asserted any claim in respect of the validity of such Intellectual Property or the Companies’ rights therein except as disclosed in Schedule 6.01(l) attached hereto, and the Borrower is not aware of any basis for the assertion of any such claims. The Borrower is not aware of any material infringement of the Companies’ rights under such Intellectual Property by other Persons. The conduct and operations of the businesses of each Company do not infringe, misappropriate, dilute or violate any Intellectual Property rights held by any other Person. Notwithstanding the foregoing, all patents in respect of the drug products known as Vancomycin and Sintrom have expired.
(m)	Insurance - The Companies have placed insurance, including property, boiler and machinery, business interruption and liability insurance, in appropriate amounts and for appropriate risks as would be considered prudent for similar businesses. Attached hereto as Schedule 6.01(m) is a true and complete list of all insurance policies held by the Companies, including the following information in respect of each policy: name of insurer, type and amount of coverage, deductible limit (if applicable) and policy expiry date.
(n)	Material Agreements - Each Material Agreement to which any Company is a party (for greater certainty, specifically including each of the Novartis Agreements) is in good standing and in full force and effect; and none of the Companies, or, to the best of the Borrower's knowledge, any of the other parties thereto, is in material breach of any of the terms or conditions contained therein. Attached hereto as Schedule 6.01(n) is a true and complete list of all Material Agreements to which the Companies are a party, including a brief description of the nature of each said Material Agreement.

- 42 -

(o)	Labour Agreements - Schedule 6.01(o) attached hereto contains a true and complete list of all contracts with labour unions and employee associations to which the Companies are a party, and the Borrower is not aware of any attempts to organize or establish any other labour union or employee association.
(p)	Environmental Laws - Except to the extent disclosed in Schedule 6.01(p) attached hereto:

(i)	each Company and its business, operations, assets, equipment, property, leaseholds and other facilities is in compliance in all material respects with all Requirements of Environmental Law, specifically including all Requirements of Environmental Law concerning the storage and handling of Hazardous Materials;
(ii)	each Company holds all material permits, licenses, certificates and approvals from Governmental Authorities which are required in connection with air emissions, discharges to surface or groundwater, noise emissions, solid or liquid waste disposal, the use, generation, storage, transportation or disposal of Hazardous Materials and all other Requirements of Environmental Law;
(iii)	there has been no material emission, spill, release, or discharge into or upon the air, soils (or any improvements located thereon), surface water or groundwater or the sewer, septic system or waste treatment, storage or disposal system servicing the premises, of any Hazardous Materials at or from any of the Properties;
(iv)	no written complaint, order, directive, claim, citation, or notice from any Governmental Authority or any other Person has been received by any Company with respect to any of the Properties in respect of air emissions, spills, releases, or discharges to soils or improvements located thereon, surface water, groundwater or the sewer, septic system or waste treatment, storage or disposal systems servicing any of the Properties, noise emissions, solid or liquid waste disposal, the use, generation, storage, transportation, or disposal of Hazardous Materials or other Requirements of Environmental Law affecting the Properties;
(v)	there are no legal or administrative proceedings, investigations or claims now pending, or to the Borrower's knowledge, threatened in writing, with respect to the presence on or under, or the discharge, emission, spill, radiation or disposal into or upon any of the Properties, the atmosphere, or any watercourse or body of water, of any Hazardous Material; nor are there any material matters under discussion between any Company and any Governmental Authority relating thereto; and there is no factual basis for any such proceedings, investigations or claims; and
(vi)	the Companies have no material indebtedness, obligation or liability, absolute or contingent, matured or not matured, with respect to the storage, treatment, cleanup or disposal of any Hazardous Materials, including without limitation any such indebtedness, obligation, or liability under any Requirements of Environmental Law regarding such storage, treatment, cleanup or disposal.

- 43 -

(q)	No Litigation - There are no actions, suits or proceedings pending or, to the Borrower's knowledge, threatened in writing against any Company in any court or before or by any Governmental Authority, except as disclosed in Schedule 6.01(q) attached hereto.
(r)	Pension Plans - Schedule 6.01(r) attached hereto contains a true and complete list of all Pension Plans established by the Companies. No Pension Plan is a Defined Benefit Pension Plan. No steps have been taken to terminate any such Pension Plan (in whole or in part), no contribution failure has occurred with respect to any such Pension Plan sufficient to give rise to a Lien under any applicable laws of any jurisdiction, and no condition exists and no event or transaction has occurred with respect to any such Pension Plan which might result in the incurrence by any Company of any material liability, fine or penalty. Each such Pension Plan is in compliance in all material respects with all applicable pension benefits and tax Laws, (i) all contributions (including employee contributions made by authorized payroll deductions or other withholdings) required to be made to the appropriate funding agency in accordance with all applicable laws and the terms of such Pension Plan have been made in accordance with all Applicable Laws and the terms of such Pension Plan, (ii) to the extent applicable, all liabilities under such Pension Plan are funded, on a going concern and solvency basis, in accordance with the terms of the respective Pension Plans, the requirements of applicable pension benefits laws and of applicable regulatory authorities and the most recent actuarial report filed with respect to the Pension Plan, and (iii) no event has occurred and no conditions exist with respect to any such Pension Plan that has resulted or could reasonably be expected to result in such Pension Plan having its registration revoked or refused for the purposes of any applicable pension benefits or tax Laws or being placed under the administration of any relevant pension benefits regulatory authority or being required to pay any Taxes or penalties under any applicable pension benefits or tax Laws.
(s)	Financial Statements - The most recent Year-end Financial Statements and Interim Financial Statements delivered to the Agent and the Lenders have been prepared in accordance with GAAP (except in the case of the Interim Financial Statements, subject to normal adjustments and the absence of footnotes) on a basis which is consistent with the previous fiscal period, and present fairly:

(i)	the assets and liabilities (whether accrued, absolute, contingent or otherwise) and financial condition of the Borrower on a consolidated basis as at the dates therein specified;
(ii)	the sales, earnings and results of operations of the Borrower on a consolidated basis during the periods covered thereby; and
(iii)	in the case of the Year-end Financial Statements, the changes in financial position of the Borrower on a consolidated basis;

and the Companies have no material liabilities (whether accrued, absolute, contingent or otherwise) except as disclosed therein and liabilities incurred in the ordinary course of business which do not directly or indirectly pertain to financing activities; and since the dates of the said Year-end Financial Statements and Interim Financial Statements, as the case may be, no material liabilities have been incurred by the Companies except in the ordinary course of business and no Material Adverse Change has occurred.

- 44 -

(t)	Financial and Other Information - All financial and other information provided by or in respect of the Companies to the Agent and the Lenders was true, correct and complete in all material respects when provided. No information, exhibit, or report furnished by the Companies to the Agent or the Lenders contains any material misstatement of fact or omits to state a material fact or any fact necessary to make the statement contained therein not materially misleading in the circumstances in which it was made.
(u)	No Guarantees – No Guarantees have been granted by any Company except for (i) Guarantees which comprise part of the Security; (ii) Guarantees in respect of Permitted Funded Debt incurred by any other Company; and (iii) Guarantees by the Borrower in favour of Novartis in respect of the obligations of Merus Luxco and Merus Netherlands under the Novartis Agreements.
(v)	Tax Returns - Each Company has duly and timely filed all tax returns required to be filed by it, and has paid all Taxes which are due and payable by it except for Taxes being contested in good faith and in respect of which reserves have been established as required by the Required Lenders acting reasonably. Each Company has also paid all other Taxes, charges, penalties and interest due and payable under or in respect of all assessments and re-assessments of which it has received written notice except for Taxes being contested in good faith and in respect of which reserves have been established as required by the Required Lenders acting reasonably. There are no actions, suits, proceedings, investigations or claims pending, or to the knowledge of the Borrower threatened in writing, against any Company in respect of Taxes, governmental charges or assessments except for any such actions, suits, proceedings, investigations or claims which are being contested in good faith and in respect of which reserves have been established as required by the Required Lenders acting reasonably.
(w)	No filing or stamp taxes - Regarding Luxembourg, no payment of any stamp, registration or other documentary tax in relation to the Loan Documents will be required except that in the case any Loan Documents are to be presented, directly or by way of reference, in court proceedings in a Luxembourg court or another official authority (autorit constitue) in Luxembourg, registration may be required by such court or authority and registration duties at a fixed rate of EUR 12 or an ad valorem rate (up to 0.24% of the amount referred to in the relevant document), depending on the nature of the registered document, will in such event become due and payable.
(x)	Statutory Liens - Each Company has remitted on a timely basis all amounts required to have been withheld and remitted (including withholdings from employee wages and salaries relating to income tax, employment insurance and Canada Pension Plan contributions), goods and services tax and all other amounts which if not paid when due could result in the creation of a Statutory Lien against any of its property, except for Permitted Liens.

- 45 -

(y)	No Default, etc. - No Default, Event of Default or Material Adverse Change has occurred and is continuing.
(z)	Transactions with Related Persons - The Companies are not party to any contract, commitment or transaction (including by way of loan) with any Related Person thereto which contains any terms which are not commercially reasonable.
(aa)	Due Diligence regarding Sintrom – The Borrower has conducted due diligence with respect to Sintrom, the Sintrom Rights and Novartis as would be considered appropriate and prudent in a transaction in the nature of the Sintrom Purchase Transaction, including a detailed review of all information made available by Novartis to the Borrower in the Data Room (as defined in the Novartis Purchase Agreement). No information was disclosed during such due diligence concerning Sintrom, the Sintrom Rights or Novartis, and the Borrower is not aware of any information, which is inconsistent in any material respect with any of the representations or warranties provided by Novartis to the Borrower in the Novartis Sintrom Agreements or which could reasonably be expected to be material to a purchaser of the Sintrom Rights other than any information disclosed in the Novartis Sintrom Agreements (including any annexes and schedules thereto). Without limiting the generality of the foregoing:

(i)

no information is disclosed in the Data Room which would constitute a material exception or material qualification to any of the representations or warranties provided by Novartis to the Borrower set out in section 12.1 of the Sintrom Purchase Agreement other than any information disclosed in the Novartis Sintrom Agreements (including any annexes and schedules thereto); and

(ii)

the Borrower (through its intellectual property counsel) has conducted searches for registrations or filings in public registries in all jurisdictions within the Territory (except Albania) in respect of the Trademarks (the terms “Territory” and “Trademarks” having the respective meanings as defined in the Sintrom Purchase Agreement), which searches disclosed that the Trademarks are registered in each country in the Territory (except Albania) and did not disclose the existence of any assignments, registered user agreements, license agreements or other agreements, pending claims, litigation matters or Liens relating to the Trademarks other than license agreements that have been terminated.

(bb) Full Disclosure - There are no facts known to the Borrower which could reasonably be expected to materially adversely affect the Companies' ability to observe and perform their respective obligations under the Loan Documents.

6.02 Survival of Representations and Warranties

The Borrower acknowledges that the Agent and the Lenders shall rely upon the representations and warranties contained in this Article in connection with the establishment and continuation of Facility 1 and also in connection with the entering into by any Lender of any Hedge Transaction with the Borrower. Notwithstanding any investigations which may be made by the Agent or the Lenders, the said representations and warranties shall survive the execution and delivery of this Agreement until full and final payment and satisfaction of the Obligations.

- 46 -

ARTICLE VII - COVENANTS

7.01 Positive Covenants

The Borrower hereby covenants and agrees with the Agent and the Lenders that it will, and will cause each of its Subsidiaries to:

(a)	Prompt Payment - in the case of the Borrower, pay all principal, interest and other amounts due hereunder at the times and in the manner specified herein;
(b)	Preservation of Corporate Existence - maintain its corporate existence in good standing, continue to carry on its business, preserve its rights, powers, licences, privileges, franchises and goodwill, exercise any rights of renewal or extensions of any leases, licences, concessions, franchises or any other rights whatsoever which are material to the conduct of its business, maintain all qualifications to carry on business in each jurisdiction in which such qualifications are required, carry on and conduct its business in a proper and efficient manner so as to protect its property and income, and not materially change the nature of its business; and in the case of the Borrower, maintain its existence as a corporation incorporated in Canada and remain a Canadian resident taxpayer for purposes of the Income Tax Act (Canada);
(c)	Compliance with Laws - comply in all material respects with all Applicable Laws (specifically including, for greater certainty, all applicable Requirements of Environmental Law), use the proceeds of all Advances hereunder for legal and proper purposes, and obtain and maintain in good standing all material leases, licences, permits and approvals from any and all Governmental Authorities required in respect of its business and operations;
(d)	Payment of Taxes, etc. - pay when due all rents, Taxes, rates, levies, assessments and governmental charges, fees and dues lawfully levied, assessed or imposed in respect of its property which are material to the conduct of its business, and deliver to the Agent upon request receipts evidencing such payments; except for rents, Taxes, rates, levies, assessments and governmental charges, fees or dues in respect of which an appeal or review proceeding has been commenced, a stay of execution pending such appeal or review proceeding has been obtained, reserves reasonably required by the Required Lenders have been established; and the amounts in question do not in the aggregate materially detract from the ability of the Companies to carry on their businesses and to perform and satisfy all of their respective obligations hereunder;
(e)	Maintain Records - maintain adequate books, accounts and records in accordance with GAAP;
(f)	Maintenance of Assets - keep its property and assets (except obsolete assets) in good repair and working condition;
(g)	Inspection - permit the Agent and its employees and agents, upon not less than five (5) Business Days' written notice to the Borrower, to enter upon and inspect its properties, assets, books and records from time to time during normal business hours and in a manner which does not materially interfere with its business, and make copies of and abstracts from such books and records and discuss its affairs, finances and accounts with any of its officers, directors, accountants and auditors; and it agrees to execute and deliver all consents and further assurances as may be necessary or desirable in order for the Agent and its agents to obtain information from Governmental Authorities and other third parties with respect to environmental matters;

- 47 -

(h)	Insurance - obtain from financially responsible insurance companies and maintain liability insurance, all-risks property insurance on a replacement cost basis (less a reasonable deductible not to exceed amounts customary in the industry for similar businesses and properties), business interruption insurance and insurance in respect of such other risks as are customary in the industry for similar businesses and properties; all of which policies of insurance shall be in such amounts as are customary in the industry for similar businesses and properties; and the interest of the Agent shall be noted on such policies (except liability insurance policies) as first loss payee; and the Agent shall be named as an additional insured under such liability insurance policies; and the Borrower agrees to provide the Agent with certificates of insurance and certified copies of such policies from time to time upon request;
(i)	Perform Obligations - fulfil all covenants and obligations required to be performed by it under those Loan Documents to which it is a party and any other agreement or undertaking now or hereafter made between it and the Lenders or the Agent;
(j)	Notice of Certain Events - provide prompt notice to the Agent of: (i) the occurrence of any Default; (ii) the incorrectness of any representation or warranty contained herein in any material respect; (iii) any material contravention of or non-compliance by any Company with any terms and conditions of any Loan Document; (iv) any Material Adverse Change; (v) any litigation which is material in relation to the Companies taken as a whole or in which the amount claimed under such specific litigation is in excess of Five Hundred Thousand Dollars ($500,000); (vi) any material labour dispute affecting any Company; (vii) any notice of (A) a payment default or (B) any other material default (unless such other material default is cured within any applicable grace or cure period relating thereto) in respect of any Funded Debt of any Company; (viii) any notice in respect of the termination or suspension of, or a material default under, any Material Agreement (for greater certainty, specifically including any of the Novartis Agreements) or Material Permit; or (ix) the issuance of any management letter to the Borrower by its auditor;
(k)	Bank Accounts and Service Agreements - maintain all of its bank accounts and Service Agreements with BMO and its Affiliates, subject to the following exceptions: (i) Merus Luxco may maintain a bank account in Luxembourg provided that the Agent shall have received a pledge of all monies on deposit in such account as required pursuant to section 8.01(b) herein; and (ii) the Companies may maintain bank accounts with other banks and financial institutions provided that (A) such bank accounts are in jurisdictions where BMO and its Affiliates do not provide banking services and the aggregate amount of deposits in such accounts does not exceed Five Hundred Thousand Dollars ($500,000) at any time; or (B) such bank accounts were established by the Borrower with Royal Bank of Canada provided that: (i) no cheques will be drawn on such accounts at any time more than thirty (30) days after the Closing Date, (ii) no receipts will be deposited in such accounts more than thirty (30) days after the Closing Date; and (iii) the Borrower will transfer cash into such accounts only to the extent necessary to cover outstanding cheques and preauthorized debits; and such accounts are closed as soon as reasonably practicable but in any event no later than one hundred twenty (120) days after the Closing Date;

- 48 -

(l)	Use of Advances - utilize the proceeds of all Advances for the Borrower's own business purposes; and not permit such proceeds to be used, directly or indirectly, by any other Person or for any other purpose;
(m)	Environmental Information - if requested by the Agent from time to time upon the instructions of the Required Lenders: (i) provide the Agent with an environmental questionnaire in the Agent's standard form completed by a knowledgeable officer of the Borrower in respect of any Property; and (ii) if the information contained therein is inconsistent in any material respect with the representations in paragraph 6.01(p) herein, provide the Agent with a phase I environmental report in respect of such Property, and promptly take all such action as may be required to comply with all reasonable recommendations contained therein;
(n)	Interest Rate Hedging – within ninety (90) days after the Closing Date, enter into and thereafter maintain at all times Interest Rate Hedge Transactions in an aggregate notional amount of not less than fifty percent (50%) of the Outstanding Advances under Facility 1; and
(o)	Further Assurances - provide the Agent and the Lenders with such further information, financial data, documentation and other assurances as they may reasonably require from time to time.

7.02 Negative Covenants

The Borrower hereby covenants and agrees with the Agent and the Lenders that it will not, and will ensure that each of its Subsidiaries does not, without the prior written consent of the Agent on behalf of the Required Lenders (which consent may be withheld in their sole and unfettered discretion unless otherwise expressly provided herein):

(a)	Funded Debt - create, incur or assume any Funded Debt, except Permitted Funded Debt;
(b)	Liens - grant or suffer to exist any Lien in respect of any of its property, except Permitted Liens;
(c)	Disposition of Assets - directly or indirectly sell, transfer, assign, lease or otherwise dispose of any of its assets (including, without limitation, intellectual and industrial property), except that:

(i)

each Company may sell inventory in the ordinary course of business;

(ii)

if no Default has occurred and is continuing, each Company may sell or dispose of any other assets from time to time in the ordinary course of business (but for greater certainty a sale and leaseback transaction shall not be considered to be in the ordinary course of business), provided that in each Fiscal Year the aggregate amount received by the Companies from such dispositions less the aggregate amount incurred by the Companies in such Fiscal Year to purchase replacement capital assets shall not exceed One Million Dollars ($1,000,000); and for greater certainty the provisions of paragraph 2.04(d) shall apply to all such dispositions; and

- 49 -

(iii) each Company may transfer all or any portion of its assets to any Secured Company to the extent permitted under Section 7.02(j) herein.

(d)	Guarantees - become obligated under Guarantees, except: (i) Guarantees which comprise part of the Security; (ii) Guarantees in respect of Permitted Funded Debt incurred by any other Company; and (iii) Guarantees by the Borrower in favour of Novartis in respect of the obligations of Merus Luxco under the Novartis Agreements;
(e)	Luxembourg Financial Assistance Prohibitions - with respect to any Luxembourg Guarantor, create, grant or permit to subsist any Permitted Lien to the extent that doing so would constitute a breach of the financial assistance prohibitions contained at Article 49-6 (where applicable) of the Luxembourg act on commercial companies of 10 August 1915, as amended (the "Companies Act") or constitute a misuse of corporate assets (abus de biens sociaux) as defined at Article 171-1 of the Companies Act;
(f)	Investments - make or acquire any Investments, except that the following Investments may be made or acquired if both immediately before and immediately after each such Investment no Default or Event of Default has occurred and is continuing:

(i)	Investments may be made in direct obligations of Canada or the United States of America, including Canadian or United States of America federal, provincial or state obligations, with maturities of one (1) year or less from the date of acquisition of the investment, provided that if required by the Required Lenders, the Company making such Investment shall provide such additional items of Security as the Required Lenders may require in order that such investments shall be specifically pledged to the Agent;
(ii)	Investments may be made in certificates of deposit having maturities of less than one (1) year, issued by BMO; and
(iii)	a Company may acquire Intellectual Property rights (including the IP Ancillary Rights) in respect of any drug product, provided that (A) the purchase price thereof is financed entirely from the proceeds of equity or Subordinated Debt (and for greater certainty, no portion of such purchase price shall be financed, directly or indirectly, by indebtedness incurred hereunder); and (B) the Required Lenders have provided their prior written consent to such acquisition, which consent shall not be unreasonably withheld or delayed;

(g) Capital Expenditures - incur Capital Expenditures, except that the following Capital Expenditures may be incurred if both immediately before and immediately after each such Capital Expenditure no Default has occurred and is continuing:

- 50 -

(i) in each Fiscal Year the Companies may incur Capital Expenditures in the maximum aggregate amount of (i) Five Hundred Thousand Dollars ($500,000) plus (ii) an amount (if positive) equal to Five Hundred Thousand Dollars ($500,000) less the Capital Expenditures incurred by the Companies in the aggregate in the immediately preceding Fiscal Year;

(h)	Distributions - make any Distributions, other than Distributions to any other Company, unless both immediately before and immediately after each such Distribution no Default has occurred and is continuing;
(i)	Certain Payments - make any payment in respect of principal, interest, fees or any other amounts in respect of Subordinated Debt except (i) to the extent expressly permitted under the subordination and postponement agreement relating thereto or (ii) any payment by a Company to a Secured Company; and for greater certainty any such permitted payment in respect of Subordinated Debt shall not be considered a "Distribution" for the purposes of paragraph 7.02(h);
(j)	Corporate Changes – materially change its capital structure or the nature of its business, maintain a place of business or any material assets in any jurisdiction other than Canada or Luxembourg or Germany or any other such jurisdiction as may be approved in writing by the Agent upon the instructions of the Required Lenders, such approval not to be unreasonably withheld (provided that it shall be reasonable for such approval to be withheld if the Agent is unable to obtain a First-Ranking Security Interest in Collateral in such jurisdiction), or enter into any transaction whereby all or a substantial portion of its undertaking, property and assets would become the property of any other Person, whether by way of reconstruction, reorganization, recapitalization, consolidation, amalgamation, merger, transfer, sale or otherwise; except that at any time when no Default or Event of Default has occurred and is continuing any Company may from time to time do any one or more of the following: change its name; amend its constating documents (provided that such amendment does not directly or indirectly affect its ability to borrow, give security or give Guarantees and does not interfere with or restrict its ability to observe and perform all of its obligations under the Loan Documents to which it is a party); amalgamate or merge with any Secured Company; issue shares (preferred or common) or other equity interests of any Company to any Secured Company; issue shares (preferred or common) or other equity interests of the Borrower to any Person; transfer all or any shares it holds in the capital of any other Company to any Secured Company provided that the Agent continues to hold a First-Ranking Security Interest in such transferred shares; transfer all or any portion of its assets to any Secured Company; or voluntarily dissolve after having transferred all of its assets to any Secured Company; provided that in connection with each such transaction (i) the Borrower has given not less than thirty (30) days' prior written notice thereof (other than any issuance of shares or other equity of the Borrower in respect of which the Borrower shall provide prompt notice after such issuance) to the Agent, (ii) the Agent continues to hold a First-Ranking Security Interest in the shares or assets which are the subject of such transaction and in the reasonable opinion of the Agent such security interest is not materially different from the security interest held by the Agent immediately prior to such transaction; and (iii) concurrently with any such action the Borrower shall provide or cause to be provided to the Agent all additional or replacement items of Security (including legal opinions) as the Agent may reasonably require in connection therewith;

- 51 -

(k)	Defined Benefit Pension Plans – establish, assume or otherwise become a party to or liable under any Defined Benefit Pension Plan;
(l)	Excluded Subsidiaries – permit any Excluded Subsidiary to carry on business, own any assets which are material to the business and operations of the Companies taken as a whole, or own assets having an aggregate fair market value equal to more than Fifty Thousand Dollars ($50,000);
(m)	New Subsidiaries - create or acquire any Subsidiary unless (i) all of the issued and outstanding shares in the capital of such Subsidiary are owned directly or indirectly by the Borrower; (ii) such new Subsidiary provides a Guarantee in respect of the Obligations and all Security required to be provided by it hereunder; and (iii) all of the issued and outstanding shares of such new Subsidiary are pledged to the Agent, and in each case accompanied by legal opinions as contemplated herein;
(n)	Fiscal Year - change its Fiscal Year (which for greater certainty presently ends on September 30 in each year);
(o)	Auditors - change its auditors to a firm that is not a nationally recognized auditing firm, except with the prior written consent of the Required Lenders which shall not be unreasonably withheld;
(p)	Dealing with Related Persons - enter into any contract with any Related Person (other than a contract relating to Subordinated Debt held by such Related Person) unless all terms and conditions thereof (specifically including the price) are commercially reasonable, or make a loan to any Related Person; but for greater certainty this paragraph (p) shall not apply to restrict the payment of any Distributions made in compliance with the restrictions contained in paragraph 7.02(h); or
(q)	Use of Advances - use the proceeds of any Advance for any purposes other than those expressly contemplated in this Agreement.

7.03 Financial Covenants

The Borrower agrees to maintain, on a consolidated basis, the financial ratios listed below, each determined as at the end of each Fiscal Quarter:

(a) The ratio of Senior Funded Debt to EBITDA in the immediately preceding twelve (12) month period shall not be greater than:

(i)	2.75 to 1 on the Closing Date and thereafter up to and including the Fiscal Quarter ending September 30, 2015; and
(ii)	2.25 to 1 on December 31, 2015 and thereafter.

- 52 -

(b)	The ratio of Total Funded Debt to EBITDA in the immediately preceding twelve (12) month period shall not be greater than 3.00 to 1.
(c)	The Fixed Charge Coverage Ratio shall not be less than 1.25 to 1.

For the purpose of determining compliance with the foregoing financial covenants on following dates, EBITDA for the immediately preceding twelve (12) month period shall be deemed to have been increased by the following amounts:

• Closing Date - $17,000,000

• September 30, 2014 - - $17,000,000

• December 31, 2014 - $12,750,000

• March 31, 2015 - $8,500,000

• June 30, 2015 - $4,250,000

7.04 Reporting Requirements

The Borrower shall deliver, or cause to be delivered (by email in accordance with section 13.08), the following financial and other information to the Agent at the times indicated below:

(a) quarterly, within forty-five (45) days after the end of each Fiscal Quarter (or in the case of the last Fiscal Quarter in each Fiscal Year, ninety (90) days thereafter):

(i)	the Interim Financial Statements in respect of such Fiscal Quarter accompanied by management discussion and analysis;
(ii)	a Compliance Certificate in respect of such Fiscal Quarter certified by the President, Chief Financial Officer or other senior officer of the Borrower acceptable to the Agent in the form of Exhibit "F" attached hereto; and
(iii)	a variance analysis providing explanations for variances between actual results for such Fiscal Quarter and the projections contained in the most recent Annual Business Plan presented to the Agent and Lenders;

(b) annually, within ninety (90) days after the end of each Fiscal Year:

(i)	the Year-End Financial Statements in respect of such Fiscal Year, accompanied by management discussion and analysis and a copy of the Borrower's auditor's letter to management;
(ii)	a Compliance Certificate in respect of such Fiscal Year certified by the President, Chief Financial Officer or other senior officer of the Borrower acceptable to the Agent in the form of Exhibit "F" attached hereto;

- 53 -

(iii)	a variance analysis providing explanations for variances between actual results for such Fiscal Year and the projections contained in the most recent Annual Business Plan presented to the Agent and Lenders; and
(iv)	a calculation of Excess Cash Flow in respect of such Fiscal Year;

(c)

annually, not later than sixty (60) days after the commencement of each Fiscal Year, the consolidated annual business plan of the Borrower for such Fiscal Year, including projections in respect of profit and loss, balance sheet, cash flow, Capital Expenditures and financial covenant calculations set out in this Agreement, including disclosure of all material assumptions utilized (the "Annual Business Plan"); and

(d)

such additional information and documents as the Lenders or the Agent may reasonably require from time to time to ensure the ongoing compliance by the Companies with the terms and conditions of this Agreement, in form reasonably acceptable to the Lenders and the Agent.

7.05 Sintrom Marketing Authorizations

The Borrower hereby advises the Agent and the Lenders that the Borrower intends to file (or cause Merus Luxco to file) applications for transfer of the Sintrom Marketing Authorizations to Merus Luxco within nine (9) months after the completion of the Sintrom Purchase Transaction, and the Borrower agrees that in any event such applications will be filed no later than eighteen (18) months thereafter. The Borrower confirms that in accordance with and subject to the terms and conditions of the Novartis Sintrom Agreements, until the earlier of (i) the completion of such transfers; or (ii) two years from the date hereof; Novartis is obliged to sell Sintrom in each applicable country and remit the profits thereof (less certain fees and charges) to Merus Luxco, all as more particularly set out in therein. The Borrower hereby represents and warrants to the Agent and the Lenders that based on its previous experience in obtaining transfers of Marketing Authorizations in Europe in respect of Emselex, the Borrower reasonably believes that each Sintrom Marketing Authorization will be transferred to Merus Luxco within four (4) months of filing the relevant transfer application.

- 54 -

ARTICLE VIII - SECURITY

8.01 Security to be Provided by the Companies

The Borrower agrees to provide (or cause to be provided) the security listed below as continuing security for the payment of the Obligations and the payment and performance of all other present and future, direct and indirect, indebtedness and obligations of the Borrower to the Agent and the Lenders, specifically including the obligations of the Borrower arising under or in respect of this Agreement, the Hedge Transactions and the other Loan Documents:

(a)	Guarantees from all present and future Material Subsidiaries of the Borrower in respect of all present and future, direct and indirect, indebtedness and obligations of the Borrower to the Agent and the Lenders, each such Guarantee to be in an unlimited amount except for any Guarantee provided by a Luxembourg Guarantor which shall be subject to Section 8.07 hereof;
(b)	a general security agreement (or equivalent) from each Company creating a First- Ranking Security Interest in respect of all of its present and future property, assets and undertaking, except as follows:

(i)	each Luxembourg Guarantor shall provide (A) a pledge of all monies on deposit in its bank accounts; and (B) a pledge over receivables owed to such Luxembourg Guarantor; and
(ii)	Merus Netherlands shall provide (A) a deed of non-possessory pledge over movables; and (B) a disclosed pledge over receivables, provided however that such disclosed pledge over receivables shall not be required unless and until Merus Netherlands has accounts receivable owing to it by account debtors other than Merus Luxco;

(c)	to the extent required by the Required Lenders in their discretion from time to time, collateral mortgages or debentures or other forms of security from the Companies creating a First-Ranking Security Interest in respect of all Owned Properties;
(d)	to the extent required by the Required Lenders in their discretion from time to time, debentures, collateral mortgages or other forms of security from the Companies creating a First-Ranking Security Interest in respect of any or all Leased Properties which the Required Lenders acting reasonably consider to be material;
(e)	a security agreement from each Company creating a First-Ranking Security Interest in respect of its equity investment held in each Subsidiary directly owned by such Company, and including for greater certainty a pledge by the Borrower of its equity interest in Merus Luxco;
(f)	if required by the Required Lenders in their discretion from time to time, a security agreement creating an assignment and First-Ranking Security Interest in respect of its rights to and interest in any Intellectual Property which the Required Lenders acting reasonably consider to be material, together with any necessary consents from other Persons which may be required in connection with the granting of said assignment and security interest; and without limiting the generality of the foregoing such security shall be required in respect of all Intellectual Property in respect of the Key Products;

- 55 -

(g)	if required by the Required Lenders in their discretion from time to time, specific assignments by the Companies of all rights and benefits arising under each Material Agreement, accompanied by an agreement from the other contracting party thereto, in form and substance satisfactory to the Agent and the Lenders; provided however that specific assignments shall not be required in respect of any of the Novartis Agreements;
(h)	assignments of the interest of all Companies in all policies of insurance (which requirement shall be satisfied if the Agent's interest as first mortgagee and loss payee is recorded on such policies); and
(i)	such other security and further assurances as the Agent may reasonably require from time to time, not inconsistent with the provisions of this Agreement.

8.02 Security to be Provided by Others

It is a condition precedent to the first Advance and each subsequent Advance hereunder that the Agent shall have received the following Security, each in form and substance satisfactory to the Agent and the Lenders:

(a)	a subordination, postponement and standstill agreement from each holder of indebtedness which is intended to constitute Subordinated Debt; and
(b)	if requested by the Agent upon the instructions of the Required Lenders, a Landlord Agreement in respect of any one or more of the Leased Properties.

It shall constitute an Event of Default if any item of Security listed above is not provided to the Agent.

8.03 General Provisions re Security; Registration

The Security shall be in form and substance satisfactory to the Agent and the Lenders in their sole discretion. The Security shall be held by the Agent for the benefit of the Lenders. The Agent may require that any item of Security be governed by the laws of the jurisdiction where the property subject to such item of Security is located. The Security shall be registered by the Borrower where necessary or desirable to record and perfect the charges contained therein, as determined by the Agent in its sole discretion, specifically including registrations in the Canadian Intellectual Property Office in respect of any patents or trade marks which the Lenders acting reasonably consider to be material. Notwithstanding the foregoing:

(a) prior to the occurrence of a Default or Event of Default the Security relating to Intellectual Property in respect of Emselex shall be registered only in those countries where the sales of such Key Product are considered by the Required Lenders acting reasonably to be material, which as at the date of this Agreement are acknowledged to be as follows: Germany, Switzerland, Great Britain, Netherlands and Belgium; and the Borrower agrees to effect Security registrations in the foregoing countries in respect of the Intellectual Property relating to Emselex as soon as reasonably possible following the first Advance hereunder and complete such registrations within six (6) months following the first Advance hereunder;

- 56 -

(b)

prior to the occurrence of a Default or Event of Default the Security relating to Intellectual Property in respect of Sintrom shall be registered only in those countries where the sales of such Sintrom are considered by the Required Lenders acting reasonably to be material, which as at the date of this Agreement are acknowledged to be as follows: Spain, Italy, Greece, Bulgaria and Romania; and the Borrower agrees to register the Sintrom Licence Agreement (or notice thereof) and such Security in the foregoing countries (to the extent such registration is permitted in such jurisdictions) in respect of the Intellectual Property relating to Sintrom as soon as reasonably possible following the first Advance hereunder and complete such registrations within six (6) months following the first Advance hereunder; and

(c)

the Borrower agrees to register the Security (or notice thereof) relating to inventory of Merus Luxco located in Germany as soon as reasonably possible following the first Advance hereunder and complete such registrations within six (6) months following the first Advance hereunder.

8.04 Opinions re Security

Except as otherwise expressly provided herein, the Borrower shall cause to be delivered to the Agent the opinions of the solicitors for the Companies regarding their corporate status, the due authorization, execution and delivery of the Security provided by them, all registrations in respect of the Security, the results of all applicable searches in respect of them, and the enforceability of such Security; all such opinions to be in form and substance satisfactory to the Agent and its counsel.

8.05 After-Acquired Property, Further Assurances

The Borrower shall execute and deliver from time to time, and cause each Subsidiary to execute and deliver from time to time, all such further documents and assurances as may be reasonably required by the Agent and the Lenders from time to time, not inconsistent with the terms of this Agreement, in order to provide the Security contemplated hereunder, specifically including: supplemental or additional security agreements, assignments and pledge agreements which shall include lists of specific assets to be subject to the security interests required hereunder.

8.06 Security for Hedge Transactions

If a Lender continues to be a party to one or more Hedge Transactions with the Borrower after all other indebtedness and obligations of the Borrower to such Lender hereunder have been repaid and satisfied in full (or assigned by such Lender to an assignee), for greater certainty such Lender shall continue to be a Lender for all purposes of this Agreement and the obligations under such Hedge Transactions shall continue to be secured by the Security as provided herein, but such Lender shall not thereafter be a "Required Lender" as such term is defined herein.

8.07	Luxembourg Guarantee Limitation
(a)	Notwithstanding anything to the contrary contained in this Agreement or in any other Loan Documents, the aggregate obligations and exposure of a Luxembourg Guarantor in respect of the obligations of an affiliated entity which is not a direct or indirect subsidiary of such Luxembourg Guarantor shall be limited at any time to an aggregate amount not exceeding 90% of the greater of:

- 57 -

(i)

an amount equal to the sum of the Luxembourg Guarantor's Net Assets and its subordinated debt (dettes subordonnes), as referred to in the Luxembourg Act of 19 December 2002 on the Register of Commerce and Companies, on accounting and on annual accounts of the companies, as amended (the 2002 Law) and as reflected in the financial information of the Luxembourg Guarantor available to the Agent as at the date of this Agreement (or its accession as a Guarantor), including, without limitation, its most recently and duly approved financial statements (comptes annuels) and any (unaudited) interim financial statements signed by its board of managers (grants) or directors (administrateurs); and

(ii)

an amount equal to the sum of the Luxembourg Guarantor's Net Assets and its subordinated debt (dettes subordonnes), as referred to in the 2002 Law and as reflected in the financial information of the Luxembourg Guarantor available to the Agent as at the date the guarantee is called, including, without limitation, its most recently and duly approved financial statements (comptes annuels) and any (unaudited) interim financial statements signed by its board of managers (grants) or directors (administrateurs).

For this purpose, "Net Assets" (actifs) will be determined in accordance with Article 34 of the 2002 Law.

(b)	With respect to the Guarantee provided by Merus Luxco in respect of the Obligations concurrently with the execution of this Agreement, the Borrower hereby represents and warrants that the amount referred to in paragraph (a) above is One Hundred Seventeen Million Euros (€117,000,000).
(c)	The limitation set forth at paragraph (a) above shall not apply to any amounts borrowed under this Agreement and made available, in any form whatsoever, to such Luxembourg Guarantor or any of its direct or indirect subsidiaries.

8.08 Insurance by Agent

If the Borrower does not provide the Agent with evidence of continuing insurance coverage which satisfies the requirements of this Agreement, the Agent may, but shall have no obligation to, purchase such insurance in order to protect the interests of the Agent and the Lender in the Collateral. Such insurance may also, but need not, also protect the Companies’ interests in the Collateral. The Borrower may cancel any such insurance purchased by the Agent, but only after providing the Agent with evidence satisfactory to the Agent that the Borrower has obtained all insurance coverage required by this Agreement. The Borrower agrees to immediately reimburse the Agent upon demand for all costs and expenses incurred by the Agent in respect of the purchase of any such insurance, and until so paid such expenses shall constitute part of the Obligations, shall bear interest as provided in section 10.09 and shall be secured by the Security.

- 58 -

8.09 Insurance Proceeds

If insurance proceeds become payable in respect of loss of or damage to any property owned by a Company:

(a)	if an Event of Default has occurred and is continuing at such time, the Required Lenders shall apply such proceeds against the Obligations (unless otherwise agreed by the Required Lenders in their sole discretion);
(b)	if no Event of Default has occurred and is continuing at such time, and such proceeds are less than Five Hundred Thousand Dollars ($500,000) the Required Lenders agree to consent to the payment of such proceeds to such Company if:

(i)	such property has been repaired or replaced and the proceeds will reimburse the Company for payments it has made for such purpose; or
(ii)	the Company confirms in writing to the Agent that it will forthwith use such proceeds to repair or replace such property; and

(c) if no Event of Default has occurred and is continuing at such time, and such proceeds are equal to or greater than Five Hundred Thousand Dollars ($500,000), the Required Lenders shall apply such proceeds against the Obligations (unless otherwise agreed by the Required Lenders in their sole discretion).

8.10 Successors and Assigns

In case of assignment, transfer or novation by a Lender to a new lender or a participant, of all or any part of its rights and obligations under this Agreement or any of the other Loan Documents, the Lenders and the new lender or participant shall agree that, for the purposes of Article 1278 and/or Article 1281 of the Luxembourg Civil Code (to the extent applicable), any assignment, amendment, transfer and/or novation of any kind permitted under, and made in accordance with the provisions of the Agreement or any agreement referred to herein to which a Luxembourg Guarantor is a party (including any Security), any security created or guarantee given under the Agreement or in relation to the Agreement shall be preserved and continue in full force and effect to the benefit of the new lender or participant.

- 59 -

ARTICLE IX - CONDITIONS PRECEDENT

9.01 Conditions Precedent to First Advance

The Lenders shall have no obligation to make the first Advance to the Borrower hereunder unless at the time of making such Advance the following terms and conditions shall have been satisfied, in each case to the satisfaction of the Agent and the Lenders in their sole discretion:

(a) the Lenders shall have completed and shall be satisfied with their due diligence in respect of the Companies, specifically including due diligence with respect to:

(i)	the Year-end Financial Statements in respect of the Fiscal Years ended September 30, 2012 and September 30, 2013, and the Interim Financial Statements in respect of the Fiscal Quarter ended June 30, 2014;
(ii)	financial projections for the Fiscal Years ending September 30, 2014, September 30, 2015 and September 30, 2016, taking into account the Sintrom Purchase Transaction and the increase in the Facility 1 Maximum Amount contemplated herein;
(iii)	the most current aged accounts receivable and accounts payable listings for the Companies;
(iv)	insurance policies;
(v)	the terms and conditions of the Novartis Enablex Agreements and all other Material Agreements;
(vi)	the terms and conditions of all Material Permits;
(vii)	the status of any litigation which may affect the Companies;
(viii)	the corporate and capital structure of the Companies;
(ix)	key management of the Companies; and
(x)	business, environmental, regulatory, tax and legal matters;

(b)

the Lenders shall have completed and shall be satisfied with their due diligence in respect of the Borrower and the Sintrom Purchase Transactions, specifically including the terms and conditions of the Novartis Sintrom Agreements (both as to legal and business matters):

(c)

the Agent shall have received a certificate from an officer of the Borrower confirming that the transactions contemplated by the Novartis Sintrom Agreements (other than transactions expressly provided therein to occur at a future time) shall be completed concurrently with the making of the Advance under Facility 1, without waiver of any conditions precedent contained therein for the benefit of the Borrower, and that all approvals from Governmental Authorities or third parties which are necessary in connection therewith have been given unconditionally and without containing any onerous terms, except as provided in Section 7.05 herein;

- 60 -

(d)	the Security shall have been executed and delivered and all registrations necessary or desirable in connection therewith shall have been made (except to the extent described in section 8.03), and any other documentation required by the Agent and the Lenders shall have been executed and delivered, all in form and substance satisfactory to the Agent and the Lenders in their sole discretion;
(e)	the Agent and the Lenders shall have received satisfactory evidence that there are no Liens affecting any of the Companies or the Sintrom Rights, except for Permitted Liens;
(f)	the lenders under the Borrower’s existing credit facilities shall have provided a statement of the amount of the Borrower’s indebtedness thereunder and a written undertaking to release and discharge all security and guarantees held in connection therewith upon repayment of such amount, and arrangements satisfactory to the Agent and the Lenders shall have been made for the repayment of such indebtedness using the proceeds of the first Advance hereunder;
(g)	to the extent requested by the Agent, the Agent and the Lenders shall have received particulars of all Permitted Liens, specifically including the assets encumbered thereby, the amounts due thereunder, and confirmation from the holders thereof that the terms thereof are being complied with;
(h)	the Agent shall have received satisfactory evidence that the property and assets of the Companies are insured in accordance with the requirements herein;
(i)	the Agent shall have received satisfactory evidence that the Borrower has available cash (for greater certainty, excluding the proceeds from any Advances hereunder) in an amount not less than Sixty-Seven Million Dollars ($67,000,0000);
(j)	the Agent and the Lenders shall have received a pro forma Compliance Certificate which evidences the Borrower’s compliance with the financial ratios and covenants set out in section 7.03 herein as at the Closing Date, determined as if the Sintrom Purchase Transaction had been completed;
(k)	any necessary governmental, regulatory and third party approvals necessary in connection with this Agreement and the transactions contemplated herein shall have been given unconditionally and without containing any onerous terms;
(l)	the Agent shall have received a certificate of status, certificate of compliance or similar certificate for each Company (other than a Luxembourg Guarantor) issued by its governing jurisdiction;
(m)	the Agent shall have received an officer's certificate and certified copies of resolutions of the board of directors of each Company concerning the due authorization, execution and delivery of the Loan Documents to which it is a party, and such related matters as the Agent and the Lenders may reasonably require;

- 61 -

(n)	for each Luxembourg Guarantor, the Agent shall have received (i) an electronic certified excerpt of the Luxembourg Companies Register dated no more than one Business Days prior to the date of this Agreement (ii) a solvency certificate dated as of the date of this Agreement (signed by a director or an authorized signatory) that it is not subject to nor, as applicable, does it meet or threaten to meet the criteria of bankruptcy (faillite), insolvency, voluntary or judicial liquidation (liquidation volontaire ou judiciaire), composition with creditors (concordat prventif de faillite), controlled management (gestion contrle), reprieve from payment (sursis de paiement), general settlement with creditors, reorganization or similar laws affecting the rights of creditors generally and no application has been made or is to be made by its director or, as far as it is aware, by any other Person for the appointment of a commissaire, juge-commissaire, liquidateur, curateur or similar officer pursuant to any voluntary or judicial insolvency, winding-up, liquidation or similar proceedings and (iii) an electronic certified copy of a certificate of non-registration of judgments (certificat de non-inscription d’une dcision judiciaire), issued by the Luxembourg Companies Register on the date of this Agreement and reflecting the situation no more than one Business Day prior to the date of this Agreement, certifying that, as of the date of the day immediately preceding such certificate, the Luxembourg Guarantor has not been declared bankrupt (en faillite), and that it has not applied for general settlement or composition with creditors (concordat prventif de faillite), controlled management (gestion controlee), or reprieve from payment (sursis de paiement), judicial or voluntary liquidation (liquidation judiciaire ou volontaire), such other proceedings listed at Article 13, items 2 to 11, 13 and Article 14 of the Luxembourg Act dated 19 December 2002 on the Register of Commerce and Companies, on Accounting and on Annual Accounts of the Companies (as amended from time to time), (and which include foreign court decisions as to faillite, concordat or analogous procedures according to Council Regulation (EC) n1346/2000 of 29 May 2000 on insolvency proceedings);
(o)	the Agent and the Lenders shall have received an opinion from the solicitors for each Company (other than with respect to Merus Netherlands in which case such opinion will be provided by Agent’s counsel) regarding its corporate status, the due authorization, execution, delivery and enforceability of the Loan Documents (other than the Loan Documents governed by Luxembourg law in which case such opinion on enforceability of such Loan Documents will be provided by Agent’s counsel) provided by it, and such other matters as the Agent and the Lenders may reasonably require, in form and substance satisfactory to the Agent and the Lenders in their sole discretion;
(p)	the Borrower shall have paid to the Agent all fees and expenses (including the Agent’s legal expenses) relating to the establishment of Facility 1, specifically including all underwriting fees, arrangement fees and similar fees as agreed in writing between the Borrower and the Agent;
(q)	the Borrower shall have satisfied all requirements of each Lender under AML Legislation; and
(r)	the Agent and the Lenders shall have received such additional evidence, documents or undertakings as it may reasonably require to complete the transactions contemplated hereby in accordance with the terms and conditions contained herein.

- 62 -

ARTICLEX - DEFAULT AND REMEDIES

10.01 Events of Default

The occurrence of any one or more of the following events, after the expiry of any applicable cure period set out below, shall constitute an event of default under this Agreement (an "Event of Default"):

(a)	any Company fails to pay any principal, Interest or other amount under this Agreement or any other Loan Document when due;
(b)	any representation or warranty provided by a Company to the Agent or the Lenders herein or in any other Loan Document was incorrect in any material respects on the date on which such representation or warranty was made;
(c)	the Borrower fails to perform or comply with any of the covenants set out in section 7.03;
(d)	any Company fails to perform or comply with any of its covenants or obligations contained in this Agreement, the Security or any other agreement made between it and any Lenders (other than those set out in paragraphs (a), (b), and (c) above) after receipt of notice of such non-compliance from the Agent; provided that if such non-compliance is capable of remedy within ten (10) days and such Company diligently attempts to remedy such non-compliance and informs the Agent of its efforts in this regard, and such non-compliance is remedied within such period, then such non-compliance shall be deemed not to constitute an Event of Default;
(e)	any Company is in default in the payment or performance of any of its indebtedness or obligations under any agreement relating to Funded Debt (other than the Outstanding Advances) in excess of Five Hundred Thousand Dollars ($500,000) after the expiry of any grace or cure periods relating thereto;
(f)	an Insolvency Event occurs in respect of any Company;
(g)	any document constituting part of the Security shall for any reason (other than the fault of the Agent or any Lender) cease to be in full force and effect or shall be declared in a final judgment of a court of competent jurisdiction to be null and void; or any Company contests the validity or enforceability thereof or denies it has any further liability or obligation thereunder; or any document (other than a Guarantee) constituting part of the Security shall for any reason fail to create a valid and perfected First-Ranking Security Interest in and to the property purported to be subject thereto, except that if such failure is capable of remedy within thirty (30) days, the Borrower or such Company diligently attempts to remedy such failure and diligently informs the Agent of its efforts in this regard, and the failure is remedied within such thirty (30) day period, then the failure shall not constitute an Event of Default;
(h)	any Person which has provided a Guarantee in respect of the Obligations terminates or purports to terminate its liability under such Guarantee or its liability thereunder in respect of any future Advances, or disputes the validity or enforceability of such Guarantee or any Security provided by it;

- 63 -

(i)	any Person having the right to do so takes possession of any property of a Company with a value in excess of Five Hundred Thousand Dollars ($500,000) by way of or in contemplation of enforcement of security, or a distress or execution or similar process is levied or enforced against any such property;
(j)	one or more final judgments or decrees for the payment of money shall have been obtained or entered against any one or more of the Companies in excess of Five Hundred Thousand Dollars ($500,000) in the aggregate and shall remain unpaid for a period in excess of thirty (30) days; unless such judgement is fully covered by insurance (subject to a reasonable deductible amount) and the insurer thereof has confirmed such coverage in writing;
(k)	any Governmental Authority shall take any action to condemn, seize or appropriate any property of any Company with a value in excess of Five Hundred Thousand Dollars ($500,000) unless such Governmental Authority has paid a fair and reasonable expropriation amount;
(l)	any Person (or group of Persons acting in concert) (i) has Control of the Borrower at any time; or (ii) collectively holds, directly or indirectly, shares in the capital of the Borrower at any time to which are attached votes representing more than fifty-one percent (51%) of all votes attached to all issued and outstanding shares in the capital of the Borrower;
(m)	the Borrower's auditors include any adverse qualification in their audit letter relating to the Year-end Financial Statements, unless the Required Lenders acting reasonably are satisfied that such qualification is not material;
(n)	any of the Novartis Agreements is terminated, or Novartis is in material breach (after the expiry of any applicable grace or cure periods relating thereto) of any of its material obligations under any of the Novartis Agreements, unless such breach is waived in writing by Merus with the prior written consent of the Required Lenders;
(o)	applications to transfer the Sintrom Marketing Authorizations have not been filed within eighteen (18) months after the Closing Date;
(p)	the Sintrom Marketing Authorizations have not been transferred to Merus Luxco within thirty-six (36) months after the Closing Date; or
(q)	a Material Adverse Change occurs and is continuing.

10.02 Acceleration, etc.

(a)

Upon the occurrence of an Event of Default which is continuing the Agent shall, upon the instructions of the Required Lenders, issue a written notice to the Borrower (a "Acceleration Notice") declaring all of the Obligations to be immediately due and payable.

(b)

Upon receipt of an Acceleration Notice the Borrower shall immediately pay and satisfy the Obligations, including payment to the Agent of the following amounts (without duplication): (i) the Outstanding Advances and all accrued and unpaid interest, fees and other amounts relating thereto; (ii) the net aggregate amount of the Borrower's liability under all Hedge Transactions outstanding on such date in the event of a default or termination thereunder, determined in accordance with the terms thereof (and for greater certainty, determined after netting any amounts payable to the Borrower thereunder against amounts payable by the Borrower thereunder); and (iii) an amount equal to the face amount of all Bankers' Acceptances and BA Equivalent Loans then outstanding. The Agent shall hold all such amounts paid by the Borrower in respect of such Hedge Transactions, Bankers’ Acceptances and BA Equivalent Loans as security for the Borrower's obligations thereunder.

- 64 -

(c)	At any time on or after the Acceleration Date the Agent may exercise any and all rights and remedies hereunder and under any other Loan Documents, including the enforcement of all or any portion of the Security.
(d)	From and after the date of the occurrence of an Event of Default and for so long as such Event of Default continues, both before and after the issuance of an Acceleration Notice, all Outstanding Advances shall bear interest or fees at the rates otherwise applicable plus two percent (2%) per annum in order to compensate the Lenders for the additional risk.

10.03 Acceleration of Certain Contingent Obligations

Upon the occurrence of an Event of Default which is continuing, any Lender which has issued a Bankers' Acceptance, BA Equivalent Note or LIBOR Loan or entered into a Hedge Transaction with the Borrower may make a Prime Rate Loan, Base Rate Loan or U.S. Dollar Prime-Based Loan to the Borrower in an amount equal to the face amount of such Bankers' Acceptance, BA Equivalent Note or LIBOR Loan, or the amount required to unwind such Hedge Transaction (such amount to be determined in accordance with the terms thereof), as the case may be; and the proceeds of any such Loan shall be held by such Lender and used to satisfy the Lender's obligations under the said Bankers' Acceptance, BA Equivalent Note or LIBOR Loan as such becomes due, or to effect the unwinding of such Hedge Transaction. Any such Loan shall bear interest at the rate and in the manner applicable to Prime Rate Loans, Base Rate Loans or U.S. Dollar Prime-Based Loans, as applicable, under Facility 1.

10.04 Combining Accounts, Set-Off

Upon the occurrence and during the continuation of an Event of Default, in addition to and not in limitation of any rights now or hereafter granted under Applicable Law, each Lender may at any time and from time to time:

(a)	combine, consolidate or merge any or all of the deposits or other accounts maintained with such Lender by such Company (whether term, notice, demand or otherwise and whether matured or unmatured) and such Company's obligations to such Lender hereunder; and
(b)	set off, apply or transfer any or all sums standing to the credit of any such deposits or accounts in or towards the satisfaction of such obligations.

- 65 -

Each Lender may exercise any rights pursuant to this section 10.04 without prior notice to any Company, but agrees to provide written notice to the Agent and the Borrower promptly after exercising any such rights.

10.05 Appropriation of Monies

After the occurrence and during the continuation of an Event of Default the Agent may from time to time, but subject to section 11.03, apply any Proceeds of Realization against any portion or portions of the Obligations, and the Borrower may not require any different application. The taking of a judgment or any other action or dealing whatsoever by the Agent or the Lenders in respect of the Security shall not operate as a merger of any of the Obligations hereunder or in any way affect or prejudice the rights, remedies and powers which the Agent or the Lenders may have, and the foreclosure, surrender, cancellation or any other dealing with any Security or the said obligations shall not release or affect the liability of the Borrower or any other Person in respect of the remaining portion of the Obligations.

10.06 No Further Advances

The Lenders shall not be obliged to make any further Advances (including honouring any cheques drawn by the Borrower which are presented for payment) from and after the earliest to occur of the following: (i) delivery by the Agent to the Borrower of a written notice that a Default or an Event of Default has occurred and is continuing and that as a result thereof no further Advances will be made (whether or not such notice also requires immediate repayment of the Obligations); (ii) the occurrence of an Insolvency Event; and (iii) receipt by the Agent or any Lender of any garnishment notice, notice of a Statutory Lien or other notice of similar effect in respect of any Company pursuant to the Income Tax Act (Canada), the Excise Tax Act (Canada) or any similar notice under any other statute in effect in any jurisdiction.

10.07 Judgment Currency

If for the purposes of obtaining judgment against the Borrower in any court in any jurisdiction with respect to this Agreement it becomes necessary for a Lender to convert into the currency of such jurisdiction (in this section called the "Judgment Currency") any amount due to the Lender by the Borrower hereunder in any currency other than the Judgment Currency, the conversion shall be made at the Exchange Rate prevailing on the Business Day before the day on which judgment is given. In the event that there is a change in the Exchange Rate prevailing between the Business Day before the day on which the judgment is given and the date of payment of the amount due, the Borrower will, on the date of payment, pay such additional amounts (if any) or be entitled to receive reimbursement of such amount, if any, as may be necessary to ensure that the amount paid on such date is the amount in the Judgment Currency which when converted at the Exchange Rate prevailing on the date of payment is the amount then due under this Agreement in such other currency. Any additional amount due by the Borrower under this section will be due as a separate debt and shall not be affected by judgment being obtained for any other sums due under or in respect of this Agreement.

10.08 Remedies Cumulative

All rights and remedies granted to the Agent and the Lenders in this Agreement, and any other documents or instruments in existence between the parties or contemplated hereby, and any other rights and remedies available to the Agent and the Lenders at law or in equity, shall be cumulative. The exercise or failure to exercise any of the said remedies shall not constitute a waiver or release thereof or of any other right or remedy, and shall be non-exclusive.

- 66 -

10.09 Performance of Covenants by Agent

If the Borrower fails to perform any covenant or obligation to be performed by it pursuant to this Agreement, the Agent may in its sole discretion perform any of the said obligations but shall be under no obligation to do so; and any amounts expended or advanced by the Agent for such purpose shall be payable by the Borrower upon demand together with interest at the highest rate then applicable to Facility 1.

- 67 -

ARTICLE XI - THE AGENT AND THE LENDERS

11.01 Decision-Making

(a) Any amendment to this Agreement relating to the following matters, and the granting of any waiver or consent by the Lenders in respect of such matters, shall require the unanimous agreement of the Lenders:

(i)	changes to the interest rates and fees payable in respect of Facility 1;
(ii)	increases in the maximum amount of credit available under Facility 1;
(iii)	extensions of the maturity date of Facility 1;
(iv)	changes to the scheduled dates or the scheduled amounts for Repayments hereunder;
(v)	releases of all or any portion of the Security, except to the extent provided in paragraph (c) below;
(vi)	the definitions of “Required Lenders” and “Proportionate Share” in section 1.01;
(vii)	any provision of this Agreement which expressly states that the unanimous consent of the Lenders is required in connection with any action to be taken or consent to be provided by the Lenders; and
(viii)	this section 11.01.

(b)	Except for the matters described in paragraph (a) above, any amendment to this Agreement shall be effective if made among the Borrower, the Agent and the Required Lenders, and for greater certainty any such amendment which is agreed to by the Required Lenders shall be final and binding upon all Lenders.
(c)	The Agent may from time to time without notice to or the consent of the Lenders execute and deliver partial releases of the Security in respect of any item of Collateral (whether or not the proceeds of sale thereof are received by the Agent) which the Companies are permitted to dispose of pursuant to this Agreement without obtaining the prior written consent of the Lenders; and in releasing any such security the Agent may rely upon and assume the correctness of all information contained in any certificate or document provided by the Borrower, without further enquiry. Otherwise, any release or discharge in respect of the Security or any portion thereof shall require the written consent of the Lenders acting unanimously.
(d)	Except for the matters which require the unanimous consent of the Lenders as set out in the foregoing paragraphs of this section 11.01, and except as otherwise specifically provided in this Agreement, any action to be taken or decision to be made by the Lenders pursuant to this Agreement (specifically including for greater certainty the issuance of written notice to the Borrower of the occurrence of a Default or Event of Default, the issuance of a demand for payment of the Obligations, a decision to make an Advance despite any condition precedent relating thereto not being satisfied, the provision of any waiver in respect of a breach of any covenant or the granting of any consent) shall be effective if approved by the Required Lenders; and any such decision or action shall be final and binding upon all the Lenders.

- 68 -

(e) Any action to be taken or decision to be made by the Lenders pursuant to this Agreement which is required to be unanimous shall be made at a meeting of the Lenders called by the Agent pursuant to paragraph 11.06(l) or by a written instrument executed by all of the Lenders. Any action to be taken or decision to be made by the Lenders pursuant to this Agreement which is required to be made by the Required Lenders shall be made at a meeting of the Lenders called by the Agent pursuant to paragraph 11.06(l) or by a written instrument executed by the Required Lenders. Any such instrument may be executed by fax or pdf and in counterparts.

11.02 Security

(a)

Except to the extent provided in paragraph (b), the Security shall be granted in favour of and held by the Agent for and on behalf of the Lenders in accordance with the provisions of this Agreement. The Agent shall, in accordance with its usual practices in effect from time to time, take all steps required to perfect and maintain the Security, including: taking possession of the certificates representing the securities required to be pledged hereunder; filing renewals and change notices in respect of such Security; and ensuring that the name of the Agent is noted as loss payee or mortgagee on all property insurance policies covering the Collateral. If the Agent becomes aware of any matter concerning the Security which it considers to be material, it shall promptly inform the Lenders. The Agent shall comply with all instructions provided by the Lenders in connection with the enforcement or release of the Security which it holds. The Agent agrees to permit each Lender to review and make photocopies of the original documents comprising the Security from time to time upon reasonable notice.

(b)

If any Company has provided security in favour of any Lender directly such as but not limited to security provided in favour of BMO prior to the date hereof and security under the Bank Act (Canada), such Lender agrees to pay to the Agent all amounts received by it in connection with the enforcement of such security, and all such amounts shall be deemed to constitute Proceeds of Realization and shall be dealt with as provided in section 11.03. Each Lender which holds any such Security agrees that it shall not enforce such security unless and until the Required Lenders have made a determination to enforce the Security pursuant to paragraph 11.01(d).

11.03 Application of Proceeds of Realization

Notwithstanding any other provision of this Agreement, the Proceeds of Realization of the Security or any portion thereof shall be distributed in the following order:

(a) first, in payment of all costs and expenses incurred by the Agent and the Lenders in connection with such realization, including legal, accounting and receivers' fees and disbursements;

- 69 -

(b)	second, against the remaining Obligations (except those referred to in paragraph (c) below), on a pari passu basis among the Lenders to whom such Obligations are payable;
(c)	third, to pay any Obligations owed to Non-Funding Lenders, on a pari passu basis among the Non-Funding Lenders to whom such Obligations are payable; and
(d)	fourth, if all obligations of the Borrower listed above have been paid and satisfied in full, any surplus Proceeds of Realization shall be paid in accordance with Applicable Law.

11.04 Payments by Agent

(a) The following provisions shall apply to all payments made by the Agent to the Lenders hereunder:

(i)	the Agent shall be under no obligation to make any payment (whether in respect of principal, interest, fees or otherwise) to any Lender until an amount in respect of such payment has been received by the Agent from the Borrower;
(ii)	if the Agent receives a payment of principal, interest, fees or other amount owing by a Borrower under Facility 1 which is less than the full amount of any such payment due, the Agent shall distribute such amount received among the Lenders in each Lender’s Proportionate Share of Facility 1;
(iii)	if any Lender has advanced more or less than its Proportionate Share of its Commitment under Facility 1, such Lender’s entitlement to such payment shall be increased or reduced, as the case may be, in proportion to the amount actually advanced by such Lender;
(iv)	if a Lender’s Proportionate Share of an Advance under Facility 1 thereof has been advanced for less than the full period to which any payment by the Borrower relates, such Lender’s entitlement to receive a portion of any payment of interest or fees shall be reduced in proportion to the length of time such Lender’s Proportionate Share has actually been outstanding (unless such Lender has paid all interest required to have been paid by it to the Agent pursuant to the CBA Model Provisions);
(v)	the Agent acting reasonably and in good faith shall, after consultation with the Lenders in the case of any dispute, determine in all cases the amount of all payments to which each Lender is entitled and such determination shall be deemed to be prima facie correct;
(vi)	upon request, the Agent shall deliver a statement detailing any of the payments to the Lenders referred to herein;
(vii)	all payments by the Agent to a Lender hereunder shall be made to such Lender at its address set out herein unless notice to the contrary is received by the Agent from such Lender; and

- 70 -

(viii) if the Agent has received a payment from a Borrower on a Business Day (not later than the time required for the receipt of such payment as set out in this Agreement) and fails to remit such payment to any Lender entitled to receive its Proportionate Share of such payment on such Business Day, the Agent agrees to pay interest on such late payment at a rate determined by the Agent in accordance with prevailing banking industry practice on interbank compensation.

(b) The Agent may in its sole discretion from time to time make adjustments in respect of any Lender’s share of a Drawdown, Conversion, Rollover or Repayment under Facility 1 in order that the Outstanding Advances due to such Lender under Facility 1 shall be approximately in accordance with such Lender’s Proportionate Share of Facility 1.

11.05 Protection of Agent

(a)	Unless the Agent has actual knowledge or actual notice to the contrary, it may assume that each Lender's address set out in Exhibit A attached hereto is correct, unless and until it has received from such Lender a notice designating a different address.
(b)	The Agent may engage and pay for the advice or services of any lawyers, accountants or other experts whose advice or services may to it seem necessary, expedient or desirable and rely upon any advice so obtained (and to the extent that such costs are not recovered from the Borrower pursuant to this Agreement, each Lender agrees to reimburse the Agent in such Lender's Proportionate Share of such costs).
(c)	Unless the Agent has actual knowledge or actual notice to the contrary, it may rely as to matters of fact which might reasonably be expected to be within the knowledge of any Company upon a statement contained in any Loan Document.
(d)	Unless the Agent has actual knowledge or actual notice to the contrary, it may rely upon any communication or document believed by it to be genuine.
(e)	The Agent may refrain from exercising any right, power or discretion vested in it under this Agreement unless and until instructed by the Required Lenders as to whether or not such right, power or discretion is to be exercised and, if it is to be exercised, as to the manner in which it should be exercised (provided that such instructions shall be required to be provided by all of the Lenders in respect of any matter for which the unanimous consent of the Lenders is required as set out herein).
(f)	The Agent may refrain from exercising any right, power or discretion vested in it which would or might in its sole and unfettered opinion be contrary to any law of any jurisdiction or any directive or otherwise render it liable to any Person, and may do anything which is in its opinion in its sole discretion necessary to comply with any such law or directive.
(g)	The Agent may refrain from acting in accordance with any instructions of the Required Lenders to begin any legal action or proceeding arising out of or in connection with this Agreement or take any steps to enforce or realize upon any Security, until it shall have received such security as it may reasonably require (whether by way of payment in advance or otherwise) against all costs, claims, expenses (including legal fees) and liabilities which it will or may expend or incur in complying with such instructions.

- 71 -

(h)

The Agent shall have no obligation to disclose to any Person any information relating to the Companies or any Related Person if such disclosure would or might in its opinion in its sole discretion constitute a breach of any law or regulation or be otherwise actionable at the suit of any Person.

(i)

The Agent does not accept any responsibility for the accuracy and/or completeness of any information supplied in connection herewith or for the legality, validity, effectiveness, adequacy or enforceability of any Loan Document and shall not be under any liability to any Lender as a result of taking or omitting to take any action in relation to any Loan Document except in the case of its gross negligence or wilful misconduct.

11.06 Duties of Agent

The Agent shall:

(a)	as a non-fiduciary agent for the Borrower, maintain a record of the Outstanding Advances owing to each Lender, which record shall conclusively be presumed to be correct and accurate, absent manifest error;
(b)	hold and maintain the Security to the extent provided in section 11.02;
(c)	provide to each Lender copies of all financial information received from the Borrower promptly after receipt thereof, and copies of any Draw Requests, Conversion Notices, Rollover Notices, Repayment Notices and other notices received by the Agent from the Borrower upon request by any Lender;
(d)	promptly advise each Lender of Advances required to be made by it hereunder and disburse all Repayments to the Lenders hereunder in accordance with the terms of this Agreement;
(e)	promptly notify each Lender of the occurrence of any Default of which the Agent has actual knowledge or actual notice;
(f)	at the time of engaging any agent, receiver, receiver-manager, consultant, monitor or other party in connection with the Security or the enforcement thereof, obtain the agreement of such party to comply with the applicable terms of this Agreement in carrying out any such enforcement activities and dealing with any Proceeds of Realization;
(g)	account for any monies received by it in connection with this Agreement, the Security and any other agreement delivered in connection herewith or therewith;
(h)	each time the Borrower requests the written consent of the Lenders in connection with any matter, use its best efforts to obtain and communicate to the Borrower the response of the Lenders in a reasonably prompt and timely manner having due regard to the nature and circumstances of the request;

- 72 -

(i)	give written notice to the Borrower in respect of any other matter in respect of which notice is required in accordance with or pursuant to this Agreement, promptly or promptly after receiving the consent of the Lenders, if required under the terms of this Agreement;
(j)	except as otherwise provided in this Agreement, act in accordance with any instructions given to it by the Required Lenders;
(k)	refrain from exercising any right, power or discretion vested in it under this Agreement or any document incidental thereto if so instructed by the Required Lenders (in respect of any matter which requires the consent of the Required Lenders), or by all of the Lenders (in respect of any matter which requires the unanimous consent of the Lenders); and
(l)	call a meeting of the Lenders at any time not earlier than five (5) days and not later than thirty (30) days after receipt of a written request for a meeting provided by any Lender.

11.07 Lenders' Obligations Several; No Partnership

The obligations of each Lender under this Agreement are several. The failure of any Lender to carry out its obligations hereunder shall not relieve the other Lenders of any of their respective obligations hereunder. No Lender shall be responsible for the obligations of any other Lender hereunder. Neither the entering into of this Agreement nor the completion of any transactions contemplated herein shall constitute the Lenders a partnership.

11.08 Sharing of Information

The Agent and the Lenders may share among themselves any information they may have from time to time concerning the Companies whether or not such information is confidential; but shall have no obligation to do so (except for any obligations of the Agent to provide information to the extent required in this Agreement).

11.09 Acknowledgement by Borrower

The Borrower hereby acknowledges notice of the terms of the provisions of this Article XI and agrees to be bound hereby to the extent of its obligations hereunder.

11.10 Amendments to Article XI

The Agent and the Lenders may amend any provision in this Article XI, except section 11.01, without prior notice to or the consent of the Borrower, and the Agent shall provide a copy of any such amendment to the Borrower reasonably promptly thereafter; provided however if any such amendment would materially adversely affect any rights, entitlements, obligations or liabilities of the Borrower, including without limitation increasing any fees payable by the Borrower pursuant to section 11.12, such amendment shall not be effective until the Borrower provides its written consent thereto, such consent not to be unreasonably withheld or arbitrarily delayed.

- 73 -

11.11 Deliveries, etc.

As between the Companies on the one hand, and the Agent and the Lenders on the other hand:

(a)	all statements, certificates, consents and other documents which the Agent purports to deliver to a Company on behalf of the Lenders shall be binding on each of the Lenders, and none of the Companies shall be required to ascertain or confirm the authority of the Agent in delivering such documents;
(b)	all certificates, statements, notices and other documents which are delivered by a Company to the Agent in accordance with this Agreement shall be deemed to have been duly delivered to each of the Lenders; and
(c)	all payments which are delivered by the Borrower to the Agent in accordance with this Agreement shall be deemed to have been duly delivered to each of the Lenders.

11.12 Agency Fees

The Borrower agrees to pay to the Agent an annual agency fee in such amount as may be agreed in writing from time to time between the Borrower and the Agent, payable in advance on the date of this Agreement and annually on each anniversary date thereafter during the term of this Agreement.

11.13 Assignment Fee

Each Lender which assigns its interests to another Person agrees to pay an assignment fee of Three Thousand Five Hundred Dollars ($3,500) to the Agent.

11.14 Non-Funding Lender

(a)

Each Non-Funding Lender shall be required, to the extent permitted by applicable law, to provide to the Agent, immediately upon receipt of a written request from the Agent, cash in an amount, as shall be determined from time to time by the Agent in its discretion, equal to all obligations of such Non-Funding Lender to the Agent that are owing or may become owing pursuant to this Agreement, including, without limitation, such Non-Funding Lender's obligation to pay its Proportionate Share of any indemnification or expense reimbursement amounts not paid by the Borrower. Such cash shall be held by the Agent in one or more accounts in the name of the Agent and shall not be required to be interest-bearing. The Agent shall be entitled to apply such cash from time to time in satisfaction of all or any portion of such obligations of such Non-Funding Lender, as determined by the Agent in its discretion.

(b)

The Agent shall be entitled to set off any Non-Funding Lender's Proportionate Share of all payments received from the Borrower against such Non-Funding Lender's obligations to fund payments and Advances required to be made by it and to purchase participations required to be purchased by it in each case under this Agreement and the other Loan Documents. The Agent shall be entitled to withhold and deposit in one or more non-interest bearing accounts in the name of the Agent all amounts (whether principal, interest, fees or otherwise) received by the Agent from the Borrower and due to such Non-Funding Lender pursuant to this Agreement, which amounts shall be used by the Agent (A) first, to reimburse the Agent for any amounts owing to it by such Non-Funding Lender pursuant to this Agreement or any other Loan Document, (B) second, to reimburse the other Lenders in respect of any Advances which may have been made by them in their discretion in order to fund, in whole or in part, any shortfall in Advances which were required to have been made by such Non-Funding Lender (and to the extent that any said Advance made by a Lender is so reimbursed, such Advance shall be deemed to have been assigned by such Lender to the Non-Funding Lender), (C) third, to be held in such account and applied by the Agent from time to time against all other obligations of such Non-Funding Lender to the Agent owing pursuant to this Agreement in such amount as shall be determined from time to time by the Agent in its discretion including, without limitation, such Non-Funding Lender's obligation to pay its Proportionate Share of any indemnification or expense reimbursement amounts not paid by the Borrower, and (D) fourth, at the Agent's discretion, to fund from time to time such Non-Funding Lender's Proportionate Share of Advances under Facility 1.

- 74 -

(c)

A Non-Funding Lender shall have no voting or consent rights with respect to matters under this Agreement or the other Loan Documents, unless and until it is no longer a Non-Funding Lender. Accordingly, the Commitments and the aggregate unpaid principal amount of the Advances owing to any Non-Funding Lender shall be disregarded in the determination of the Required Lenders.

(d)

Neither the Agent nor any of its Affiliates nor any of their respective officers, directors, employees, agents or representatives shall be liable to any Lender (including, without limitation, a Non-Funding Lender) for any action taken or omitted to be taken by them in connection with amounts payable by the Borrower to a Non-Funding Lender and received by the Agent and applied in accordance with the provisions of this Agreement, save and except for the negligence or wilful misconduct of the Agent as determined by a final non-appealable judgment of a court of competent jurisdiction.

- 75 -

ARTICLE XII - CBA MODEL PROVISIONS

12.01 CBA Model Provisions Incorporated by Reference

The CBA Model Provisions (except for the footnotes contained therein) form part of this Agreement and are incorporated herein by reference, subject to the following variations:

(a) Each term set out below which is used as a defined term in the CBA Model Provisions shall be deemed to have been replaced as set out below; and for greater certainty the said replacement term shall have the meaning ascribed thereto in section 1.01 of this Agreement:

• "Administrative Agent" shall be replaced by "Agent";

• "Applicable Percentage" shall be replaced by "Proportionate Share";

• “Interest Period” shall be replaced by “LIBOR Period”;

• "LIBO Rate Loan" shall be replaced by "LIBOR Loan";

• "Loans" shall be replaced by "Advances";

• “Obligors” shall be replaced by “Borrower” (and all necessary changes required by the context shall be deemed to have been made); and

• "Provisions" shall be replaced by "CBA Model Provisions".

(b)	The defined term “Foreign Lender” in the CBA Model Provisions does not include a lender that is resident under the laws of Canada for purposes of the Income Tax Act, Canada.
(c)	"Pro rata share", "rateably" and similar terms in the CBA Model Provisions shall have the meaning ascribed to the term "Proportionate Share" as defined in section 1.01 of this Agreement, if the context requires.
(d)	The terms "Related Parties" and "Related Party" in the CBA Model Provisions shall be deemed to have the meanings ascribed to the defined terms "Related Persons" and "Related Person" in this Agreement, respectively.
(e)	In the third line of subsection 7.7(1) of the CBA Model Provisions, the phrase "…in consultation with the Borrower…" is hereby amended to read "…upon notice to the Borrower…".
(f)	The parties hereby acknowledge and agree that the indemnity contained in clause 9(b)(iii) of the CBA Model Provisions is in addition to and not in substitution for the indemnity contained in section 13.05 of this Agreement.

- 76 -

12.02 Inconsistencies with CBA Model Provisions

To the extent that there is any inconsistency between a provision of this Agreement and a provision of the CBA Model Provisions, the provision of this Agreement shall govern. For greater certainty, a provision of this Agreement and a provision of the CBA Model Provisions shall be considered to be inconsistent if both relate to the same subject-matter and the provision in the CBA Model Provisions imposes more onerous obligations or restrictions than the corresponding provision in this Agreement.

- 77 -

ARTICLE XIII - GENERAL

13.01 Waiver

The failure or delay by the Agent or any Lender in exercising any right or privilege with respect to the non-compliance with any provisions of this Agreement by the Borrower and any course of action on the part of the Agent or any Lender, shall not operate as a waiver of any rights of the Agent or such Lender unless made in writing by Agent or such Lender, as the case may be. Any such waiver shall be effective only in the specific instance and for the purpose for which it is given and shall not constitute a waiver of any other rights and remedies of the Agent or such Lender with respect to any other or future non-compliance.

13.02 Expenses of Agent and Lenders

Whether or not the transactions contemplated by this Agreement are completed or any Advance has been made, the Borrower agrees to pay on demand by the Agent from time to time all reasonable expenses incurred by the Agent or any Lender in connection with this Agreement, the Security and all documents contemplated hereby, specifically including: reasonable expenses incurred by the Agent and the Lenders in respect of due diligence, appraisals, insurance consultations, credit reporting and responding to demands of any Governmental Authority; reasonable legal expenses incurred by the Agent and the Lenders in connection with the preparation and interpretation of this Agreement and the Security and the administration of Facility 1 generally, including the preparation of waivers and partial discharges of Security; and all reasonable legal expenses incurred by the Agent and the Lenders in connection with the protection and enforcement of the Security.

13.03 Debit Authorization

The Borrower hereby authorizes the Agent to debit any account maintained by the Borrower with the Agent, and to set off and compensate against any and all accounts, credits and balances maintained by the Borrower with the Agent, in order to pay (i) any interest or other amounts payable by the Borrower from time to time pursuant to this Agreement when due; and (ii) any expenses referred to in section 13.02 which are not paid by the Borrower within thirty (30) days after receipt by the Borrower of a written request from the Agent for payment of such expenses. The Agent agrees to give written notice to the Borrower of any such debit promptly thereafter.

13.04 General Indemnity

In addition to any other liability of the Borrower hereunder, the Borrower hereby agrees to indemnify and save harmless the Indemnitees from and against all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements (including reasonable legal fees) of any kind or nature whatsoever which may be imposed on, incurred by or asserted against the Indemnitees (except to the extent arising from the negligence or wilful misconduct of such Indemnitees) which relate or arise out of or result from:

(a) any failure by the Borrower to pay and satisfy its obligations hereunder including, without limitation, any costs or expenses incurred by reason of the liquidation or re- employment in whole or in part of deposits or other funds required by the Lenders to fund or maintain Facility 1 or as a result of the Borrower's failure to take any action on the date required hereunder or specified by it in any notice given hereunder;

- 78 -

(b)	any investigation by Governmental Authorities or any litigation or other similar proceeding related to any use made or proposed to be made by the Borrower of the proceeds of any Advance; and
(c)	any instructions given to any Lender to stop payment on any cheque issued by the Borrower or to reverse any wire transfer or other transaction initiated by such Lender at the request of the Borrower.

13.05 Environmental Indemnity

In addition to any other liability of the Borrower hereunder, the Borrower hereby agrees to indemnify and save harmless the Indemnitees from and against:

(a)	any losses suffered by the Indemnitees for, in connection with, or as a direct or indirect result of, the failure of any Company to comply with all Requirements of Environmental Law;
(b)	any losses suffered by the Indemnitees for, in connection with, or as a direct or indirect result of, the presence of any Hazardous Material situated in, on or under any property owned by any of the Companies or upon which any of them carries on business; and
(c)	any and all liabilities, losses, damages, penalties, expenses (including reasonable legal fees) and claims which may be paid, incurred or asserted against the Indemnitees for, in connection with, or as a direct or indirect result of, any legal or administrative proceedings with respect to the presence of any Hazardous Material on or under any property owned by any of the Companies or upon which any of them carries on business, or the discharge, emission, spill, radiation or disposal by any of them of any Hazardous Material into or upon any Land, the atmosphere, or any watercourse or body of water; including the costs of defending and/or counterclaiming or claiming over against third parties in respect of any action or matter and any cost, liability or damage arising out of a settlement entered into by the Indemnitees of any such action or matter;

except to the extent arising from the negligence or wilful misconduct of such Indemnitees.

13.06 Survival of Certain Obligations despite Termination of Agreement

The termination of this Agreement shall not relieve the Borrower from its obligations to the Agent and the Lenders arising prior to such termination, such as obligations arising as a result of or in connection with any breach of this Agreement, any failure to comply with this Agreement or the inaccuracy of any representations and warranties made or deemed to have been made prior to such termination, and obligations arising pursuant to all indemnity obligations contained herein. Without limiting the generality of the foregoing, the obligations of the Borrower to the Agent and the Lenders arising under or in connection with sections 13.04 and 13.05 of this Agreement and section 3.2 of the CBA Model Provisions shall continue in full force and effect despite any termination of this Agreement.

- 79 -

13.07 Interest on Unpaid Costs and Expenses

If the Borrower fails to pay when due any amount in respect of costs or expenses incurred by the Agent or any other amount incurred by the Agent and required to be paid by it hereunder (other than principal or interest on any Advance), it shall pay interest on such unpaid amount from the time such amount is due until paid at the rate equal to the highest rate of interest then applicable under Facility 1.

13.08 Notice

Without prejudice to any other method of giving notice, all communications provided for or permitted hereunder shall be in writing and delivered to the addressee by prepaid private courier or sent by facsimile to the applicable address and to the attention of the officer of the addressee as follows:

(a)	to the Borrower:
	Merus Labs International Inc.
	100 Wellington St. W
	Suite 2110, PO Box 151
	Toronto, Ontario M5K 1H1
	Canada
	Attention: Mr. Andrew Patient
	Fax No: (416) 593-4434
(b)	to the Agent at the following address with respect to Advances, Rollovers, Conversions and Repayments and related matters,:
	Bank of Montreal
	Agent Bank Services
	234 Simcoe Street, 3rd Floor
	Toronto, Ontario M5T 1T4
	Attention: Manager, Agent Bank Services
	Fax No.: (416) 598-6218
(c)	to the Agent at the following address with respect to all other matters (for greater certainty, including financial reporting):
	Bank of Montreal
	First Canadian Place, 4th Floor
	Toronto, Ontario M5X 1A1
	Attention: Agency Deal Specialist
	Fax No.: (416) 359-7796
(d)	to any Lender, at its address noted on Exhibit "A" attached hereto.

Any communication transmitted by prepaid private courier shall be deemed to have been validly and effectively given or delivered on the Business Day after which it is submitted for delivery. Any communication transmitted by facsimile shall be deemed to have been validly and effectively given or delivered on the day on which it is transmitted, if transmitted on a Business Day on or before 5:00 p.m. (local time of the intended recipient), and otherwise on the next following Business Day. Any party may change its address for service by notice given in the foregoing manner.

- 80 -

13.09 Severability

Any provision of this Agreement which is illegal, prohibited or unenforceable in any jurisdiction, in whole or in part, shall not invalidate the remaining provisions hereof; and any such illegality, prohibition or unenforceability in any such jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

13.10 Further Assurances

The Borrower shall, at its expense execute and deliver or cause to be executed and delivered to the Agent, acting reasonably, promptly upon request from time to time all such other and further documents, agreements, opinions, certificates and instruments in compliance with this Agreement, or if necessary or desirable to more fully record or evidence the obligations intended to be entered into herein, or to make any recording, file any notice or obtain any consent.

13.11 Time of the Essence

Time shall be of the essence of this Agreement.

13.12 Promotion and Marketing

For the purpose of promotion and marketing, the Borrower hereby authorizes and consents to the reproduction, disclosure and use by the Lenders and the Agent of its name, identifying logo and Facility 1. The Borrower acknowledges and agrees: that the Lenders shall be entitled to determine, in their sole discretion, whether to use such information; that no compensation will be payable by the Lenders or the Agent in connection therewith; and that the Lenders and the Agent shall have no liability whatsoever to it or any of its employees, officers, directors, affiliates or shareholders in obtaining and using such information as contemplated herein.

13.13 Public Filing of Agreement

The Borrower agrees not to file a copy of this Agreement or any other Loan Document on SEDAR, or otherwise publicly disclose any information contained therein, except (i) on a confidential basis to their respective officers, directors, employees, accountants, lawyers and other professional advisors; (ii) to any bona fide prospective purchaser of the shares of the Borrower or all or substantially all of the assets of the Companies, provided that such Person executes and delivers a confidentiality agreement in form and substance acceptable to the Required Lenders acting reasonably; and (iii) as may be required pursuant to Applicable Law (including without limitation filing a copy of this Agreement on SEDAR or EDGAR). If any such disclosure is required pursuant to Applicable Law, the Borrower will provide at least 2 Business Days' prior written notice to the Agent before making such disclosure if doing so would not cause any Company to breach Applicable Law, and during such period the Agent and the Lenders acting reasonably may indicate to the Borrower which portions of such Loan Documents that they wish not be disclosed, in order to protect the rights of the Agent and the Lenders to maintain the confidentiality of information which the Agent and the Lenders believe is confidential and proprietary to the Agent and the Lenders. The Borrower agrees to comply with any such request unless such compliance would, in the good faith judgment of the Borrower and its legal counsel, contravene Applicable Law. The terms of this section shall survive the termination of this Agreement for a period of two (2) years after termination of this Agreement.

- 81 -

13.14 Entire Agreement; Waivers and Amendments to be in Writing

(a)

This Agreement supersedes all discussion papers, term sheets and other writings which may have been issued by the Agent or the Lenders prior to the date hereof relating to Facility 1, which shall have no further force or effect. This Agreement and any other documents or instruments contemplated herein or therein shall constitute the entire agreement and understanding among the Borrower, the Lenders and the Agent relating to the subject-matter hereof.

(b)

Subject to Section 11.01(b) and Section 11.09, no provision of this Agreement, or any other document or instrument in existence among the parties may be modified, waived or terminated except by an instrument in writing executed by the party against whom such modification, waiver or termination is sought to be enforced.

13.15 Inconsistencies with Security

To the extent that there is any inconsistency between a provision of this Agreement and a provision of any document constituting part of the Security, the provision of this Agreement shall govern. For greater certainty, a provision of this Agreement and a provision of the Security shall be considered to be inconsistent if both relate to the same subject-matter and the provision in the Security imposes more onerous obligations or restrictions than the corresponding provision in this Agreement.

13.16 Governing Law

This Agreement shall be interpreted in accordance with the laws of the Province of British Columbia. Without prejudice to the right of the Agent and the Lenders to commence any proceedings with respect to this Agreement in any other proper jurisdiction, the parties hereby attorn and submit to the jurisdiction of the courts of the Province of British Columbia.

13.17 Execution by Fax and Counterparts

This Agreement may be executed in several counterparts, each of which, when so executed, shall be deemed to be an original and which counterparts together shall constitute one and the same Agreement. This Agreement may be executed by facsimile or pdf, and any signature contained hereon by facsimile or pdf shall be deemed to be equivalent to an original signature for all purposes.

13.18 Binding Effect

This Agreement shall be binding upon and shall enure to the benefit of the parties and their respective successors and permitted assigns; "successors" includes any corporation resulting from the amalgamation of any party with any other corporation.

[The remainder of this page is intentionally blank. Signature page follows.]

IN WITNESS WHEREOF the parties hereto have executed this Agreement.

MERUS LABS INTERNATIONAL INC.

By: “signed”

         name:

         title:

By:

         name:

         title:

BANK OF MONTREAL, as Administrative Agent	BANK OF MONTREAL, as Co-Lead Arranger and as
	a Lender
By: “signed”
name:	By: “signed”
title:	name:
	title:
By:
name:	By: “signed”
title:	name:
	title:
CIT GROUP SECURITIES (CANADA) INC.,	CIT FINANCIAL LTD.,
as Co-Lead Arranger	as a Lender
By: “signed”	By: “signed”
name:	name:
title:	title:
By:	By:
name:	name:
title:	title:
EXPORT DEVELOPMENT CANADA,	LAURENTIAN BANK OF CANADA,
as a Lender	as a Lender
By: “signed”	By: “signed”
name:	name:
title:	title:
By: “signed”	By: “signed”
name:	name:
title:	title:

Credit Agreement – signature page

EXHIBIT A - LENDERS AND LENDERS' COMMITMENTS

Lender	Facility 1	% of Facility 1
Bank of Montreal	35,000,000	43.75%
CIT Financial Ltd.	23,000,000	28.75%
Export Development Canada	12,000,000	15.00%
Laurentian Bank of Canada	10,000,000	12.50%
Total	80,000,000	100.00%

BA Lenders
Bank of Montreal
Laurentian Bank of Canada
Non-BA Lenders
CIT Financial Ltd.
Export Development Corporation
Lenders’ Addresses for Service
Bank of Montreal, Corporate Finance
11th  Floor, First Canadian Place
Toronto, Ontario, M5X 1A1
Attn:	Director, Corporate Finance
Fax:	(416) 360-7168
CIT Financial Ltd.
207 Queens Quay, West, Suite 700
Toronto, ON, M5J 1A7
Attn: Corporate Finance Canada
Fax: 416-594-5995
Export Development Canada
150 Slater Street
Ottawa, ON, K1A 1K3
Attn:	Loan Services - Syndications
Fax:	(613) 598 2514
Laurentian Bank of Canada
130 Adelaide Street West, Suite 300
Toronto, Ontario, M5H 3P5
Attn:	Senior Account Manager, Mid Market
Fax:	(416) 865-5904

EXHIBIT B - DRAW REQUEST

To: Bank of Montreal, as Administrative Agent

     This Draw Request is delivered pursuant to the Credit Agreement made among Merus Labs International Inc. (the “Borrower”), Bank of Montreal, as Administrative Agent (the “Agent”) and the Lenders (as therein defined) dated September 5, 2014 (the “Credit Agreement”). Terms used herein as defined terms shall have the respective meanings ascribed in the Credit Agreement.

1. The Borrower hereby requests an Advance under Facility 1 as follows:

(a)	date of Advance:
(b)	amount of Advance:
(c)	type of Availment Option:
(d)	if Availment Option is one of the following, indicate period requested:

(i)	Banker's Acceptance (or BA Equivalent Loan, if applicable):
	(may have a maturity date of 28 to 182 days (inclusive))
(ii)	LIBOR Loan:
	(Libor Period may be for 1, 2 or 3 months)

(e) payment instructions (if any):

2. The Borrower hereby certifies that as at the date hereof:

(a)	the representations and warranties in Article VI of the Credit Agreement, other than those which are expressly stated to have been made as at the date of the Credit Agreement, are true and correct in all material respects as if made on the date hereof;
(b)	no Default or Event of Default has occurred and is continuing, nor shall the Advance result in the occurrence of a Default or Event of Default; and
(c)	no Material Adverse Change has occurred and is continuing.

- 2 -

Dated this                                            day of                                            ,                                            .

MERUS LABS INTERNATIONAL INC.

By:

       name:

       title:

By:

       name:

       title:

EXHIBIT C – ROLLOVER NOTICE

To: Bank of Montreal, as Administrative Agent

     This Rollover Notice is delivered pursuant to the Credit Agreement made among Merus Labs International Inc. (the “Borrower”), Bank of Montreal, as Administrative Agent (the “Agent”) and the Lenders (as therein defined) dated September 5, 2014 (the “Credit Agreement”). Terms used herein as defined terms shall have the respective meanings ascribed in the Credit Agreement

     The Borrower hereby requests a Rollover under Facility 1 as follows:

(a)	date of maturing Advance:
(b)	amount of maturing Advance:
(c)	type of Availment Option requested:
(d)	if Availment Option is one of the following, indicate period requested:

(i)	Banker's Acceptance (or BA Equivalent Loan, if applicable):
	(may have a maturity date of 28 to 182 days (inclusive))
(ii)	LIBOR Loan:
	(Libor Period may be for 1, 2, or 3 months)

2. The Borrower hereby certifies that as at the date hereof:

(a)	the representations and warranties in Article VII of the Credit Agreement, other than those which are expressly stated to have been made as at the date of the Credit Agreement, are true and correct in all material respects as if made on the date hereof;
(b)	no Default or Event of Default has occurred and is continuing, nor shall the Rollover result in the occurrence of a Default or Event of Default; and
(c)	no Material Adverse Change has occurred and is continuing.

- 2 -

Dated this                                            day of                                            ,                                            .

MERUS LABS INTERNATIONAL INC.

By:

       name:

       title:

By:

       name:

       title:

EXHIBIT D – CONVERSION NOTICE

To: Bank of Montreal, as Administrative Agent

     This Conversion Notice is delivered pursuant to the Credit Agreement made among Merus Labs International Inc. (the “Borrower”), Bank of Montreal, as Administrative Agent (the “Agent”) and the Lenders (as therein defined) dated September 5, 2014 (the “Credit Agreement”). Terms used herein as defined terms shall have the respective meanings ascribed in the Credit Agreement.

1. The Borrower hereby requests a Conversion under Facility 1 as follows:

(a)	type of Advance to be converted:
(b)	maturity date of maturing Advance:
(c)	amount of maturing Advance to be converted:
(d)	if Availment Option is one of the following, indicate period requested:

(i)	Banker's Acceptance (or BA Equivalent Loan, if applicable):
	(may have a maturity date of 28 to 182 days (inclusive))
(ii)	LIBOR Loan:
	(Libor Period may be for 1, 2, or 3 months)

2. The Borrower hereby certifies that as at the date hereof:

(a)	the representations and warranties in Article VII of the Credit Agreement, other than those which are expressly stated to have been made as at the date of the Credit Agreement, are true and correct in all material respects as if made on the date hereof;
(b)	no Default or Event of Default has occurred and is continuing, nor shall the Conversion result in the occurrence of a Default or Event of Default; and
(c)	no Material Adverse Change has occurred and is continuing.

- 2 -

Dated this                                            day of                                            ,                                            .

MERUS LABS INTERNATIONAL INC.

By:

       name:

       title:

By:

       name:

       title:

EXHIBIT E - REPAYMENT NOTICE

To: Bank of Montreal, as Administrative Agent

     This Repayment Notice is delivered pursuant to the Credit Agreement made among Merus Labs International Inc. (the “Borrower”), Bank of Montreal, as Administrative Agent (the “Agent”) and the Lenders (as therein defined) dated September 5, 2014 (the “Credit Agreement”). Terms used herein as defined terms shall have the respective meanings ascribed in the Credit Agreement.

1. The Borrower hereby irrevocably commits to make a Repayment under Facility 1 as follows:

(a)	date of Repayment:
(b)	amount of Repayment:
(c)	type of Availment Option to be repaid:.

Dated this                                            day of                                            ,                                            .

MERUS LABS INTERNATIONAL INC.

By:

       name:

       title:

By:

       name:

       title:

EXHIBIT F – COMPLIANCE CERTIFICATE

To: Bank of Montreal, as Administrative Agent

     This Compliance Certificate is delivered pursuant to the Credit Agreement made among Merus Labs International Inc. (the “Borrower”), Bank of Montreal, as Administrative Agent (the “Agent”) and the Lenders (as therein defined) dated September 5, 2014 (the “Credit Agreement”). Terms used herein as defined terms shall have the respective meanings ascribed in the Credit Agreement.

1. The following are the financial ratios and covenants in respect of Merus Labs International Inc. and its Subsidiaries on a consolidated basis, calculated in accordance with the provisions of the Credit Agreement, as at the end of the Fiscal Quarter ended ___________________ (or in respect of the financial period(s) ended on such date, as indicated below):

(a)	Senior Funded Debt to EBITDA : _____________________________________________
(b)	Total Funded Debt to EBITDA Ratio:__________________________________________
(c)	Fixed Charge Coverage Ratio: ________________________________________________

2.	Attached hereto is an analysis of any material variances in the financial results in such Fiscal Quarter from the projections contained in the most recent Annual Business Plan delivered to the Lenders.
3.	The undersigned officer of the Borrower hereby certifies on behalf of the Borrower and without personal liability that as at the date hereof:

(a)	the foregoing information and all information contained in the attachments hereto is true, correct and complete as at the end of the Fiscal Quarter;
(b)	the representations and warranties in Article VII of the Credit Agreement, other than those which are expressly stated to have been made as at the date of the Credit Agreement, are true and correct in all material respects as if made on the date hereof;
(c)	no Default or Event of Default has occurred and is continuing; and
(d)	no Material Adverse Change has occurred and is continuing.

Dated this                                            day of                                            ,                                            .

name:

title:

EXHIBIT G - FORM OF BA EQUIVALENT NOTE

[insert date]

          FOR VALUE RECEIVED, the undersigned hereby promises to pay to the order of [name of Non-BA Lender] at its office at [insert address from Credit Agreement], the sum of                                                                                                Dollars ($                                   ) in lawful money of Canada on [insert date of maturity].

Dated this                                            day of                                            ,                                            .

MERUS LABS INTERNATIONAL INC.

By:

       name:

       title:

By:

       name:

       title:

EXHIBIT H - CBA MODEL PROVISIONS

[See attached.]

Schedule 6.01(b) – Corporate Information

Legal Names, Etc.

Legal Name	Type of Entity	Registered Organization (Yes/No)	FEIN/BN or equivalent	State or Provincial ID or Organizational Number	Jurisdiction of Formation
Merus Labs International Inc.	Corporation	No	[Redacted]	[Redacted]	British Columbia
ECG Holdings Inc.	Corporation	Yes	[Redacted]	[Redacted]	Delaware
Merus Labs Luxco S. r.l.	Corporation	No	[Redacted]	[Redacted]	Luxembourg
Merus Labs Netherlands B.V.	Corporation	No	[Redacted]	[Redacted]	Netherlands
Orbis Pharma Inc.	Corporation	No	None	[Redacted]	Ontario
89759701 Canada Inc.	Corporation	No	None	[Redacted]	Canada

Note:

• [Excluded Subsidiaries Redacted] are deemed excluded subsidiaries for the purposes of the credit agreement.

Schedule 6.01(b) – Corporate Information

Changes in Corporate Identity; Other Names

Company/Subsidiary	Corporate Name of Entity	Action	Date of Action	Jurisdiction of Formation	List of All Other Names Used During Past Five Years
Company	Merus Labs International Inc.	Amalgamation between Merus Labs International Inc. and Merus Labs Inc.	10/1/12	British Columbia	Merus Labs International Inc. Merus Labs Inc.
Company	Merus Labs International Inc.	Amalgamation between Old Merus and Envoy	12/19/11	British Columbia	Merus Labs International Inc. Envoy Capital Group Inc.
Subsidiary	Merus Labs Inc.	Arrangement whereby Merus Labs Inc. became a wholly owned subsidiary of Old Merus.	1/22/10	British Columbia	0865346 B.C. Ltd.
Predecessor to Company	Envoy Capital Group Inc.	Continuation	12/16/11	Ontario to British Columbia	N/A
Predecessor to Company	Envoy Capital Group Inc.	Change of Name	3/30/07	Ontario	Potential Mines Ltd.

-2-

Schedule 6.01(b) – Corporate Information

Chief Executive Offices

Corporate/Subsidiary	Address	Country	State/Province
Merus Labs International Inc.	100 Wellington St. West, Ste. 2110, P.O. Box 151, Toronto, ON M5T 3A3	Canada	Ontario
ECG Holdings Inc.	c/o United Corporate Services 874 Walker Road, Unit C, Dover, Delaware	United States	Delaware
Orbis Pharma Inc.	100 Wellington St. West, Ste. 2110, P.O. Box 151, Toronto, ON M5T 3A3	Canada	Ontario
Merus Labs Luxco S. r.l.	[Address Redacted]	Luxembourg	N/A
Merus Labs Netherlands B.V.	[Address Redacted]	Netherlands	N/A
8975701 Canada Inc.	181 Bay Street Suite 440 Toronto, Ontario M5J 2T3	Canada	Ontario

-3-

Schedule 6.01(b) – Corporate Information

Other Places of Business

None.

-4-

Schedule 6.01(b) – Corporate Information

Locations of Collateral with a value in excess of $50,000 in Possession of Persons Other
Than Companies

Merus Labs International Inc. (at July 31, 2014)

Finished Goods Inventory:	Approximate Value (at cost)
[Redacted name and address of person in possession]	$[value of inventory redacted]
Raw Materials Inventory:
[Redacted name and address of person in possession]	$[value of inventory redacted]

Merus Labs Luxco S. r.l / Merus Labs Netherlands BV (at July 31, 2014)

Finished Goods Inventory:	Approximate Value (at cost)
[Redacted name and address of person in possession]	$[value of inventory redacted]
[Redacted name and address of person in possession]	$[value of inventory redacted]

Raw Materials Inventory:

[Redacted name and address of person in possession] $[value of inventory redacted]

-5-

Schedule 6.01(b) – Corporate Information

Number and Classes of Issued and Outstanding Shares

Grantor	Holder	Type	Certificate Number	Number of Shares	Percentage Owned
Merus Labs International Inc.	Various (public company)	Common Shares	Various	76,999,180	N/A
Merus Labs International Inc.	[Name of Holder Redacted]	Preferred Shares	1-AP 2-AP	[Redacted]	100%
Orbis Pharma Inc.	Merus Labs International Inc.	Common Shares	004, 005	[Redacted]	100%
ECG Holdings Inc.	Merus Labs International Inc.	Common Shares	1, 2	[Redacted]	100%
Merus Labs Luxco S. r.l.	Merus Labs International Inc.	Ordinary Shares		[Redacted]	100%
Merus Labs Luxco S. r.l.	Merus Labs International Inc.	Preferred Shares		[Redacted]	100%
Merus Labs Netherlands B.V.	Merus Labs International Inc.	Common Shares	None	[Redacted]	100%
8975701 Canada Inc.	Merus Labs International Inc.	Common Shares	None	[Redacted]	100%

-6-

Schedule 6.01(h)

Material Permits

           Vancocin Marketing Authorizations

[Marketing Authorizations Redacted]

          Enablex Marketing Authorizations

[Marketing Authorizations Redacted]

-7-

Schedule 6.01(i)

Specific Permitted Liens

None.

-8-

Schedule 6.01(j)

Owned Property

None.

-9-

Schedule 6.01(k)

Leased Properties

Company	Address	Arrangement	Property Owner (Name and Address)
Merus Labs International Inc.	100 Wellington St. West, Suite 2110, Toronto, Ontario M5T 3A3	[Redacted Lease Rates]	Cadillac Fairview Corporation 20 Queen St. West, th 5 Floor, Toronto, ON M5H 3R4
Merus Labs International Inc.	470 Granville St., Ste. 503, Vancouver, British Columbia V6C 1V5	[Redacted Lease Rates]	Lotte and John Hecht Memorial Foundation c/o Equitable real Estate Investment Corporation Ltd. #505-325 Howe Street, Vancouver, BC V6C 1Z7

-10-

Schedule 6.01(l)

Intellectual Property

[Intellectual Property Redacted]

-11-

Schedule 6.01(m)

Insurance Policies

[Insurance Policies Redacted]

-12-

Schedule 6.01(n)

Material Agreements

1.	Asset Purchase Agreement (Enablex/Emselex) – Novartis Pharma AG and Merus Labs Luxco S. r.l – July 11, 2012
2.	Supply Agreement (Enablex/Emselex) – Novartis Pharma AG and Merus Labs Netherlands BV – July 11, 2012
3.	License Agreement (Enablex/Emselex) – Novartis Pharma AG and Merus Labs Luxco Sarl – July 11, 2012
4.	Contract Manufacturing Agreement – [Name of Counter-Party Redacted] and Merus Labs Luxco Sarl – April 18, 2013
5.	Manufacturing Services Agreement – [Name of Counter-Party Redacted] and Merus Labs Inc. – May 29, 2012
6.	Supply Agreement for Darifenacin Hydrobromide – [Name of Counter-Party Redacted] and Merus Labs Luxco Sarl – February 20, 2014
7.	Series A Preferred Shares Subscription Agreement – [Name of Counter-Party Redacted] and Merus Labs International Inc. – July 11, 2014
8.	Series A Preferred Shares Subscription Agreement – [Name of Counter-Party Redacted] and Merus Labs International Inc. – July 11, 2014
9.	Definitive Acquisition Agreement – Dacha Strategic Metals Inc. – July 4, 2014
10.	Asset Purchase Agreement (Sintrom) – Novartis Pharma AG and Merus Labs Luxco S. r.l – to be executed and dated concurrently with the Credit Agreement
11.	Supply Agreement (Sintrom) – Novartis Pharma AG and Merus Labs Netherlands BV – to be executed and dated concurrently with the Credit Agreement
12.	License Agreement (Sintrom) – Novartis Pharma AG and Merus Labs Luxco S. r.l – to be executed and dated concurrently with the Credit Agreement

-13-

Schedule 6.01(o)

Labour Agreements

None.

-14-

Schedule 6.01(p)

Environmental Matters

None.

-15-

Schedule 6.01(q)

Litigation

Enablex – Notices of Allegation

In June 2014, Merus received notification from Apotex Inc. (“Apotex”) that it has filed with Health Canada an Abbreviated New Drug Submission (“ANDS”) seeking market approval for a generic version of Enablex (darifenacin hydrobromide tablets) for the Canadian marketplace. In connection with this filing, we received Notices of Allegation (“NOAs”) from Apotex against our Enablex patents listed on the Canadian patent register which expire in August of 2016 and beyond. The NOAs were issued under the Canada Patented Medicines (Notice of Compliance) Regulations (the “Regulations”). Enablex is currently protected in Canada by three issued patents listed on the Canadian patent register. Merus intends to vigorously defend the Enablex intellectual property rights and pursue all available legal and regulatory pathways in defense of the product. Under the Regulations, Merus is entitled to apply to Federal Court for an order preventing Health Canada from granting market authorization to Apotex in respect of the ANDS until after the expiration of the applicable patents. If the Federal Court were to decide in favour of Merus in such an action, Health Canada would be prohibited from granting market authorization to Apotex until Merus’ patents listed on the patent register expire. If Apotex is successful in obtaining a Notice of Compliance from Health Canada prior to the anticipated expiry of our patents, then we may experience generic competition for our Enablex product earlier than originally anticipated with the result that our revenues from our Enablex product may be less than anticipated due to a combination of (i) decreased pricing, and (ii) reduced market share resulting from generic competition.

Factive – Arbitration Proceeding

The Company has received notice of a request for arbitration from the original owner of the Company’s former Factive product. The request for arbitration is based on the original license agreement entered into by the original owner and Cornerstone Therapeutics, Inc. (now Chiesi USA, Inc.). The request for arbitration names the Company as a respondent together with Cornerstone and Vansen Pharma, Inc. The request for arbitration includes the allegation that Cornerstone did not have the legal right to transfer the Factive product to the Company. The original owner is seeking an award for damages relating to an alleged breach of contract, as well of disgorgement of revenues and other benefits derived by the Company from sales of Factive. The Company denies any liability to the original owner.

Schedule 6.01(r)

Pension Plans

None.

-17-

EX-99.2

MERUS LABS INTERNATIONAL INC.

ANNOUNCES ACQUISITION OF SINTROM ®

Toronto, September 8, 2014 - Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG (“Novartis”), in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom has been available in Europe for over 50 years and in calendar year 2013 the product had net sales of approximately US$28 million in the territories acquired.

The Company funded the Sintrom acquisition with cash on hand and a debt facility provided to Merus by a syndicate of lenders which also refinanced the Company’s existing debt. Other financial terms of the acquisition were not disclosed. Pursuant to the acquisition, Merus inlicensed the Sintrom trademark, certain related intellectual property, and acquired other information and materials required to continue commercializing the brand in the territories acquired.

“We are pleased to have completed this product acquisition with Novartis, a top tier pharmaceutical company. The addition of this product will substantially increase the revenues and associated EBITDA of the Company, as well as, bring further scale and diversity to our existing product portfolio. We are also pleased to have entered into a new debt facility with a syndicate of lenders which will assist with financing solutions for future product acquisition opportunities,” said Elie Farah, President and CEO of Merus Labs International Inc.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

Forward Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934 and include such statements as: the acquisition of the product broadening the Company’s existing product portfolio; the prospective increase in revenues and EBITDA of the Company, expanding its geographic focus, bringing scale to its business and completing future product acquisitions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus’ actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus’ products, changes in competition, the ability of Merus to integrate acquisitions or complete future acquisitions, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation of the sale and pricing of pharmaceutical products. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus’ plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

For further information please contact:

Merus Labs International Inc.

Elie Farah

Chief Executive Officer

Tel: (416) 593-3701

efarah@meruslabs.com

Andrew Patient

Chief Financial Officer

Tel: (416) 593-3725

apatient@meruslabs.com

EX-99.3

FORM 51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Merus Labs International Inc. (the “Company” or “Merus”)

100 Wellington Street West

Suite 2110, PO Box 151

Toronto, Ontario, M5K 1H1

Item 2 Date of Material Change

September 8, 2014

Item 3 News Release

A news release was issued by the Company on September 8, 2014 and distributed through Marketwired and filed on SEDAR.

Item 4 Summary of Material Change

On September 8, 2014, a wholly owned subsidiary of the Company (the “Merus Subsidiary”) acquired from Novartis AG (“Novartis”), in certain European countries including the key countries of Spain, Italy, Greece, Romania and Bulgaria (the “Territory”), the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol) (the “Acquisition”). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases.

The Company paid Novartis US$111 million for the Acquisition, which was completed pursuant to an asset purchase agreement executed among the Company, the Merus Subsidiary and Novartis (the “Asset Purchase Agreement”). The Company funded the Acquisition with cash on hand and approximately $58 million from a new $80 million bank facility (the “Bank Facility”) under a credit agreement entered into by the Company with the Bank of Montreal, CIT Financial Ltd., Export Development Canada and Laurentian Bank of Canada. The remaining approximately $22 million of the Bank Facility was used to refinance the existing debt of Merus.

Item 5 Full Description of Material Change

5.1 Full Description of Material Change

On September 8, 2014, the Merus Subsidiary acquired from Novartis AG, in certain European countries including the key countries of Spain, Italy, Greece, Romania and Bulgaria, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom (acenocoumarol). Acenocoumarol is an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom has been available in Europe for over 50 years.

The Company paid Novartis US$111 million for the Acquisition, which was completed pursuant to an asset purchase agreement executed among the Company, the Merus Subsidiary and Novartis. Pursuant to the Acquisition, Merus inlicensed the Sintrom trademark, certain related intellectual property, and acquired other information and materials required to continue commercializing the brand in the Territories. The Merus Subsidiary did not acquire an assignment of any Novartis sales contracts or assume any outstanding Novartis liabilities in connection with the acquisition.

- 2 -

Under the Asset Purchase Agreement, the Company and the Merus Subsidiary entered into a license agreement with Novartis under which the Merus Subsidiary acquired an exclusive, perpetual, royalty-free, fully paid-up license to market, sell and commercialize Sintrom in the Territories. The license rights include the rights to use the trademark Sintrom in the Territories.

In addition, the Company and the Merus Subsidiary entered into a supply agreement with Novartis under which Novartis has agreed to manufacture, distribute, and sell Sintrom during the first phase of the transition period for the economic benefit of the Merus Subsidiary. During the second stage of the transition period, while Merus transfers the product manufacturing to a contract manufacturer, Merus will distribute and sell Sintrom and Novartis will continue to supply the product. The arrangements under the supply agreement are comparable to the arrangements between the Merus Subsidiary and Novartis for the Company’s Enablex product acquired from Novartis in 2012.

The Company funded the Acquisition with cash on hand and new funding of approximately $58 million from an $80 million bank facility under a credit agreement entered into by the Company with Bank of Montreal, CIT Financial Ltd., Export Development Canada and Laurentian Bank of Canada. The credit agreement was entered into concurrent with the funding of the Acquisition. The loan under the Bank Facility is non-revolving term loan that matures in 5 years. The Company is required to make equal quarterly payments of principal amortized over the 5 year term. Interest is payable monthly based on the Bank of Montreal base rate plus agreed upon margins. The Bank Facility is secured by a first priority pledge of all assets of the Company and its key subsidiaries, including the pledge by the Company of shares of its key subsidiaries. The balance of the advance under the Bank Facility of approximately $22 million was applied to repay the Company’s previously outstanding loan with Bank of Montreal and Royal Bank of Canada, which has now been repaid in full.

5.2 Disclosure for Restructuring Transactions

Not applicable.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7 Omitted Information

Not applicable

Item 8 Executive Officer

Andrew Patient

Chief Financial Officer

Telephone: (416) 593-3725

- 3 -

Item 9 Date of Report

September 8, 2014

EX-99.4

ASSET PURCHASE AGREEMENT

between

NOVARTIS AG

NOVARTIS PHARMA AG

AND

MERUS LABS LUXCO SARL

MERUS LABS INTERNATIONAL INC.

TABLE OF CONTENTS

1.	DEFINITIONS AND INTERPRETATION	4
2.	SALE AND TRANSFER OF ASSETS	9
3.	GRANT OF LICENSES	10
4.	ASSUMED LIABILITIES AND EXCLUDED LIABILITIES	10
5.	OBLIGATIONS OF THE PURCHASER	11
6.	TRANSITION SERVICES PROVIDED BY NOVARTIS	12
7.	MAINTENANCE OF MARKETING AUTHORIZATIONS PENDING COMPLETION OF TRANSFER	13
8.	CO-OPERATION ON PHARMACOVIGILANCE AND SAFETY	14
9.	PURCHASE PRICE AND PAYMENT OF PURCHASE PRICE	14
10.	CLOSING	14
11.	THIRD PARTY AGREEMENTS	14
12.	NOVARTIS’ REPRESENTATIONS AND WARRANTIES	15
13.	PURCHASER’S REPRESENTATIONS AND WARRANTIES	15
14.	CLAIMS FOR BREACH OF REPRESENTATIONS AND WARRANTIES	15
15.	INDEMNIFICATION	15
16.	MARKETING AUTHORIZATION DEREGISTRATION RIGHT	15
17.	CONFIDENTIALITY; PRESS RELEASE	15
18.	***	16
19.	GUARANTEE OF PURCHASER’S PERFORMANCE BY MERUS	16
20.	MISCELLANEOUS	16

List of Annexes
Annex 1	Trademarks
Annex 2	Marketing Authorizations
Annex 3	Drug Substance
Annex 4	Disclosures (by Purchaser)
Annex 5	Third Party Agreements
Annex 6	List of Countries included in the Territory
Annex 7	Novartis Policies (NP4, NOVARTIS ABC Policy)
Annex 8	Purchaser’s Transition Plan
Annex 9	Data Room List
Annex 10	Redacted Version of Asset Purchase Agreement
Annex 11	Purchaser’s Press Release

ASSET PURCHASE AGREEMENT

This ASSET PURCHASE AGREEMENT (“Agreement”) is made as of this 8th day of September, 2014 (“Closing Date”), by and between Novartis AG, a company organized under the laws of Switzerland and Novartis Pharma AG, a company organized under the laws of Switzerland, both located at Lichtstrasse 35, 4056 Basel, Switzerland (collectively, referred to as “Novartis”) and Merus Labs Luxco SARL, a company organized under the laws of Luxembourg, located at 26-28, rue Edward Steichen, L-2540 Luxembourg (“Purchaser”) and Merus Labs International Inc., a company organized under the laws of Canada, 100 Wellington Street West, Suite 2110, P.o. Box 151, Toronto, Ontario, M5K 1H1 Canada (“Merus”). Novartis, Purchaser and Merus are each referred to individually as a “Party” and together as the “Parties.”

RECITALS

          WHEREAS, Novartis and its Affiliates developed and commercialize, by themselves or through third parties, the Product and the contained Drug Substance (as defined below) in certain countries;

          WHEREAS, Novartis desires to sell, transfer and convey to Purchaser and the Purchaser desires to purchase from Novartis, all assets relating to the Product (other than the Excluded Assets) in the Territory in the Field (as defined below).

          WHEREAS, Novartis and/or its Affiliates own registered trademarks and know-how exclusively related to the Product in the Territory and they are willing to grant Purchaser certain rights to such intellectual property as set forth herein and in the License Agreement;

          WHEREAS, Novartis owns certain know-how and technology related to the Product and other Novartis products and is willing to grant a license to such know-how and technology to Purchaser as set forth in the License Agreement;

          WHEREAS, Novartis is willing to provide certain services involving the supply of Product and Drug Substance in the Territory and certain other assistance for a Transition Period (as defined below) as set forth in this Agreement and the Supply Agreement between Novartis Pharma AG and Purchaser, Merus Labs Netherlands B.V., a company incorporated under the laws of The Netherlands, located at Herengracht 483, 1017 BT Amsterdam, The Netherlands (“Buyer”) and Merus; and

          WHEREAS, Merus desires to guarantee the performance of the obligations of Purchaser under this Agreement;

          NOW, THEREFORE, the Parties hereby agree as follows:

1.	DEFINITIONS AND INTERPRETATION
1.1	Definitions. For the purpose of this Agreement, the following terms shall have the following meanings:

“Accounting Standards” means the IFRS (International Financial Reporting Standards) as generally and consistently applied throughout Novartis’ organization.

“Adverse Event” means any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

“Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, “control” shall mean, direct or indirect, ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the entity or Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. In the case of entities organized under the laws of certain countries, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity.

“Assumed Liabilities” shall have the meaning set forth in Clause 4.1.

“Business” means the right to commercialize the Product in the Territory in the Field and to manufacture or have manufactured the Product for the use in the Territory in the Field.

“Business Day” means a day (other than a Saturday, Sunday or a public holiday) on which the banks are open for business in Basel, Switzerland and Luxembourg.

“Closing” or “Closing Date” means the date first written above, subject to the provisions of Clause 10.

“Commercial Information” means information that is available to and used by Novartis at the Closing Date for the commercialization of the Product in the Territory in the Field including but not limited to artwork relating to Product packaging and design.

“Confidentiality Agreement” means the confidentiality agreement between Novartis Pharma AG and Merus International Inc. dated 9 October 2013 relating to the divestments of certain products, including the Product.

“Data Room” shall mean the electronic and hard copy data rooms that Novartis established to permit Purchaser and its Affiliates to conduct due diligence relating to the transactions contemplated by this Agreement a table of content of which is included in Annex 9.

“Drug Substance” means the active ingredient in the Product, i.e. acenocoumarol, as described in Annex 3.

“Excluded Assets” shall have the meaning set forth in Clause 2.2.

“Excluded Liabilities” shall have the meaning set forth in Clause 4.2.

*** [Redacted Defined Term]

“Field” means use for the treatment and prevention of thromboembolic diseases.

“Force Majeure” means any event which is beyond the reasonable control of the Party affected, including but not limited to the following events: earthquake, storm, flood, fire or other acts of nature, epidemic, war, riot, public disturbance, strike or lockouts, government actions, terrorist attack or the like.

“Indemnified Party” shall have the meaning set forth in Clause 15.3.

“Indemnifying Party” shall have the meaning set forth in Clause 15.3.

“Inventory” means all stock of Drug Substance and/or Product that are solely and specifically related to (and for use in) the Business and that are maintained, held, or stored by or on behalf of Novartis or its Affiliates for the use in the Territory in the Field.

“Know-How” means all existing and available technical information, know-how, proprietary information and data, of any type whatsoever, in any tangible or intangible form whatsoever, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, records, books, reports, drawings, operating procedures, and other technology related to the Product or Drug Substance or to their manufacture, validation, registration, use or commercialization and including without limitation all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, quality control, packaging, manufacturing, analytical, shelf life, testing, release testing, formulation, validation, stability, marketing, preclinical and clinical data, results or information, and manufacturing or development processes, relevant to the manufacture, validation, registration, use or commercialization of the Product in the Territory in the Field, and that are in existence, and owned or controlled by Novartis and/or its Affiliates on the Closing Date.

*** [Redacted Defined Term]

“Liabilities” means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured or not or determined or determinable, including product liability, and, more generally, any liability arising under any law, action or governmental order and any liability arising under any contract or undertaking.

“License Agreement” means the license agreement to be signed in connection with this Asset Purchase Agreement.

“Licensed IP” means the Know How other than the Sintrom Know-How.

“Loss” means any and all direct economic losses, including but not limited to damages, internal and external costs and expenses.

“Marketing Authorizations” or “MAs” means the marketing authorizations or any equivalent regulatory approvals listed in Annex 2 for the Product in the Territory.

“Marketing Authorization Data” means the existing and available dossiers containing the relevant Know-How used by Novartis and/or its Affiliates to obtain and maintain the Marketing Authorizations.

“MA Transfer Date” means, in relation each country of the Territory, the date upon which the relevant Regulatory Authority approves and notifies the Marketing Authorization naming the Purchaser or the Purchaser’s Affiliate or designate as the marketing authorization holder.

“Medical Information” means any medical or clinical information about the Product in the Field available to and used by Novartis at the Closing Date, including clinical and technical matters, such as therapeutic uses for the approved indications, safety information, drug-disease information, and other product characteristics.

“Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity.

“Phase 1 Period” means the period, on a country-by-country basis, from the Closing Date until the earlier of:

(a)	the MA Transfer Date; and
(b)	two (2) years from the Closing Date.

“Phase 2 Period” means the period, on a country-by-country basis, from the MA Transfer Date until the earlier of:

(a)	the approval of the manufacturing (or sourcing from a third party) of the Product by Purchaser or its Affiliate or designate; and
(b)	three (3) years from the Closing Date.

“Product” means the product including the contained Drug Substance, which is commercialized by Novartis and its Affiliates under the Trademarks and the Marketing Authorization(s) in the Territory and in the Field as of the Closing Date. Product means finished pack and bulk drug product, as the case may be.

“Purchase Price” shall have the meaning set forth in Clause 9.1 below.

“Regulatory Authority” means any governmental agency or authority responsible for granting Marketing Authorizations for Product, including the United States Food and Drug Administration, the European Medicines Agency, any successor entity thereto, and any corresponding national or regional regulatory authorities.

*** [Redacted Defined Term]

“Sintrom Know-How” means any Know-How relating exclusively to the Product in the Territory in the Field.

“Supply Agreement” means the supply agreement for the Product and the Drug Substance as the case may be which Novartis Pharma AG, Purchaser, Buyer and Merus have signed in connection with this Asset Purchase Agreement.

“Swiss Code of Obligations” means the Swiss Code of Obligations of March 30, 1911, as amended from time to time.

“Tender” means the supply of Product to governments, hospitals and pharmacies through tender offers.

“Territory” means the countries listed in Annex 6.

“Third Party Agreements” means the existing agreements between Novartis and third parties at the time of the Closing related to the Business, listed as Third Party Agreements identified in Annex 5.

“Trademarks” means the registered trademarks in the Territory as listed in Annex 1, including all goodwill associated therewith.

“Transferred Assets” shall have the meaning set forth in Clause 2.1.

“Transition Period” means the period, on a country-by-country basis, from the beginning of the Phase 1 Period until the end of the Phase 2 Period but no longer than for a maximum of three (3) years from the Closing Date.

“Transition Plan” shall have the meaning set forth in Clause 5.1.

“Transition Services” shall have the meaning set forth in Clause 6.

“Warranty Claim” shall have the meaning set forth in Clause 12.3.

1.2 Interpretation. In this agreement unless otherwise specified:

(a)	“includes” and “including” shall mean respectively includes and including without limitation;
(b)	a Party includes its permitted assignees and/or the respective successors in title to substantially the whole of its undertaking;
(c)	words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders;
(d)	the Annexes and other attachments form part of the operative provision of this Agreement and references to this Agreement shall, unless the context otherwise requires, include references to the Annexes and attachments;
(e)	the headings in this Agreement are for information only and shall not be considered in the interpretation of this Agreement;

(f)	general words shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of acts, matters or things;
(g)	any reference to "writing" or "written" includes faxes and any legible reproduction of words delivered in permanent and tangible form (but does not include email); and
(h)	the Parties agree that the terms and conditions of this Agreement are the result of negotiations between the Parties and that this Agreement shall not be construed in favour of or against any Party by reason of the extent to which any Party participated in its preparation.

2.	SALE AND TRANSFER OF ASSETS
2.1	Sale of Assets. Novartis shall, or shall cause its Affiliates to, with effect as of the Closing Date, sell, transfer, and convey to Purchaser, and Purchaser shall purchase from Novartis and its Affiliates, all of Novartis’ and its Affiliates’ rights, titles, and interests in and to the following assets to the extent that they relate to the Product in the Territory (“Transferred Assets”):

(a)	the Marketing Authorizations;
(b)	the Marketing Authorization Data;
(c)	the Commercial Information;
(d)	the Medical Information;
(e)	the Sintrom Know-How;
(f)	the Third Party Agreements, subject to Clause 11 below.

2.2 Excluded Assets. Notwithstanding Clause 2.1, Novartis shall not sell, transfer, or convey to Purchaser, and Purchaser shall not purchase and acquire the following (“Excluded Assets”):

(a)	subject to the license rights granted to the Purchaser in the License Agreement, the Licensed IP and the Trademarks;
(b)	the name “Novartis”, “Ciba-Geigy” or “Sandoz”, or any trademark, service mark, trade dress, logo, trade name or corporate name similar or related thereto;
(c)	the accounts receivable and the accounts payable relating to the Business, the Product or the Transferred Assets for the period prior to the Closing Date;
(d)	any real property or leaseholds (together with all fixtures and fittings related to any property), physical plant, machinery, equipment, motor vehicles or office equipment;

(e)	any rights or assets belonging to the generic business of Sandoz (which is the generic division of Novartis), or any of its successors, containing the Drug Substance;
(f)	any rights or assets belonging to the over-the-counter business (which is a division of Novartis), or any of its successors, containing the Drug Substance;
(g)	any rights or assets belonging to the business of Alcon (which is a division of Novartis), or any of its successors, containing the Drug Substance;
(h)	any rights or assets belonging to Novartis Vaccines and Diagnostics (which is a division of Novartis) or any of its successors, containing the Drug Substance;
(i)	any rights or assets outside the human pharmaceutical field (such as, for example, the use of the Drug Substance in the veterinary pharmaceutical field);
(j)	any rights for countries outside the Territory;
(k)	any rights under Novartis’ insurance policies which are related to the Business; and
(l)	any rights or assets outside the Field.

2.3	Sale of Inventory. Purchaser shall cause Buyer to purchase (or shall cause its Affiliates to purchase) the Inventory in separate transactions in accordance with the terms and conditions contained in the Supply Agreement. It is agreed and understood by and between the Parties that the Purchase Price does not include the Inventory.
2.4	Restriction to Territory. Novartis may continue to manufacture, market and sell the Product itself or through its Affiliates or third party collaborators outside the Territory. Novartis may manufacture or have manufactured the Product in the Territory for commercialization outside the Territory.
3.	GRANT OF LICENSES
3.1	Licenses. Under the terms and conditions of the License Agreement, (a) Novartis shall grant to Purchaser, effective upon the Closing Date, the necessary licenses under the Licensed IP and Trademarks to conduct the Business in the Territory. The entire consideration for the licenses shall form part of this Agreement (including the Purchase Price and transfer of assets) and the licenses shall be fully paid-up, royalty-free and perpetual. Purchaser shall, grant Novartis, effective upon the Closing Date, the necessary licenses under the Sintrom Know-How to fulfill its obligations under this Agreement and the Supply Agreement.
4.	ASSUMED LIABILITIES AND EXCLUDED LIABILITIES
4.1	Assumed Liabilities. Subject to the terms of the Supply Agreement and Clause 15.2 of this Agreement, effective as of the time of the Closing, Purchaser shall assume, be responsible for and pay, perform and discharge when due, and, if necessary, reimburse Novartis for the following (collectively “Assumed Liabilities”):

(a)

any Liabilities arising from product liability claims or trademark infringement claims or lawsuits brought by any third party relating to Product or Drug Substance manufactured by or for Purchaser or its Affiliates (or its third party collaborators) or sold by Purchaser or its Affiliates (or on their behalf) in the Territory after the Closing Date (including sales made by Novartis and its Affiliates to third parties during the Phase 1 Period as set out in the Supply Agreement) including returns, chargebacks, and discounts related thereto; and

(b)

any other Liabilities primarily related to the Business or Transferred Assets arising after the Closing Date.

4.2	Excluded Liabilities. Subject to the provisions of this Agreement and the Supply Agreement, Novartis shall remain responsible for and pay, perform and discharge any Liabilities arising from its activities related to the Drug Substance and Product distributed, used or sold by or on behalf of Novartis or its Affiliates prior to the Closing Date, including returns, chargebacks, and discounts to the extent accrued prior to the Closing Date (“Excluded Liabilities”).
5.	OBLIGATIONS OF THE PURCHASER
5.1	Transfer of Marketing Authorizations. Purchaser shall file, or shall cause to file, in accordance with a transition plan to be finalized and agreed to by Purchaser and Novartis not later than 30 days after Closing (“Transition Plan”; the current draft is attached to this Agreement as Annex 8), applications for the transfer of the Marketing Authorizations for the Product in the Field in each country of the Territory within nine (9) months from the Closing Date. Should there be any variations in a country in the Territory which exists as at the Closing Date and which prevents, by operation of applicable law, the Purchaser from filing for transfer of the MA in such country, then in such country the Purchaser shall have a period of three (3) months from the date of completion of such variation to make the appropriate filing contemplated by this Clause 5.1 it being understood and agreed by the Parties that such extended period shall in no event be longer than eighteen (18) months from the Closing Date. Purchaser shall provide Novartis with a detailed action submission plan for the transfer of the Marketing Authorizations for the Product in the Territory promptly following the Closing Date. Such plan shall comply with the Transition Plan and include all requirements and actions necessary to obtain approval of the Marketing Authorization transfer by the Regulatory Authorities in each relevant country in the Territory (including, if necessary, for example the establishment of the Purchaser’s Affiliate or local agent, requirements of a Certificate of the Pharmaceutical Product, Regulatory Authority inspections).
5.2	Transfer of Manufacturing.

(a) It is the intention of the Parties to jointly select a contract manufacturer for both Drug Substance and Product. The Parties agree to engage in a joint selection process with agreed selection criteria. Either Party shall be free to discontinue the selection process at any time at their own discretion and, in such case, the Parties are free to choose their own manufacturing solution. In such case, the Transition Services to be provided by Novartis for the transfer of manufacturing will be strictly limited to the services agreed to in the relevant subsections of Clause 6.1 and Novartis shall not be obligated to provide support for transfer of manufacturing beyond Clause 6.1.

(b) Irrespective of Clause 5.2(a), Purchaser or its Affiliates shall assume its own manufacturing (or sourcing from a third party) of the Drug Substance and the Product, immediately upon transfer of the Marketing Authorization on a country- by-country basis, and in no event later than three (3) years from the Closing Date.

5.3	Retention of Profit Under Supply Agreement. If Purchaser is in breach, for any reason, of Clause 5.1 or 5.2 above, Novartis Pharma AG has the right, without any further notice, to immediately cease the transfer of, and retain, the Profit as set out in the Supply Agreement until such breach is cured. For the avoidance of doubt, Novartis Pharma AG shall be entitled to keep moneys that have been retained during the period of non-compliance of Purchaser with its obligations according to Clause 5.1 and 5.2 even after such breach has been cured.
6.	TRANSITION SERVICES PROVIDED BY NOVARTIS
6.1	Transition Services. During the Transition Period, Novartis shall provide the following transition services (“Transition Services”) in the Territory:

(a)	Selling and distributing Product and invoicing customers for the Product in the Territory during the Phase 1 Period;
(b)	supplying the Product in accordance with the Supply Agreement in Phase 2;
(c)	providing Purchaser and Buyer, with all existing and available regulatory documentation concerning the Product owned or controlled by Novartis and general assistance for (but not to undertake) the transfer of the Marketing Authorizations;
(d)	providing Purchaser or Purchaser's Affiliates, including Buyer, with all existing and available documentation owned or controlled by Novartis describing the manufacturing process in detail and general technical advice for the transfer of the manufacturing process of the Product;
(e)	for all work deemed over and above that is described in subparagraph (c) above, upon reasonable written request from Purchaser, and at Purchaser's expense, providing regulatory assistance to facilitate the transfer of the Marketing Authorizations from Novartis and/or its Affiliates; and
(f)	for all work deemed over and above that described in subparagraph (d) above, upon reasonable written request from Purchaser, and at Purchaser's expense, providing technical assistance in order to facilitate the assumption by Purchaser or its Affiliates of the manufacturing of the Product (including Drug Substance).

Novartis shall not be obligated to perform any Transition Services pursuant to Clauses 6.1(e) and 6.1(f) of this Agreement which exceed 100 (one hundred) hours in the aggregate.

Notwithstanding the above, Novartis reserves the right to charge Purchaser or Purchaser’s Affiliates a reasonable fee for any Transition Services that Novartis considers to be onerous from an effort and/or cost perspective.

6.2	Transition Period. It is agreed and understood by and between the Parties that Novartis shall only provide the Transition Services in the Territory until the end of the Transition Period (i.e., for a maximum of three (3) years).
7.	MAINTENANCE OF MARKETING AUTHORIZATIONS PENDING COMPLETION OF TRANSFER
7.1	Maintenance. Until completion of the transfer of the Marketing Authorizations to Purchaser (or its Affiliates), but for no longer than a period of two (2) years after Closing:

(a)	Novartis shall use its commercially reasonable efforts to maintain the Marketing Authorizations;
(b)	Novartis shall continue to remain responsible for, at its sole expense, pursuing those on-going variations, amendments and renewals which are pending at the Closing Date or withdraw them, if mutually agreed to by Novartis and the Purchaser; provided, however, that Novartis shall not be responsible vis- -vis Purchaser for the outcome of such variations, amendments and renewals, in particular, any negative regulatory decision or feedback; and
(c)	Novartis shall not initiate any additional variations or amendments, except in the event they are indispensable for the continuation of the Business and upon Purchaser’s written request.

7.2

Responsibility. For the avoidance of doubt, Novartis does not warrant and shall not be responsible for the successful maintenance or renewal of the Marketing Authorizations after the Closing Date, except if an authority cancels a Marketing Authorization or refuses its renewal as a result of Novartis’ gross negligence or wilful misconduct. Furthermore, Novartis is not responsible for conducting any studies, including clinical and stability studies, or for developing new analytical methodologies or validating and co-validating existent methodologies concerning the Drug Substance and/or the Product, which may be requested by the Regulatory Authority after the Closing Date, regardless of whether the MA Transfer Date has occurred or not. Purchaser shall notify Novartis when it initiates such studies of Drug Substance and/or Product in the Territory and, upon written request by Novartis, shall provide Novartis with the final results and, provided that the results are suitable for use outside the Territory, grant access to the data underlying these final results.

7.3

Costs. Purchaser, or its Affiliates, shall bear the third party fees levied by the relevant Regulatory Authorities and any other relevant cost for (a) the maintenance of the Marketing Authorizations and for the transfer to Purchaser (or its Affiliates) after the Closing; and (b) any variations, amendments and renewals pursuant to Clauses 7.1(b) and 7.1(c) above.

8.	CO-OPERATION ON PHARMACOVIGILANCE AND SAFETY
8.1	Adverse Events. The Parties shall co-operate with regard to the reporting and handling of Adverse Events in accordance with the applicable regulatory laws and regulations on pharmacovigilance.
8.2	Pharmacovigilance Agreement. Following the Closing Date, and in time to ensure that all regulatory requirements are met, the Parties shall enter into a pharmacovigilance agreement.
9.	PURCHASE PRICE AND PAYMENT OF PURCHASE PRICE
	Purchase Price. The purchase price for the Transferred Assets and entire consideration for the rights granted under the License Agreement shall be USD 111’000’000.00 (one hundred and eleven million United States Dollars), exclusive of any applicable VAT and shall be non-refundable (“Purchase Price”).
	*** [Redacted Payment Information]
10.	CLOSING
	*** [Redacted Closing Information]
11.	THIRD PARTY AGREEMENTS
11.1	Assignment of Third Party Agreements. Upon receipt of Purchaser’s written request, Novartis shall assign its rights and obligations related to the divestment of the Product in the Field in the Territory under the relevant Third Party Agreements, including Third Party Agreements originally entered by Sandoz Ltd (“Sandoz”) or Ciba-Geigy Ltd (“Ciba-Geigy”), of which Novartis is the legal successor, to Purchaser or any of its Affiliates, including Buyer, on a date to be agreed after the Closing Date and subject to consent by the respective third parties. Novartis shall use reasonable efforts in obtaining such consent, however, Novartis cannot guarantee that such consent is given. In the event that such consent is not obtained or Purchaser does not request for assignment of a Third Party Agreement, Novartis shall terminate such Third Party Agreement as soon as practicable but shall remain as the contracting party under the relevant Third Party Agreement for its duration and the Purchaser shall, as Novartis’ agent, perform and discharge all outstanding obligations and liabilities of Novartis (or as applicable, Novartis’ Affiliates) under the Third Party Agreement, and shall indemnify Novartis against any actions, proceedings, liabilities, losses, costs, demands or claims Novartis may incur arising out of the Purchaser’s failure to do so.
11.2	Termination of Third Party Agreements. Subject to the conditions set forth in the relevant Third Party Agreement, and upon receipt of Purchaser’s written request, Novartis shall terminate any relevant Third Party Agreement not assigned to the Purchaser as provided in Clause 11.1 as soon as reasonably practicable after the end of Phase 1.
11.3	Assignment or Termination of Parts of a Third Party Agreement. Where only part of a Third Party Agreement relates to the Product(s) or where such Third Party Agreement is not exclusively related to the Product then nothing in this Agreement shall oblige Novartis to assign such Third Party Agreement to the Purchaser or Purchaser’s Affiliates and Novartis shall remove the Product from the scope of the Third Party Agreement as soon as practicable after the Closing Date, unless otherwise agreed in writing.

11.4	Tenders. Where feasible, as Novartis shall in its sole discretion decide, the Tenders will be treated in the same manner as the Third Party Agreements (as appropriate). The Parties will cooperate to ensure (where feasible) an efficient transfer to Purchaser of the Tenders outstanding as of the Closing Date or that are issued during the Transition Period with the aim of continuing the supply of the Products through the Tenders.
12.	NOVARTIS’ REPRESENTATIONS AND WARRANTIES
	*** [Redacted Representations and Warranties]
13.	PURCHASER’S REPRESENTATIONS AND WARRANTIES
	*** [Redacted Representations and Warranties]
14.	CLAIMS FOR BREACH OF REPRESENTATIONS AND WARRANTIES
	*** [Redacted Claims for Breach of Representations and Warranties]
15.	INDEMNIFICATION
	*** [Redacted Indemnification]
16.	MARKETING AUTHORIZATION DEREGISTRATION RIGHT
16.1	For the avoidance of doubt and notwithstanding any other rights that Novartis may have in this Agreement, Novartis and/or its Affiliates shall have the right to withdraw and/or deregister the Marketing Authorizations for the Product in the Territory in any country where the Purchaser has failed to complete the transfer of the Marketing Authorization for the Product within a period of three (3) years after the Closing Date.
17.	CONFIDENTIALITY; PRESS RELEASE
17.1	Confidentiality. Subject to the exceptions contained in Clauses 4 and 5 of the Confidentiality Agreement and Clause 17.2 of this Agreement, Purchaser (and its Affiliates, third party suppliers, or distributors) shall keep confidential and not disclose to any third party any confidential information pertaining to the Business and the Transferred Assets, which is received or obtained as a result of entering into or performing this Agreement, including, know-how concerning the manufacture of the Drug Substance and Product.
17.2	Notwithstanding any provision of this Asset Purchase Agreement or the Confidentiality Agreement, Novartis acknowledges that the Purchaser may have public disclosure obligations and may be required to disclose this Agreement and a summary of the transaction, including the Purchase Price, in its continuous disclosure documents as required by applicable laws, regulations and rules including any requirements imposed on public companies by applicable securities laws and regulations, such as posting any required information on SEDAR or in public disclosure documents provided, however, that the Parties agree that the form of redacted version of this Agreement to be so filed or disclosed shall be the form agreed to by the Parties and attached to this Agreement as Annex 10, subject to revisions as required by a Governmental Entity to be in compliance applicable law.

17.3	Press Releases. Other than the press release intended by Purchaser, which is attached hereto as Annex 11, neither Party shall issue any press release, trade announcement or make any other public announcement with regard to the transactions contemplated by this Agreement without the other Party’s prior written consent, which shall not be unreasonably withheld. This restriction shall not apply to announcements required by any Regulatory Authority. However, in such event the Parties shall, to the extent reasonably practicable, coordinate the wordings of any such announcements. Purchaser and Merus acknowledge that Novartis shall have the right to disclose a brief summary of the transaction, including the Purchase Price, in its official financial reports.
18.
	*** [Redacted Restrictions on Affiliates of Novartis]
19.	GUARANTEE OF PURCHASER’S PERFORMANCE BY MERUS
	*** [Redacted Guarantee of Purchaser’s Performance by Merus]
20.	MISCELLANEOUS
20.1	Governing Law and Jurisdiction. This Agreement shall be governed by and construed under the laws of Switzerland, without giving effect to the conflicts of laws provision thereof, and with the exclusion of the Vienna Convention on the International Sale of Goods. Any claim or dispute arising out of or relating to this Agreement that cannot be resolved amicably between the Parties within thirty (30) days after the controversy has arisen shall be subject to the exclusive jurisdiction of the courts located in Basel-Stadt, Switzerland. Each Party irrevocably agrees and consents to the jurisdiction of the courts located in Basel-Stadt, Switzerland and waives any objection it may have to the venue of such courts, including with respect to the convenience of the forum and jurisdiction.
	*** [Redacted Information Regarding Assignment of Rights and Obligations]
20.2	Force Majeure. If and to the extent that either Party is prevented or delayed by Force Majeure from performing any of its obligations under this Agreement and promptly so notifies in writing the other Party, specifying the matters constituting Force Majeure together with such evidence in verification thereof as it can reasonably give and specifying the period for which it is estimated that the prevention or delay will continue, then the Party so affected shall be relieved of liability to the other for failure to perform or for delay in performing such obligations (as the case may be), but shall nevertheless use its commercially reasonable efforts to resume full performance thereof.
20.3	Notices. All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to have been duly given when: (a) delivered by hand (with written confirmation of receipt); (b) sent by fax (with written confirmation of receipt), provided that a copy is immediately sent by an internationally recognized overnight delivery service (receipt requested); or (c) when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested), in each case to the appropriate addresses and fax numbers set forth below (or to such other addresses and fax numbers as a Party may designate by written notice):

If to Purchaser:

Merus Labs Luxco SARL

26-28, rue Edward Steichen

L-2540 Luxembourg

Attn: Managing Director

Tel: +352 271127044

Fax: +352 271127200

If to Merus:

Merus Labs International Inc.

100 Wellington Street West,

Suite 2110, PO Box 151

Toronto, Ontario, M5K 1H1

Canada

Attn: Elie Farah

Tel: 416.593.3701

Fax: 416.593.4434

If to Novartis:

Novartis Pharma AG

Lichtstrasse 35

CH-4056 Basel, Switzerland

Attn: Head of BD&L

Fax: +41 61 324 2100

With a copy To:

Novartis Pharma AG

Lichtstrasse 35

CH-4056 Basel, Switzerland

Attn: General Counsel

Fax: +41 61 324 7399

20.4 Waiver and Amendments. The failure of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.

20.5	Severability. Without prejudice to any other rights that the Parties have pursuant to this Agreement, every provision of this Agreement is intended to be severable. If any provision of this Agreement shall be invalid or unenforceable, such invalidity or unenforceability shall not affect the other provisions of this Agreement, which shall remain in full force and effect. The Parties hereto agree to consult each other and to agree upon a new stipulation which is permissible under the law and which comes as close as possible to the original purpose and intent of the invalid, void or unenforceable provision.
20.6	Entire Agreement. This Agreement (together with the License Agreement and the Supply Agreement) constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, between the Parties with respect to the subject matter hereof.
20.7	Relationship of the Parties. Nothing contained in this Agreement shall be deemed to constitute a partnership, joint venture, or legal entity of any type between Novartis, Purchaser and Merus, or to constitute one as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other.
20.8	Expenses. Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement.
20.9	Extension to Affiliates. Novartis shall have the right to extend the rights, immunities and obligations granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to Novartis. Novartis shall remain primarily liable for any acts or omissions of its Affiliates.
20.10	Compliance with Law. Each Party shall perform its obligations under this Agreement in accordance with all applicable laws. No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any applicable law.
20.11	English Language. This Agreement is written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement and in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail.
20.12	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

NOVARTIS AG		NOVARTIS PHARMA AG
By:	“signed”	By:	“signed”
Name:		Name:
Title:		Title:
Date:		Date:
By:	“signed”	By:	“signed”
Name:		Name:
Title:		Title:
Date:		Date:
MERUS LABS LUXCO SARL		MERUS LABS INTERNATIONAL INC.
By:	“signed”	By:	“signed”
Name:		Name:
Title:		Title:
Date:		Date:
By:	“signed”	By:	“signed”
Name:		Name:
Title:		Title:
Date:		Date: